[
  "human: What are the latest and highest quality treatments for diabetes? Only provide 2 queries",
  "Director-Agent: What are the latest and highest quality treatments for diabetes? Only provide 2 queries\n[{'index': 1, 'function': {'arguments': '{\"queries\": [\"Latest FDA-approved medications and technologies for diabetes management in 2023-2024, including GLP-1 agonists, SGLT2 inhibitors, and automated insulin delivery systems\", \"Comparative effectiveness of current first-line diabetes treatments based on recent clinical trials and meta-analyses, including HbA1c reduction, cardiovascular outcomes, and quality of life measures\"]}', 'name': 'execute_worker_search_agents'}, 'id': 'toolu_01FxPUgebALvKFYAEpHkCmLg', 'type': 'function'}]\nFunction 'execute_worker_search_agents' result:\nLatest FDA-approved medications and technologies for diabetes management in 2023-2024, including GLP-1 agonists, SGLT2 inhibitors, and automated insulin delivery systems\n[{'function': {'arguments': '{\"query\":\"Latest FDA-approved medications and technologies for diabetes management in 2023-2024, including GLP-1 agonists, SGLT2 inhibitors, and automated insulin delivery systems\"}', 'name': 'exa_search'}, 'id': 'call_Zw4KLdozhGgh4TTkKUyaSYvw', 'type': 'function'}]\nFunction 'exa_search' result:\n{\n  \"requestId\": \"4b6b048331a9449c16555ad97033feaf\",\n  \"autopromptString\": \"Latest FDA-approved medications and technologies for diabetes management in 2023-2024, including GLP-1 agonists, SGLT2 inhibitors, and automated insulin delivery systems\",\n  \"autoDate\": \"2023-01-01T00:00:00.000Z\",\n  \"resolvedSearchType\": \"neural\",\n  \"context\": \"Title: FDA Clears First Device to Enable Automat\\n\\nTitle: Registration and Real-Life Studies on Aut\\n\\n\",\n  \"results\": [\n    {\n      \"id\": \"https://www.fda.gov/news-events/press-announcements/fda-clears-first-device-enable-automated-insulin-dosing-individuals-type-2-diabetes\",\n      \"title\": \"FDA Clears First Device to Enable Automated Insulin Dosing for Individuals with Type 2 Diabetes\",\n      \"url\": \"https://www.fda.gov/news-events/press-announcements/fda-clears-first-device-enable-automated-insulin-dosing-individuals-type-2-diabetes\",\n      \"publishedDate\": \"2024-08-26T17:00:00.000Z\",\n      \"author\": \"Office of the Commissioner\",\n      \"text\": \"- [Skip to main content](https://www.fda.gov/news-events/press-announcements/fda-clears-first-device-enable-automated-insulin-dosing-individuals-type-2-diabetes#main-content)\\n- [Skip to FDA Search](https://www.fda.gov/news-events/press-announcements/fda-clears-first-device-enable-automated-insulin-dosing-individuals-type-2-diabetes#search-form)\\n- [Skip to in this section menu](https://www.fda.gov/news-events/press-announcements/fda-clears-first-device-enable-automated-insulin-dosing-individuals-type-2-diabetes#section-nav)\\n- [Skip to footer links](https://www.fda.gov/news-events/press-announcements/fda-clears-first-device-enable-automated-insulin-dosing-individuals-type-2-diabetes#footer)\\n\\n[In this section:\\\\\\nPress Announcements](https://www.fda.gov/news-events/press-announcements/fda-clears-first-device-enable-automated-insulin-dosing-individuals-type-2-diabetes#section-nav)\\n\\n1. [Home](https://www.fda.gov/)\\n2. [News & Events](https://www.fda.gov/news-events)\\n3. [FDA Newsroom](https://www.fda.gov/news-events/fda-newsroom)\\n4. [Press Announcements](https://www.fda.gov/news-events/fda-newsroom/press-announcements)\\n5. FDA Clears First Device to Enable Automated Insulin Dosing for Individuals with Type 2 Diabetes\\n\\n1. [Press Announcements](https://www.fda.gov/news-events/fda-newsroom/press-announcements)\\n\\nFor Immediate Release:August 26, 2024\\n\\n[Español](https://www.fda.gov/news-events/press-announcements/la-fda-autoriza-el-primer-dispositivo-que-permite-la-dosificacion-automatica-de-insulina-para)\\n\\nToday, the U.S. Food and Drug Administration expanded the indications of the Insulet SmartAdjust technology, an interoperable automated glycemic controller previously indicated for the management of type 1 diabetes in individuals two years and older, to also include management of type 2 diabetes in individuals 18 years and older. An interoperable automated glycemic controller is software that automatically adjusts insulin delivery to a person with diabetes by connecting to an alternate controller-enabled insulin pump (ACE pump) and integrated continuous glucose monitor (iCGM).\\n\\n**“The FDA has long worked with the diabetes community to ensure access to additional options and flexibilities for diabetes management,” said Michelle Tarver, M.D., Ph.D., acting director of the FDA’s Center for Devices and Radiological Health. “Automated insulin dosing technology has previously been available only for people with type 1 diabetes. Today’s action helps expand access to this important diabetes management tool to millions of adults living in the U.S. with type 2 diabetes.  The FDA is committed to advancing new device innovation that can improve the health and quality of life for people living with chronic diseases that require day-to-day maintenance like diabetes.”**\\n\\nMore than 11% of Americans are diagnosed with diabetes, a condition in which the body does not make enough or properly use the blood glucose-regulating hormone insulin. In people with type 2 diabetes, patients may take medications that can help increase insulin secretion or improve insulin sensitivity, in addition to following a healthy eating plan and physical activity. Many patients also need to use insulin therapy to keep their blood sugar in a safe range.\\n\\nPreviously, insulin therapy options for people with type 2 diabetes were limited to methods such as injection with a syringe, an insulin pen or an insulin pump, all of which require patients to self-administer insulin one or more times a day and check blood glucose frequently to achieve the best results. Today’s clearance provides a new option that can automate many of these manual tasks, potentially reducing the burden of living with this chronic disease.\\n\\nThe FDA reviewed data from a clinical study in which 289 individuals 18 years and older with type 2 diabetes on insulin used the Insulet SmartAdjust technology for 13 weeks. This study enrolled a diverse group of subjects from different racial and ethnic backgrounds, with a wide range of ages, education and income levels. Study participants had varying amounts of experience with diabetes and insulin use, and many subjects were also using common non-insulin diabetes medications like GLP1 agonists. Overall, the study showed that subjects’ blood sugar control improved compared to before the study and these improvements were seen across all demographic groups. There were no complications or serious adverse events related to the use of the SmartAdjust technology. Adverse events reported during the study were generally mild to moderate, and included hyperglycemia (high blood sugar), hypoglycemia (low blood sugar) and skin irritation.\\n\\nThe FDA reviewed the SmartAdjust technology software through the [510(k) premarket clearance pathway](https://www.fda.gov/medical-devices/device-approvals-denials-and-clearances/510k-clearances). A 510(k) is a premarket submission made to the FDA to demonstrate that a new device is substantially equivalent to a legally marketed predicate device.\\n\\n###\\n\\nBoilerplate\\n\\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.\\n\\n* * *\\n\\n## Inquiries\\n\\nMedia:[Jim McKinney](mailto:james.mckinney@fda.hhs.gov)240-328-7305\\n\\nConsumer:888-INFO-FDA\\n\\nBack to Top\",\n      \"summary\": \"{\\\"answer\\\":\\\"The FDA cleared the Insulet SmartAdjust technology for automated insulin dosing for individuals with type 2 diabetes. This technology was previously indicated for type 1 diabetes. The clearance was announced on August 26, 2024. The FDA reviewed data from a clinical study in which 289 individuals 18 years and older with type 2 diabetes on insulin used the Insulet SmartAdjust technology for 13 weeks.\\\"}\",\n      \"image\": \"https://www.fda.gov/themes/custom/preview/img/FDA-Social-Graphic.png\"\n    },\n    {\n      \"id\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC12213531/\",\n      \"title\": \"Registration and Real-Life Studies on Automated Insulin Delivery ...\",\n      \"url\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC12213531/\",\n      \"publishedDate\": \"2025-07-01T00:00:00.000Z\",\n      \"author\": \"\",\n      \"text\": \"## Abstract\\n\\n### Introduction:\\n\\nThe Diabetes Control and Complications Trial (DCCT) clearly documented long-term beneficial effects on both micro- and macro-vascular complications associated with type 1 diabetes (T1D) by using intensive insulin therapy (IIT) via multiple daily injections (MDIs) or insulin pumps more than 30 year ago. IIT, both during the DCCT and with translation into clinical practice, has been demonstrated to increase the risk of severe hypoglycemia and weight gain. Automated insulin delivery (AID) systems have become the standard of care in T1D management in the developed countries.\\n\\n### Materials and Methods:\\n\\nWe reviewed the registration and real-life studies for different AID systems reported to date. Many of the registration studies were sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). A systematic literature search was conducted using the MEDLINE (PubMed) database. Studies with the longest duration and/or with the largest number of participants were included.\\n\\n### Results:\\n\\nIn the last decade, the introduction of a many AID systems for patients with T1D has shown improvements in glycemic metrics as documented by HbA1c values, time in range (TIR), time below range (TBR), and quality of life. Most of the registration and real-life studies have shown safe and effective use of AID systems for all age groups living with T1D.\\n\\n### Conclusions:\\n\\nIn this review, we summarize the registration and real-life studies of US Food and Drug Administration (FDA)-approved AID systems. Real-life studies confirmed the glycemic outcomes of AID systems reported from registration studies.\\n\\n**Keywords:** artificial pancreas, time in range, time below range, hypoglycemia, hyperglycemia, HbA1c, CGM, insulin pump, CSII\\n\\n## Introduction\\n\\nThis article is part of a collection of publications to commemorate the 75th Anniversary of the NIDDK.\\n\\nMore than 40 years ago, management of type 1 diabetes (T1D) usually consisted of two to three insulin injections administered subcutaneously daily.[1](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr1-19322968251334993)Importantly, targets for treatment were debated with questions of whether achievement of lower glucose levels, based on a hemoglobin A1c (HbA1c), would be advantageous for people with diabetes. The Diabetes Control and Complications Trial (DCCT), sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), concluded in 1993 and revolutionized the care of individuals with diabetes. The DCCT clearly showed that intensive insulin treatment (IIT) using multiple daily injections (MDI) or insulin delivery via continuous subcutaneous insulin delivery (CSII; insulin pump) along with frequent self-monitoring of blood glucose (SMBG) improves glycemic control as measured by HbA1c.[2](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr2-19322968251334993)In addition, the group randomized to IIT had significant reductions in long-term microvascular complications including diabetic kidney disease (DKD), diabetic retinopathy, and diabetic peripheral neuropathy which are all commonly associated with T1D. Indeed, the results were so compelling that the study was discontinued early because it would be unethical to continue the current standard of care.[2](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr2-19322968251334993), [3](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr3-19322968251334993) At the conclusion of the DCCT in 1993, the tools used to manage diabetes were rather rudimentary compared to today’s methods. At that time, insulin pumps had fewer features and continuous glucose monitors (CGMs) to adjust insulin dosing were not available.\\n\\nIn people without diabetes, the beta-cells of the pancreas release insulin continuously (as well as in response to rising blood glucose levels) in a pulsatile form directly to the liver through portal circulation. For delivery of exogenous insulin, it is not possible to deliver this insulin directly to the liver, thus it is typically injected subcutaneously via MDI or CSII. To better mimic the physiological delivery of insulin, 40 years ago, MiniMed, Inc. (Northridge, CA) introduced the first wearable small insulin pump, MiniMed 502, in 1983.[4](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr4-19322968251334993)From the inception of this device, Alfred Mann (1925-2016), then CEO of MiniMed, had a vision of creating an artificial pancreas (AP) system.[5](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr5-19322968251334993)\\n\\nNearly a quarter a century ago, CGMs were approved by the Food and Drug Administration (FDA) as adjunctive to SMBG; however, their accuracy was sub-optimal (Mean Absolute Relative Difference; MARD > 15%-20%).[6](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr6-19322968251334993), [7](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr7-19322968251334993) Over the next 10 years, CGMs became more accurate, smaller, and stand-alone.[6](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr6-19322968251334993)Eventually they were deemed by regulatory agencies to be safely used non-adjunctively. During a similar time frame, multiple pump companies (including Accu-Chek®, Animas®, Beta Bionics®, Disetronic®, Insulet®, MiniMed®, Sequel®, SOOIL®, Tandem®, and Ypsomed®) improved their insulin delivery devices.[8](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr8-19322968251334993), [9](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr9-19322968251334993) At the same time, most of them developed or licensed different algorithms to automatically activate or halt insulin delivery based on sensor glucose values.[5](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr5-19322968251334993), [10](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr10-19322968251334993) Multiple studies were conducted to demonstrate the safety of sensor-augmented pumps (SAPs) that could suspend insulin delivery (low glucose suspend \\\\[LGS\\\\], threshold suspend \\\\[TS\\\\]) after hypoglycemia, or in advance of predicted hypoglycemia (predictive LGS/TS systems).[11](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr11-19322968251334993)- [15](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr15-19322968251334993) These advances were followed by studies that included automatic delivery/stoppage of insulin based on sensor glucose concentrations in the clinic/research settings. The first automated insulin delivery (AID) system (Medtronic 670G) was approved by the FDA in 2016.[16](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr16-19322968251334993)Since then, many more AID systems have been approved by the FDA and/or European Medicine Agency (EMA) including Medtronic 780G, Tandem Control-IQ, Omnipod 5, iLet Bionic Pancreas, do-it-yourself (DIY) Loop, and CamAPS FX. In this review, we will focus on registration and real-life studies on these approved AID systems.\\n\\n## Methods\\n\\nWe conducted a systematic literature search using the MEDLINE (PubMed) database using keywords of FDA-approved AID, hybrid closed-loop (HCL) systems, and T1D. We only reported the studies with the longest duration and/or highest participant numbers. Randomized controlled trials (RCTs) were prioritized over single-arm studies; however, if we found no RCTs, then single-arm or cross-over trials were included. [Tables 1](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#table1-19322968251334993) and [2](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#table2-19322968251334993) show the summary of registration and real-life studies of AID systems respectively. [Figure 1](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#fig1-19322968251334993) illustrates each AID system with its own registration and real-life study results where available.\\n\\n### Table 1.\\n\\nRegistration Studies for FDA-approved AID Systems[a](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#table-fn1-19322968251334993).\\n\\n| AID System (author, publication year) | Study Design (type, duration, comparison group) | Study population (number, age of participants, baseline HbA1c) | Change in HbA1c in favor of AID (ΔHbA1c) | Change in TIR in favor of AID (ΔTIR) |\\n| --- | --- | --- | --- | --- |\\n| MiniMed 670G, Bergenstal et al, 2016 and Garg et al, 2017 | Single arm, three months, compared to run-in phase | N = 124, 14-75 years old, baseline HbA1c: 7.3% | −0.5% in adults −0.6% in adolescents | +5% in adults +6% in adolescents |\\n| MiniMed 670G, Garg et al, 2023 | RCT, six months, compared to CSII | N = 151, 2-80 years old, baseline HbA1c: 9.2% | −0.8% in baseline HbA1c ≥8% group −0.3% in baseline HbA1c <8 group | +12% for both groups combined (baseline HbA1c ≥8% and <8%) |\\n| MiniMed 780G, Carlson et al, 2022 | Single arm, three months, compared to run-in phase | N = 157, 14-75 years old, baseline HbA1c: 7.5% | −0.5% | +6% |\\n| MiniMed 780G, Bergenstal et al, 2021 | Cross over, two to three months, compared to MiniMed 670G | N = 113, 14-29 years old, baseline HbA1c: 7.9% | −0.2% | +4% |\\n| Tandem Control-IQ, Brown et al, 2019 | RCT, six months, compared to SAP | N = 168, 14-71 years old, baseline HbA1c: 7.4% | −0.33% | +11% |\\n| Tandem Control-IQ, Breton et al, 2020 | RCT, four months, compared to SAP | N = 101, 6-13 years old, baseline HbA1c: 7.7% | −0.4% | +11% |\\n| Tandem Control-IQ, Wadwa et al, 2023 | RCT, three months, compared to MDI/CSII with CGM | N = 102, two-six years old, baseline HbA1c: 7.5% | −0.42% | 12.4% |\\n| Tandem Control-IQ+ Kudva et al, 2025 | RCT (type 2 diabetes), three months, compared to MDI with CGM | N = 319, 18+ years old, baseline HbA1c: 8.2% | −0.9% in AID −2.3% in AID with baseline A1c ≥9% | +16% in AID |\\n| Omnipod 5, Brown et al, 2021 | Single arm, three months, compared to run-in phase | N = 240, 6-70 years old, Baseline HbA1c: 7.7% (children), 7.2% (adults) | −0.71% in children, −0.38% in adults | +16% in children, +9% in adults |\\n| Omnipod 5, Criego et al, 2024 | Single arm, 24 months, compared to run-in phase and end of three months (end of pivotal trial) | N = 224, 6-70 years old, baseline HbA1c: 7.7% (children), 7.2% (adults) | −0.5% from run-in phase, +0.2% from pivotal trial in children, −0.3% from run-in phase, +0.1% from pivotal trial in adults | +13.5% from run-in phase, −2.0% from pivotal trial in children, +9.2% from run-in phase, −0.9% from pivotal trial in adults |\\n| Omnipod 5, Sherr et al, 2022 | Single arm, 3.5 months, compared to run-in phase | N = 80, two to six years old, baseline HbA1c: 7.4% | −0.55% | +11% |\\n| Omnipod 5, DeSalvo et al, 2024 | Single arm, 24 months, compared to run-in phase and end of three months (end of pivotal trial) | N = 80, 2-5.9 years old, baseline HbA1c: 7.4% | −0.4% from run-in phase, +0.1% from pivotal trial | +10% from run-in phase, −0.9% from pivotal trial |\\n| Omnipod 5, Renard et al, 2024 | RCT, three months, compared to CSII with CGM | N = 194, 18-70 years old, baseline HbA1c: 8.5% | −0.6% | +18% |\\n| Omnipod 5, Davis et al, 2023 | T2D study, single-arm, two months, compared to run-in phase | N = 24, mean age 60.6, baseline HbA1c: 9.4% | −1.3% | +22% |\\n| Omnipod 5, Davis et al, 2025 | T2D study, single arm, 6.5 months, compared to run-in phase (extension to pilot study) | N = 22, mean age 61.2, baseline HbA1c: 9.4% | −1.6% | +22% |\\n| Omnipod 5, Pasquel et al, 2025 | T2D study, single-arm, three months, compared to run-in phase | N = 305, mean age 57, baseline HbA1c: 8.2% | −0.8% | +20% |\\n| iLet, Russell et al, 2022 | RCT, 3.5 months, compared to standard of care (MDI, CSII with CGM, and other HCL) | N = 219, 6-79 years old, baseline HbA1c: 7.9% | −0.5% | +11% |\\n| iLet, Beck et al, 2022 | RCT, RCT, 3.5 months, compared to standard of care (MDI, CSII with CGM, and other HCL) | N = 168, 18-83 years old, baseline HbA1c: 7.8% | −0.5% | +14% |\\n| iLet, Lynch et al, 2022 | Single arm, 3.5 months, extension study, compared to baseline | N = 90, 6-79 years old, baseline HbA1c: 7.7% | −0.6% | +12% |\\n| CamAPS FX, Tauschmann et al, 2018 | RCT, three months, compared to SAP | N = 86, >6 years old, baseline HbA1c: 8.3% | −0.36% | +11% |\\n| CamAPS FX, Ware et al, 2022 (Includes data using CamAPS FX) | RCT, six months, compared to CSII | N = 46, 6-18 years old, baseline HbA1c: 8.2% | −1.05% | +15% |\\n| CamAPS FX, Ware et al, 2022 | RCT, two to four months cross over, compared to SAP | N = 74, one to seven years old, baseline HbA1c: 7.3% | −0.4% | +8.7% |\\n\\n### Table 2.\\n\\nReal-life Studies for FDA-approved AID Systems[a](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#table-fn2-19322968251334993).\\n\\n| AID system (author, publication year) | Study design (type, duration, comparison group) | Study population (number, age of participants) | Change in HbA1c in favor of AID (ΔHbA1c) | Change in TIR in favor of AID (ΔTIR) |\\n| --- | --- | --- | --- | --- |\\n| Minimed 670G, Akturk et al, 2020 | Retrospective, six months, compared to baseline | N = 127, 21-68 years old | −0.4% | +11% |\\n| MiniMed 780G, Arrieta et al, 2022 | Retrospective, up to six months, compared to baseline | N = 12 870, age range not reported | No ΔHbA1c reported | No ΔTIR reported. Achieved 74% in all, 79% in optimal settings <15 years old, 76.5% in all, 81% in optimal settings >15 years old |\\n| MiniMed 780G, Choudhary et al, 2024 | Retrospective, up to 12 months, compared to baseline | N = 101 629, age range not reported | No ΔHbA1c reported | No ΔTIR reported. Achieved 72.3% in all, and 78.8% when optimal settings were consistently used. |\\n| Tandem Control-IQ, Breton et al, 2021 | Retrospective, 12 months, compared to PLGS | N = 9451, 6-91 years old | −0.3% ΔGMI | +10% |\\n| Tandem Control-IQ, Forlenza et al, 2022 | Retrospective, >30 days post HCL, compared to baseline | N = 5575, mean age 56.7 | −0.3% ΔGMI in Medicare patients, −0.4% ΔGMI in Medicaid patients | +11% in Medicare patients, +14% in Medicaid patients |\\n| Tandem Mobi, Akturk et al, 2024 | Retrospective, six weeks, compared to baseline | N = 1280, mean age 35.1 | −0.1% ΔGMI in prior-Control IQ patients Achieved 7% GMI in prior MDI and non-Tandem AID patients | +2.5% in prior-Control-IQ patients Achieved 72.1% in prior MDI patients, 72.5% in non-Tandem AID patients |\\n| Omnipod 5, Forlenza et al, 2024 | Retrospective, ≥90 days of data | N = 69 902, median age 30 | Achieved 7.3% GMI in children, 7.2% GMI in adults | Achieved 64.4% in children, 68.8% in adults, 67.7% for overall in optimal settings |\\n| CamAPS FX, Alwan et al, 2023 | Retrospective, >30 days of data | N = 1805, median age 30.2 | Achieved 6.9% GMI | Achieved 72.6% |\\n| Loop, Lum et al, 2021 | Prospective, six months, compared to baseline | N = 558, 1-71 years old | −0.3% | +7% |\\n\\n### Figure 1.\\n\\nTime in range (70-180 mg/dL) AID system from registration and real-life studies in people with type 1 diabetesa.\\n\\nAbbreviations: Reg, registration study; Rlife, real-life study.\\n\\naThis is not intended to be a direct comparison between systems (and is for illustrations purposes only). Change from baseline time in range was shown in darker colors for each system. In some real-life studies, change from baseline was not reported. Loop only had a real-life study and iLet only had a registration study. The AID system, population, and age range were different in the studies that were included. Inclusion criteria, duration, number of study visits and AID settings were different among studies. Not only highest reached TIR but also the increase in TIR from the baseline or comparator group for each AID system should be noted (darker color vs lighter color for each system). Compared to the baseline or comparator group, increases in TIR are as follows: 670G-Reg: +8.4%, 670G-RLife: +10.6%, 780G-Reg: +5.7%, Control IQ-Reg: +10%, Control IQ-RLife: +10%, OP5-Reg: +9.3%, Cam APS FX Reg: +13%, Loop-Rlife: +6%, ILet-Reg: +12%.\\n\\n## Medtronic MiniMed 670G/780G\\n\\nMiniMed 670G, the first AID system approved by the US FDA was evaluated in 124 adolescents and adults (14-75 years old) with T1D in a multicenter single-arm pivotal study.[17](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr17-19322968251334993), [18](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr18-19322968251334993) The primary aim of the study was to evaluate the safety of the HCL system in patients with T1D. The 670G system was used during a two-week run-in phase without HCL or Auto Mode (control period).[17](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr17-19322968251334993)Auto Mode was enabled during a three-month study phase.[17](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr17-19322968251334993)From the beginning of baseline run-in to the end of the study phase at three months, HbA1c levels decreased significantly from 7.7% ± 0.8% to 7.1% ± 0.6% and from 7.3% ± 0.9% to 6.8% ± 0.6% ( _P_ < .001) in adolescents and adults respectively.[17](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr17-19322968251334993)Time in range (TIR; 70-180 mg/dL) increased significantly from 60.4% ± 10.9% to 67.2% ± 8.2% in adolescents and from 68.8% ± 11.9% to 73.8% ± 8.4% in adults ( _P_ < .001).[17](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr17-19322968251334993)In another study, Minimed 670G was compared to CSII in a six-month RCT in 151 children, adolescents, and adults (2-80 years old) with T1D.[19](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr19-19322968251334993)Participants were grouped according to their baseline HbA1c levels. For participants with high baseline HbA1c (>8%), there was a significant mean \\\\[95% confidence interval (CI)\\\\] difference in HbA1c change in the HCL group (−0.8% \\\\[−1.1% to −0.4%\\\\], _P_ < .0001).[19](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr19-19322968251334993)For individuals with lower baseline HbA1c values (<8%), there was also a significant decrease in HbA1c of −0.3% \\\\[−0.5% to −0.1%\\\\] favoring HCL group ( _P_ < .0001).[19](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr19-19322968251334993)The TIR difference was 12% \\\\[8.8%-15.1%\\\\] in favor of 670G system.[19](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr19-19322968251334993)Time below range (TBR; <70 mg/dL) decreased significantly in both high HbA1c (−2.2% \\\\[−3.6% to −0.9%\\\\]) and low HbA1c groups (−4.9% \\\\[−6.3% to −3.6%\\\\]; _P_ < .0001 for both).[19](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr19-19322968251334993)\\n\\nIn a real-life study with Minimed 670G involving 127 adults with T1D (21-68 years old), TIR significantly increased from 59.5% ± 1.1% to 70.2% ± 1.2% and 70.1% ± 1.1% at three and six months, respectively ( _P_ < .001).[20](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr20-19322968251334993)Several patients discontinued using 670G due to the need for many calibrations and multiple alarms especially at night.[21](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr21-19322968251334993)\\n\\nMinimed 780G is commonly referred to as the advanced hybrid closed-loop system (AHCL) that gives auto-correction micro-boluses up to every five minutes when the maximum basal rate is reached and sensor glucose is above >120 mg/dL.[9](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr9-19322968251334993)The 780G system was evaluated in a three-month single-arm pivotal trial with 157 patients with T1D (14-75 years old).[22](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr22-19322968251334993)The 780G use was compared to a run-in phase in which patients used SAP +/- PLGS or Auto Basal enabled for ∼14 days.[22](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr22-19322968251334993)Compared to run-in phase, in the AHCL phase, HbA1c significantly decreased from 7.5% ± 0.8% to 7.0% ± 0.5%, TIR increased from 68.8% ± 10.5% to 74.5% ± 6.9%, and TBR decreased from 3.3% ± 2.9% to 2.3% ± 1.7% in three months ( _P_ < .001 for all).[22](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr22-19322968251334993)Using the glucose target setting of 100 mg/dL and an active insulin time of two hours, the TIR further increased to 78.8% without a change in the TBR. The system was evaluated in a cross-over trial of two 12-week comparisons of AHCL (780G) to Minimed 670G in 113 patients with T1D (14-29 years old).[23](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr23-19322968251334993)The mean HbA1c level was 7.9% ± 0.7% prior to randomization and significantly decreased to 7.6% ± 0.6% by the end of the study period in the 670G arm and 7.4% ± 0.8% in the AHCL arm ( _P_ = .03). TIR increased significantly from the baseline 57% ± 12% to 63% ± 8% in the 670G group and to 67% ± 8% in the AHCL group ( _P_ < .001).[23](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr23-19322968251334993)\\n\\nMost of the early real-life study data from 780G is available from Europe due to delay in FDA approval in the United States. In a large real-life study, data from 101 629 users (34 countries) was analyzed.[24](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr24-19322968251334993)The mean duration of the observation period post-AHCL initiation was 287 days.[24](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr24-19322968251334993)The mean TIR achieved was 72.3% and increased to 78.8% when optimal settings (glucose target of 100 mg/dL and active insulin time of two hours) were consistently used. The mean Glucose Management Indicator (GMI) was 7% without an increase in TBR.[24](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr24-19322968251334993)\\n\\nIn another real-life study with AHCL in the United States, individuals with T1D were grouped by age (≤15-year-old and >15-year-old).[25](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr25-19322968251334993)Those who were ≤ 15 years old (N = 3211) achieved a TIR of 73.9% ± 8.7%, and those who were >15 years old (N = 8874) achieved a TIR of 76.5% ± 9.4% after HCL initiation without an increase in TBR.[25](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr25-19322968251334993)Participants maintained time in AHCL > 94% at six months in both groups.[25](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr25-19322968251334993)In a subgroup analysis, patients using recommended settings achieved TIR of 78.9% and 81.3% in the ≤15 years old group and >15 years old group, respectively, with no significant difference in TBR.[25](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr25-19322968251334993)\\n\\n## Tandem t: slim X2 insulin pump/Tandem Mobi with Control-IQ+ Technology\\n\\nThe Tandem Control-IQ+ system algorithm works by automatically adjusting the programmed basal insulin delivery rate every five minutes based on 30-minute predicted glucose. In addition, it can also administer an autobolus when glucose levels are predicted to exceed 180 mg/dL in the next 30 minutes.[9](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr9-19322968251334993)A six-month RCT compared Control-IQ to SAP in 168 patients with T1D (14-71 years old).[26](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr26-19322968251334993)The two groups started with an identical mean HbA1c of 7.4%. The difference in HbA1c after six months was −0.33% (95% CI \\\\[−0.53 to −0.13\\\\]; _P_ = .001). TIR increased from 61% ± 17% at baseline to 71% ± 12% at six months in the Control-IQ group and remained unchanged at 59% ± 14% in the control group ( _P_ < .001).[26](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr26-19322968251334993)A 16-week RCT compared Control-IQ to SAP in 101 children with T1D (6-13 years old). TIR increased from 53% ± 17% at baseline to 67% ± 10% in the Control-IQ group and from 51% ± 16% to 55% ± 13% in the control group ( _P_ < .001).[27](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr27-19322968251334993)Extended use for 12 weeks[28](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr28-19322968251334993)and use for over three years in a similar cohort in France showed continued HbA1c reduction and TIR improvements.[29](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr29-19322968251334993)A 13-week RCT compared Control-IQ to the standard of care (MDI or CSII with CGM) in 102 children with T1D (two-six years old).[30](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr30-19322968251334993)The HbA1c difference at 13 weeks was −0.42% (Control-IQ 7.0% and control 7.5%, 95% CI \\\\[−0.62 to −0.22\\\\]; _P_ < .001). TIR increased from 56.7% ± 18.0% at baseline to 69.3% ± 11.1% after 13 weeks ( _P_ < .001). The standard care group had similar TIR at 13 weeks (54.9% ± 14.7% to 55.9% ± 12.6%).[30](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr30-19322968251334993)\\n\\nA meta-analysis of these three RCTs included 369 participants with T1D (2-72 years old) compared Control-IQ to various control groups all of whom, by design, were using CGM.[31](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr31-19322968251334993)In the Control-IQ group (n = 256), TIR increased from 57% ± 17% at baseline to 70% ± 11%, and in the control group (n = 113), TIR increased from 56% ± 15% at baseline to 57% ± 14% ( _P_ < .001).[31](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr31-19322968251334993)\\n\\nIn a real-life study in the United States with 9451 individuals (6-91 years old) with T1D using Control-IQ, TIR increased from 63.6% at baseline (IQR: 49.9%-75.6%) to 73.6% (IQR: 64.4%-81.8%) at 12 months.[32](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr32-19322968251334993)Notably, the increase in TIR was noted shortly after adoption of Control-IQ and was sustained over the one-year period of data that was analyzed. Another real-life study evaluated 4243 Medicare and 1332 Medicaid patients with T1D using Control-IQ.[33](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr33-19322968251334993)In Medicare patients, TIR increased from 64% at baseline to 74%, and GMI decreased from 7.3% to 7.0% ( _P_ < .0001).[33](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr33-19322968251334993)In Medicaid patients, TIR increased from 46% at baseline to 60%, and GMI decreased from 7.9% to 7.5% ( _P_ < .0001).[33](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr33-19322968251334993)\\n\\nTandem Mobi is the smallest durable tubed AID system that uses the Control-IQ algorithm and offers multiple wear options including an on body sleeve.[34](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr34-19322968251334993)In a six-week real-life study of Mobi with 1280 participants with T1D, prior MDI users (n = 235) achieved a median (interquartile range) GMI of 7.0% (6.6%-7.4%) and a TIR of 72.1% (62.5%-83.8%). Prior non-Tandem users (n = 208) achieved a GMI of 7.0% (6.6%-7.3%), and a TIR of 72.5% (65.0%-81.3%).[35](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr35-19322968251334993)Prior Tandem pump users (n = 837) had a non-significant decrease in GMI from 7.0% (6.7%-7.4%) to 6.9% (6.6%-7.3%), and TIR increased significantly from 70.5% (60.5%-79.0%) to 73.0% (63.8%-81.3%) ( _P_ < .001 for both).[35](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr35-19322968251334993)\\n\\nThe updated Control-IQ+ algorithm, now on the Tandem Mobi and t: slim X2 insulin pump, expands the weight and TDI range, and is cleared for use in children down to age two years of age with T1D, and for adults with type 2 diabetes (T2D). In a recent pivotal RCT in T2D,[36](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr36-19322968251334993)a total of 319 patients underwent randomization. Glycated hemoglobin levels decreased by 0.9 percentage points (from 8.2% ± 1.4% at baseline to 7.3% ± 0.9% at week 13) in the AID group and by 0.3 percentage points (from 8.1% ± 1.2% to 7.7% ± 1.1%) in the control group (mean adjusted difference, −0.6 percentage points; 95% CI \\\\[−0.8 to −0.4\\\\]; _P_ < .001). The frequency of CGM-measured hypoglycemia was low in both groups.\\n\\n## Omnipod 5\\n\\nOmnipod 5 is the only FDA-cleared tubeless AID system in the United States that adjusts insulin delivery every five minutes based on the pre-set target glucose (110-150 mg/dL), which can be varied by time of the day.[34](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr34-19322968251334993)OP5 was evaluated in a three-month, single-arm prospective study with 240 participants with T1D (6-70 years old).[37](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr37-19322968251334993)HbA1c decreased in children by 0.71% (7.67% ± 0.95% to 6.99% ± 0.63%) and in adults by 0.38% (7.16% ± 0.86% to 6.78% ± 0.68%, _P_ < .0001 for both).[37](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr37-19322968251334993)TIR increased from standard therapy by 15.6% ± 11.5% in children and 9.3% ± 11.8% in adults ( _P_ < .0001 for both).[37](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr37-19322968251334993)In an extension study (to a three-month initial study plus up to an additional 21 months for a total of up to 24 months), 224 patients (95% of the participants) with T1D opted to continue Omnipod 5.[38](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr38-19322968251334993)“The reduction in HbA1c observed in the pivotal trial was maintained at 7.2% ± 0.7% in children and 6.9% ± 0.6% in adolescents and adults after 15 months ( _P_ < .0001).[38](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr38-19322968251334993)The increase in TIR observed in the pivotal trial was maintained to 65.9% ± 8.9% in children and 72.9% ± 11.3% in adolescents and adults during the extension phase ( _P_ < .0001).[38](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr38-19322968251334993)Another single-arm prospective study evaluated Omnipod 5 in 80 young children (two-six years old) with T1D in 13 weeks.[39](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr39-19322968251334993)HbA1c decreased by 0.55% and TIR increased by 10.9%, ( _P_ < .0001 for both).[39](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr39-19322968251334993)In an extension study that lasted up to two years with the initial three-month pivotal trial, 80 participants (100% of the participants) opted to continue Omnipod 5.[40](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr40-19322968251334993)The reduction in HbA1c observed in the pivotal trial was maintained to 7.0% ± 0.7% after 15 months ( _P_ < .0001). The increase in TIR observed in the pivotal trial was maintained to 67.2% ± 9.3% during the extension phase ( _P_ < .0001). OP5 was compared to CSII with CGM (open-loop) in 194 adults with T1D (18-70 years old) in a 13-week RCT.[41](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr41-19322968251334993)There was a greater decrease in HbA1c from baseline compared with the control group (−1.24% ± 0.75% vs −0.68% ± 0.93%, respectively; _P_ < .0001), and TIR increased from 43.9% ± 14.0% baseline to 61.2% ± 11.2% in the intervention group and from 41.3% ± 14.6% to 43.8% ± 14.5% in the control group in 13 weeks, with an adjusted mean difference of 17.5% (95% CI \\\\[14.0%-21.1%\\\\]; _P_ < .0001).[41](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr41-19322968251334993)\\n\\nA real-world study with Omnipod 5 involving 69 902 individuals with T1D showed TIR of 68.8%, 61.3%, and 53.6% for users with glucose targets of 110, 120, and 130 to 150 mg/dL, respectively.[42](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr42-19322968251334993)For the group with a glucose target of 110 mg/dL, the median TIR was 65% in children and adolescents (2-17 years) and 69.9% in adults (≥18 years).[42](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr42-19322968251334993)Users with Medicaid insurance (n = 1064; median age 21 years) and Medicare insurance (n = 1503; median age 67 years) using target glucose of 110 mg/dL had TIR of 62.2% and 72.3%, respectively, after six months.[42](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr42-19322968251334993)\\n\\nOmnipod 5 recently received FDA clearance for use in people with insulin-requiring T2D. OP5 was evaluated in an eight-week small pilot study in 24 people with T2D.[43](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr43-19322968251334993)Prior to enrollment, participants had baseline HbA1c of ≥ 8% and were using either basal-only or basal-bolus insulin injections, with or without CGM.[43](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr43-19322968251334993)HbA1c decreased by 1.3% ± 0.7% and TIR increased by 21.9% ± 15.2% ( _P_ < .0001 for both).[43](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr43-19322968251334993)In an extension phase of this study, 22 participants continued using Omnipod 5 for another 26 weeks.[44](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr44-19322968251334993)HbA1c decreased by 1.6% ± 1.2% and TIR increased by 22.4% ± 19.2% ( _P_ < .0001, for both) at the end of the extension phase.[44](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr44-19322968251334993)The SECURE-T2D trial evaluated OP5 in 305 participants with T2D using basal-only insulin injections, MDI, or CSII. After 14 days of standard therapy, the study participants used Omnipod 5 for 13 weeks. HbA1c decreased from 8.2% to 7.4% and TIR increased from 45% to 66%.[45](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr45-19322968251334993)In patients with T2D there was a significant decrease in the insulin dose at the end of the study.\\n\\n## iLet Bionic Pancreas\\n\\nThe iLet Bionic Pancreas is an AID system with three adaptive algorithms that collectively automate 100% of all insulin doses, and do not require carbohydrate counting by the user. The system is initialized with only the user’s weight. The user only needs to announce the type of meal as “Breakfast,” “Lunch,” or “Dinner,” and the size of the meals as “Usual for me,” “More,” or “Less” than usual.[34](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr34-19322968251334993)In a 13-week pivotal RCT, supported by the NIDDK, iLet (n = 219) using insulin aspart or insulin lispro was compared to standard of care (n = 107) (including other HCL systems) in participants with T1D (6-79 years old).[46](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr46-19322968251334993)HbA1c decreased from 7.9% at baseline to 7.3% in the iLet group at 13 weeks however it did not change (7.7% at both time points) in the standard care group.[46](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr46-19322968251334993)The mean baseline adjusted between-group difference in the HbA1c at 13 weeks was −0.5% (95% CI \\\\[−0.6 to −0.3\\\\]; _P_ < .001).[46](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr46-19322968251334993)The baseline-adjusted between-group difference was −0.5% separately for both children 6 to 17 years old (95% CI \\\\[−0.7 to −0.2\\\\]; _P_ < .001) and adults 18 years and older (95% CI \\\\[−0.6 to −0.3\\\\]; _P_ < .001).[46](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr46-19322968251334993)- [48](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr48-19322968251334993) The baseline-adjusted between-group difference in TIR was +11% (95% CI \\\\[9-13\\\\]; _P_ < .001), with TIR increasing from a baseline of 51% ± 20% in both groups to 65% ± 9% in the iLet group and 54% ± 17% in the standard-care group. The baseline-adjusted between-group difference in TIR was +10% (to 60%) over 13 weeks in the iLet group in children 6 to 17 years old (95% CI \\\\[+7 to +13\\\\]; _P_ < .001) and +11% (to 69%) over 13 weeks in the iLet group in adults aged 18 years and older (95% CI \\\\[+8 to +13\\\\]; _P_ < .001).[46](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr46-19322968251334993)- [48](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr48-19322968251334993) In addition, there was no increase in hypoglycemia (% <54 mg/dL). In a single-arm extension study for 13 weeks immediately following the RCT, 90 of 107 patients in the standard of care group used the iLet system.[49](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr49-19322968251334993)HbA1c decreased from 7.7% ± 1.0% at baseline to 7.1% ± 0.6% at 13 weeks (mean change –0.55% ± 0.72%, _P_ < .001), TIR increased by 12.0% ± 12.5% (from 53% ± 17% to 65% ± 9%, _P_ < .001).[49](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr49-19322968251334993)Concurrently in the pivotal RCT, 114 adults 18 years and older used the iLet with fast-acting insulin aspart and had glycemic improvement similar to that of the iLet with insulin aspart or insulin lispro. The baseline-adjusted between-group difference in HbA1c vs standard of care was −0.5% (95% CI \\\\[−0.7 to −0.3\\\\]; _P_ < .001).[46](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr46-19322968251334993)- [48](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr48-19322968251334993) The baseline-adjusted between-group difference in TIR was +14% (to 71%) over 13 weeks in the iLet group with fast-acting insulin aspart (95% CI \\\\[+11 to +17\\\\]; _P_ < .001). To date, no real-life data has been published on the use of this system.\\n\\n## CamAPS FX\\n\\nThe CamAPS FX algorithm was recently approved by the FDA, but currently it is not yet commercially available in the United States. The glucose target is customizable from 80 to 198 mg/dL.[9](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr9-19322968251334993)It is the only FDA-approved AID system for use during pregnancy in the United States.[50](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr50-19322968251334993)- [52](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr52-19322968251334993) In a three-month RCT, the CamAPS FX algorithm was compared to SAP in 86 participants with T1D (>6 years old) with elevated HbA1c.[53](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr53-19322968251334993)HbA1c decreased from 8% ± 0.6% at baseline to 7.4% ± 0.6% in the CamAPS FX group and from 7.8% ± 0.6% at baseline to 7.7% ± 0.5% in the SAP group (mean difference in change 0.36%, 95% CI \\\\[0.19-0.53\\\\]; _P_ < .0001).[53](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr53-19322968251334993)TIR was higher in the CamAPS FX group (65% ± 8%) compared to the SAP group (54% ± 9%) at the end of the study.[53](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr53-19322968251334993)Another study compared closed loop insulin delivery to usual care with CSII in a six-month RCT. In 46 children with T1D (6-18 years old) with elevated baseline HbA1c, using CamAPS FX[54](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr54-19322968251334993)HbA1c decreased from 7.9% ± 0.9% at baseline to 6.8% ± 0.5% in the CamAPS FX group and from 8.0% ± 0.6% at baseline to 7.9% ± 0.8% in the SAP group (mean difference in change 1.05%, 95% CI \\\\[0.04-0.59\\\\]; _P_ = .02).[54](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr54-19322968251334993)TIR was higher in the CamAPS FX group (63% ± 9%) compared to the SAP group (49% ± 13%) at the end of the study (15%, 95% CI \\\\[8-22.1\\\\]; _P_ = .0001)[54](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr54-19322968251334993)In a two 16 weeks cross over RCT with 74 children (one-seven years old), CamAPS FX was compared to SAP.[55](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr55-19322968251334993)TIR was 8.7% (95% CI \\\\[7.4-9.9\\\\]) higher, HbA1c was 0.4% (95% CI \\\\[−0.5 to −0.3\\\\]) lower in CamAPS FX group.[55](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr55-19322968251334993)\\n\\nIn a real-life study with 1805 participants with T1D, TIR was 72.6% ± 11.5% for all users and increased by age from 66.9% ± 11.7% for users ≤6 years old to 81.8% ± 8.7% for users ≥65 years old.[56](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr56-19322968251334993)\\n\\n## Loop\\n\\nOpen-source automated insulin dosing algorithms (also known as DIY) run on a Smartphone and are largely designed, maintained, and curated by people with diabetes and their loved ones.[57](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr57-19322968251334993)There are two main available algorithms, the OpenAPS algorithm and the Loop algorithm. Both have been implemented on a variety of platforms. Tidepool Loop, a variant of Loop was recently approved by the FDA in the United States. A prospective real-world observational study was conducted with 558 participants with T1D (1-71 years old) who initiated Loop and provided data for six months.[58](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr58-19322968251334993)HbA1c decreased from 6.8% ± 1.0% at baseline to 6.5% ± 0.8% at six months (mean difference 0.33%, 95% CI \\\\[0.26-0.4\\\\], _P_ < .001).[58](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr58-19322968251334993)TIR increased from 67% ± 16% at baseline to 73% ± 13% at six months (mean difference 6.6%, 95% CI \\\\[5.9%-7.4%\\\\]; _P_ < .001).[58](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr58-19322968251334993)\\n\\n## Discussion\\n\\nIn the last three decades, several advances in therapies including newer insulin analogs, and technologies like CGMs, CSII, and AID systems have facilitated achievement of more targeted glucose levels for many individuals with T1D and have simultaneously reduced the burden of this chronic medical condition. Publications prior to widespread adoption of more advanced diabetes technologies have demonstrated individuals with T1D have only a decade less life because of increased mortality.[59](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr59-19322968251334993), [60](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr60-19322968251334993) Whether these gaps will be closed by technological advances remains to be seen. In addition, T1D prevalence is increasing, with the diagnosis being made more frequently in adults.[61](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr61-19322968251334993)\\n\\nUnfortunately, today nearly two-third of the patients in the United States with T1D are overweight or obese.[62](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr62-19322968251334993), [63](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr63-19322968251334993) Weight gain was first reported in the IIT group > 30 years ago from the DCCT trial.[3](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr3-19322968251334993)Excessive weight gain results in features of T2D, commonly referred to as double-diabetes. Excessive weight gain adds risk for insulin resistance, cardiovascular disease, and DKD.[64](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr64-19322968251334993)The exact reasons for weight gain in patients with T1D are speculative (potentially including lifestyle changes, higher insulin dose secondary to IIT, etc.).[62](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr62-19322968251334993)Unlike for T2D, there is no effective adjunctive therapy besides insulin approved by the FDA for people with T1D.\\n\\nA recent study reported an exponential increase in the off-label use of sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonist (GLP-1RA) analogs in patients with T1D, especially those with cardiovascular disease and DKD.[65](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr65-19322968251334993)Several recent off-label uses of GLP-1RA and SGLT2 inhibitors in people with T1D have shown promising results in improving glucose control and cardio-renal biomarkers.[66](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr66-19322968251334993)- [71](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr71-19322968251334993) A small study even reported using GLP-1RA in new-onset antibody positive patients with T1D.[72](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr72-19322968251334993)While a highly selected group, these individuals were noted after one year of GLP-1RA therapy showed significant reduction and/or elimination of the need for prandial and even basal insulin.[72](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr72-19322968251334993)Studies to quantify how these agents may be used are critical,[73](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr73-19322968251334993)however, we do not endorse stopping insulin at any time in people with T1D.\\n\\nUse of SGLT2 inhibitors in patients with T1D from several registration studies have reported higher risk of diabetic ketoacidosis (DKA) especially in those on insulin pumps and thus none of them have been approved by the FDA for people with T1D due to safety concerns.[66](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr66-19322968251334993), [74](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr74-19322968251334993)- [76](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr76-19322968251334993) Unless proper mitigation of DKA can be shown with the use of SGLT2 inhibitors, the regulators in the United States are unlikely to approve their use for people with T1D. Newer technologies like continuous ketone monitors may be used in addition to DKA mitigation plans to support an indication in the T1D population.[77](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr77-19322968251334993), [78](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr78-19322968251334993) While minimal weight loss (2%-4%) was reported with SGLT2 inhibitors in participants with T1D from registration studies, whether these agents could afford other cardio-protective and renal protective benefits demonstrated in those with T2D remains to be seen.[66](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr66-19322968251334993)\\n\\nThe use of newer weekly GLP-1RAs in patients with T1D has been reported to cause significant weight loss ranging from 25 to 60 pounds (15%-25% of baseline body weight) over one to two years.[67](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr67-19322968251334993)- [70](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr70-19322968251334993) The expected weight loss from GLP-1RA results in significant changes in insulin dose (prandial and basal) and thus increasing the risk of both hypoglycemia and DKA; however, to date, small retrospective study results have been reassuring.[67](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr67-19322968251334993), [68](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr68-19322968251334993), [70](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr70-19322968251334993), [79](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr79-19322968251334993)- [81](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr81-19322968251334993) Because of a differential decrease in prandial vs basal insulin dose, it is possible that AID algorithms may need to be tweaked if newer GLP-1RAs are used in people with T1D.[73](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr73-19322968251334993), [82](http://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#bibr82-19322968251334993)\\n\\n## Summary and Conclusions\\n\\nThe benefits of AID systems in registration and real-life studies have been well documented in the past decade. In registration studies, study designs varied from single arm to RCT studies. Primary endpoints in most of the studies included changes in HbA1c or GMI and TIR with secondary endpoints of TBR and other CGM metrics. The lack of a control group in some of the single-arm studies limits the ability to compare the outcomes observed with RCTs.\\n\\nReal-life study designs were more complex with varying inclusion criteria and duration and mostly done by the sponsoring companies using their databases. This also limits the comparisons within different AID systems. However, most real-life studies confirmed the registration study data as they relate to improvement in glucose control as measured by (HbA1c, TIR). Real-life studies are important to learn about lived experiences and challenges with AID systems and to determine the effectiveness of a new technology once the constraints of inclusion and exclusion criteria are removed as are the guardrails of the frequent contacts and support provided in the clinical trials.\\n\\nPatient selection, training, and education are the mainstay to achieve optimal diabetes management while using AID systems. In addition to breakthroughs in glycemic control, AID systems improve quality of life, decrease diabetes burden, and fear of hypoglycemia. Moving forward, toward fully automated AID systems, new-generation AIDs will integrate not only CGM data but also other physiological inputs that may alter glycemia. Some of the future directions for AID systems include novel algorithms (neural network), no meal announcements, alternative routes of insulin delivery, and faster acting insulins.\\n\\nThe important issues of wider access and acceptability and their use include challenges in implementation, lack of support system, and cost. Because of increasing weight in people with T1D, the role of adjunctive therapies like GLP-1RAs and SGLT2 inhibitors needs to be evaluated for their safety and efficacy in people with T1D. Many of the AID system studies in the last decade were supported by grants from NIDDK. The critical nature of the funding provided by the NIDDK and the commitment of the program scientists, investigators, study participants, and industry to collaborate to reach this first stage in the age of automation has been essential. Continued partnerships will drive the field forward.\\n\\n## Footnotes\\n\\n**Abbreviations:** DCCT, diabetes control and complications trial; NIDDK, National Institute of Diabetes and Digestive and Kidney Diseases; SMBG, self-monitoring of blood glucose; HbA1c, glycosylated hemoglobin (%); MARD, mean absolute relative difference; DKD, diabetic kidney disease; CVD, cardiovascular disease; T2D, type 2 diabetes; T1D, type 1 diabetes; ADA, American Diabetes Association; EASD, European Association for the Study of Diabetes; GLP-1RA, glucagon-like peptide-1 receptor agonists; SGLT2, sodium-glucose cotransporter-2; FDA, Food and Drug Administration; DKA, diabetic ketoacidosis; CGM, continuous glucose monitoring; CKM, continuous ketone monitoring; LGS, low glucose suspend; TS, threshold suspend; AID, automatic insulin delivery system; HCL, hybrid closed-loop system; IIT, intensive insulin treatment; CSII, continuous sub-cutaneous insulin infusion; DIY, do it yourself; EMA, European Medicine Agency; SAPT, sensor-augmented pump therapy; OB, obesity; OW, overweight; GMI, glucose management indicator.\\n\\n**Author Contributions:** All authors contributed equally to this manuscript.\\n\\nThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: H.K.A. reports research support and honorarium through the University of Colorado from Medtronic, Dexcom, Roche, and Tandem Diabetes Care. S.K.G. has served on Advisory Boards and received consulting fees from Medtronic, Eli Lilly, and Novo Nordisk. Through the University of Colorado, he has received research grants from Eli Lilly, Medtronic, Dario, Lexicon, NCI, and Dexcom. B.P.K. reports research grants handled by the University of Virginia from the National Institutes of Health, Novo Nordisk, Dexcom, and Tandem Diabetes Care. In addition, B.P.K. has a number of patents with royalties paid to Dexcom and Novo Nordisk, outside of the submitted study. R.V. is a full-time employee of Medtronic Diabetes. R.H. reports having received speaker honoraria from Eli Lilly, Dexcom, and Novo Nordisk; receiving license fees from Braun; receiving consultancy fees from Abbott Diabetes Care; patents related to closed-loop; and being director at CamDiab. R.W.B. reports no personal financial disclosures but reports that his institution has received funding on his behalf as follows: grant funding, study supplies, and consulting fees from Insulet, Tandem Diabetes Care, and Beta Bionics; grant funding and study supplies from Dexcom; grant funding from Bigfoot Biomedical; study supplies from Medtronic, Ascencia, and Roche; consulting fees and study supplies from Eli Lilly and Novo Nordisk; and consulting fees from embecta, Sequel Med Tech, Vertex, Hagar, Ypsomed, Sanofi, and Zucara. M.D.B. reports research grants handled by the University of Virginia from the National Institutes of Health, Novo Nordisk, and Dexcom, and nonfinancial research support from Tandem Diabetes Care, outside of the submitted study. In addition, M.D.B. has a number of patents with royalties licensed to Dexcom, Sanofi, Tandem Diabetes Care, and Novo Nordisk, outside of the submitted study. M.D.B. finally reports consulting/speakership activities with Dexcom, Tandem Diabetes Care, Roche, Portal Insulin LLC, BoydSense, and Vertex. S.A.B. has received research support through her institution from Dexcom, Insulet, Roche Diagnostics, Tandem Diabetes Care, and Tolerion and has participated on a data monitoring board for MannKind. J.L.S. has received grants or contracts from Breakthrough T1D, the National Institute of Diabetes and Digestive and Kidney Diseases, Jaeb Center for Health Research, Insulet, Medtronic, Provention Bio, and Abbott paid to her institution; has received consulting fees from Abbott; has received payment or honoraria from Insulet, Medtronic Diabetes, and Zealand Pharma; has participated in advisory boards for Bigfoot Biomedical, Cecelia Health, Insulet, Medtronic Diabetes, Novo Nordisk, and Vertex Pharmaceuticals; and reports owning stock/stock options of StartUp Health T1D Moonshot. R.M.B. has received research support, has acted as a consultant, or has been on the scientific advisory board for Abbott Diabetes Care, Ascensia, CeQur, DexCom, Eli Lilly, Embecta, Hygieia, Insulet, Medscape, Medtronic, Novo Nordisk, Onduo, Roche Diabetes Care, Tandem Diabetes Care, Sanofi, United Healthcare, Vertex Pharmaceuticals, and Zealand Pharma. D.C.K is consultant FT for Afon, Glucotrack, Lifecare, Novo, Samsung, Thirdwayv, and Tingo.\\n\\n**Funding:** The author(s) received no financial support for the research, authorship, and/or publication of this article.\\n\\n## References\\n\\n- 1.\\nGarg SK, Rewers AH, Akturk HK. Ever-increasing insulin-requiring patients globally. Diabetes Technol Ther. 2018;20(S2):S21-S24. doi: 10.1089/dia.2018.0101 \\\\[ [DOI](https://doi.org/10.1089/dia.2018.0101)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/29873518/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=Ever-increasing%20insulin-requiring%20patients%20globally&author=SK%20Garg&author=AH%20Rewers&author=HK%20Akturk&volume=20&issue=S2&publication_year=2018&pmid=29873518&doi=10.1089/dia.2018.0101&)\\\\]\\n- 2.\\nNathan DM; DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: Overview. Diabetes Care. 2014;37(1):9-16. doi: 10.2337/dc13-2112\\n\\\\[ [DOI](https://doi.org/10.2337/dc13-2112)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC3867999/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/24356592/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&title=The%20diabetes%20control%20and%20complications%20trial/epidemiology%20of%20diabetes%20interventions%20and%20complications%20study%20at%2030%20years:%20Overview&volume=37&issue=1&publication_year=2014&pages=9-16&pmid=24356592&doi=10.2337/dc13-2112&)\\\\]\\n- 3.\\nNathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986. doi: 10.1056/nejm199309303291401\\n\\\\[ [DOI](https://doi.org/10.1056/nejm199309303291401)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/8366922/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=The%20effect%20of%20intensive%20treatment%20of%20diabetes%20on%20the%20development%20and%20progression%20of%20long-term%20complications%20in%20insulin-dependent%20diabetes%20mellitus&author=DM%20Nathan&author=S%20Genuth&author=J%20Lachin&volume=329&issue=14&publication_year=1993&pages=977-986&pmid=8366922&doi=10.1056/nejm199309303291401&)\\\\]\\n- 4.\\nAlsaleh FM, Smith FJ, Keady S, Taylor KM. Insulin pumps: From inception to the present and toward the future. J Clin Pharm Ther. 2010;35(2):127-138. doi: 10.1111/j.1365-2710.2009.01048.x\\n\\\\[ [DOI](https://doi.org/10.1111/j.1365-2710.2009.01048.x)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/20456732/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Pharm%20Ther&title=Insulin%20pumps:%20From%20inception%20to%20the%20present%20and%20toward%20the%20future&author=FM%20Alsaleh&author=FJ%20Smith&author=S%20Keady&author=KM%20Taylor&volume=35&issue=2&publication_year=2010&pages=127-138&pmid=20456732&doi=10.1111/j.1365-2710.2009.01048.x&)\\\\]\\n- 5.\\nAlmurashi AM, Rodriguez E, Garg SK. Emerging diabetes technologies: Continuous glucose monitors/artificial pancreases. J Indian Inst Sci. 2023;28:1-26. doi: 10.1007/s41745-022-00348-3 \\\\[ [DOI](https://doi.org/10.1007/s41745-022-00348-3)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC10043869/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/37362851/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Indian%20Inst%20Sci&title=Emerging%20diabetes%20technologies:%20Continuous%20glucose%20monitors/artificial%20pancreases&author=AM%20Almurashi&author=E%20Rodriguez&author=SK%20Garg&volume=28&publication_year=2023&pages=1-26&pmid=37362851&doi=10.1007/s41745-022-00348-3&)\\\\]\\n- 6.\\nGarg SK, Akturk HK. The future of continuous glucose monitoring. Diabetes Technol Ther. 2017;19(S3):S1-S2. doi: 10.1089/dia.2017.0097 \\\\[ [DOI](https://doi.org/10.1089/dia.2017.0097)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC5467094/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/28585872/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=The%20future%20of%20continuous%20glucose%20monitoring&author=SK%20Garg&author=HK%20Akturk&volume=19&issue=S3&publication_year=2017&pmid=28585872&doi=10.1089/dia.2017.0097&)\\\\]\\n- 7.\\nGarg SK. Past, present, and future of continuous glucose monitors. Diabetes Technol Ther. 2023;25(S3):S1-S4. doi: 10.1089/dia.2023.0041 \\\\[ [DOI](https://doi.org/10.1089/dia.2023.0041)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/36749142/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=Past,%20present,%20and%20future%20of%20continuous%20glucose%20monitors&author=SK%20Garg&volume=25&issue=S3&publication_year=2023&pmid=36749142&doi=10.1089/dia.2023.0041&)\\\\]\\n- 8.\\nKesavadev J, Saboo B, Krishna MB, Krishnan G. Evolution of insulin delivery devices: From syringes, pens, and pumps to DIY artificial pancreas. Diabetes Ther. 2020;11(6):1251-1269. doi: 10.1007/s13300-020-00831-z\\n\\\\[ [DOI](https://doi.org/10.1007/s13300-020-00831-z)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC7261311/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/32410184/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Ther&title=Evolution%20of%20insulin%20delivery%20devices:%20From%20syringes,%20pens,%20and%20pumps%20to%20DIY%20artificial%20pancreas&author=J%20Kesavadev&author=B%20Saboo&author=MB%20Krishna&author=G%20Krishnan&volume=11&issue=6&publication_year=2020&pages=1251-1269&pmid=32410184&doi=10.1007/s13300-020-00831-z&)\\\\]\\n- 9.\\nAkturk HK, Bindal A. Advances in diabetes technology within the digital diabetes ecosystem. J Manag Care Spec Pharm. 2024;30(10-B Suppl):S7-S20. doi: 10.18553/jmcp.2024.30.10-b.s7 \\\\[ [DOI](https://doi.org/10.18553/jmcp.2024.30.10-b.s7)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC11443980/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/39347970/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Manag%20Care%20Spec%20Pharm&title=Advances%20in%20diabetes%20technology%20within%20the%20digital%20diabetes%20ecosystem&author=HK%20Akturk&author=A%20Bindal&volume=30&issue=10-B%20Suppl&publication_year=2024&pmid=39347970&doi=10.18553/jmcp.2024.30.10-b.s7&)\\\\]\\n- 10.\\nWeaver KW, Hirsch IB. The hybrid closed-loop system: Evolution and practical applications. Diabetes Technol Ther. 2018;20(S2):S216-S223. doi: 10.1089/dia.2018.0091 \\\\[ [DOI](https://doi.org/10.1089/dia.2018.0091)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/29873517/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=The%20hybrid%20closed-loop%20system:%20Evolution%20and%20practical%20applications&author=KW%20Weaver&author=IB%20Hirsch&volume=20&issue=S2&publication_year=2018&pmid=29873517&doi=10.1089/dia.2018.0091&)\\\\]\\n- 11.\\nAgrawal P, Welsh JB, Kannard B, et al. Usage and effectiveness of the low glucose suspend feature of the Medtronic paradigm VEO insulin pump. J Diabetes Sci Technol. 2011;5(5):1137-1141. doi: 10.1177/193229681100500514\\n\\\\[ [DOI](https://doi.org/10.1177/193229681100500514)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC3208869/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/22027306/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Diabetes%20Sci%20Technol&title=Usage%20and%20effectiveness%20of%20the%20low%20glucose%20suspend%20feature%20of%20the%20Medtronic%20paradigm%20VEO%20insulin%20pump&author=P%20Agrawal&author=JB%20Welsh&author=B%20Kannard&volume=5&issue=5&publication_year=2011&pages=1137-1141&pmid=22027306&doi=10.1177/193229681100500514&)\\\\]\\n- 12.\\nMastrototaro J, Lee S. The integrated minimed paradigm real-time insulin pump and glucose monitoring system: Implications for improved patient outcomes. Diabetes Technol Ther\\n2009;11(Suppl. 1):S37-S43. doi: 10.1089/dia.2008.0134 \\\\[ [DOI](https://doi.org/10.1089/dia.2008.0134)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/19469676/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=The%20integrated%20minimed%20paradigm%20real-time%20insulin%20pump%20and%20glucose%20monitoring%20system:%20Implications%20for%20improved%20patient%20outcomes&author=J%20Mastrototaro&author=S%20Lee&volume=11&issue=Suppl.%201&publication_year=2009&pmid=19469676&doi=10.1089/dia.2008.0134&)\\\\]\\n- 13.MiniMed 530G: An insulin pump with low-glucose suspend automation. JAMA. 2015;313(15):1568. doi: 10.1001/jama.2015.2917\\n\\\\[ [DOI](https://doi.org/10.1001/jama.2015.2917)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/25898056/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=JAMA&title=MiniMed%20530G:%20An%20insulin%20pump%20with%20low-glucose%20suspend%20automation&volume=313&issue=15&publication_year=2015&pages=1568&pmid=25898056&doi=10.1001/jama.2015.2917&)\\\\]\\n- 14.\\nGarg S, Brazg RL, Bailey TS, et al. Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: The in-clinic aspire study. Diabetes Technol Ther. 2012;14(3):205-209. doi: 10.1089/dia.2011.0292\\n\\\\[ [DOI](https://doi.org/10.1089/dia.2011.0292)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/22316089/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=Reduction%20in%20duration%20of%20hypoglycemia%20by%20automatic%20suspension%20of%20insulin%20delivery:%20The%20in-clinic%20aspire%20study&author=S%20Garg&author=RL%20Brazg&author=TS%20Bailey&volume=14&issue=3&publication_year=2012&pages=205-209&pmid=22316089&doi=10.1089/dia.2011.0292&)\\\\]\\n- 15.\\nBergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013;369(3):224-232. doi: 10.1056/NEJMoa1303576\\n\\\\[ [DOI](https://doi.org/10.1056/NEJMoa1303576)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/23789889/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Threshold-based%20insulin-pump%20interruption%20for%20reduction%20of%20hypoglycemia&author=RM%20Bergenstal&author=DC%20Klonoff&author=SK%20Garg&volume=369&issue=3&publication_year=2013&pages=224-232&pmid=23789889&doi=10.1056/NEJMoa1303576&)\\\\]\\n- 16.\\nFDA approves first automated insulin delivery device for type 1 diabetes. [https://www.fda.gov/news-events/press-announcements/fda-approves-first-automated-insulin-delivery-device-type-1-diabetes](https://www.fda.gov/news-events/press-announcements/fda-approves-first-automated-insulin-delivery-device-type-1-diabetes) \\\\[ [DOI](https://doi.org/10.1001/jama.2024.19129)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/39302654/)\\\\]\\n- 17.\\nGarg SK, Weinzimer SA, Tamborlane WV, et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther. 2017;19(3):155-163. doi: 10.1089/dia.2016.0421\\n\\\\[ [DOI](https://doi.org/10.1089/dia.2016.0421)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC5359676/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/28134564/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=Glucose%20outcomes%20with%20the%20in-home%20use%20of%20a%20hybrid%20closed-loop%20insulin%20delivery%20system%20in%20adolescents%20and%20adults%20with%20type%201%20diabetes&author=SK%20Garg&author=SA%20Weinzimer&author=WV%20Tamborlane&volume=19&issue=3&publication_year=2017&pages=155-163&pmid=28134564&doi=10.1089/dia.2016.0421&)\\\\]\\n- 18.\\nBergenstal RM, Garg S, Weinzimer SA, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA. 2016;316(13):1407-1408. doi: 10.1001/jama.2016.11708\\n\\\\[ [DOI](https://doi.org/10.1001/jama.2016.11708)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/27629148/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=JAMA&title=Safety%20of%20a%20hybrid%20closed-loop%20insulin%20delivery%20system%20in%20patients%20with%20type%201%20diabetes&author=RM%20Bergenstal&author=S%20Garg&author=SA%20Weinzimer&volume=316&issue=13&publication_year=2016&pages=1407-1408&pmid=27629148&doi=10.1001/jama.2016.11708&)\\\\]\\n- 19.\\nGarg SK, Grunberger G, Weinstock R, et al. Improved glycemia with hybrid closed-loop versus continuous subcutaneous insulin infusion therapy: Results from a randomized controlled trial. Diabetes Technol Ther. 2023;25(1):1-12. doi: 10.1089/dia.2022.0421\\n\\\\[ [DOI](https://doi.org/10.1089/dia.2022.0421)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC10081723/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/36472543/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=Improved%20glycemia%20with%20hybrid%20closed-loop%20versus%20continuous%20subcutaneous%20insulin%20infusion%20therapy:%20Results%20from%20a%20randomized%20controlled%20trial&author=SK%20Garg&author=G%20Grunberger&author=R%20Weinstock&volume=25&issue=1&publication_year=2023&pages=1-12&pmid=36472543&doi=10.1089/dia.2022.0421&)\\\\]\\n- 20.\\nAkturk HK, Giordano D, Champakanath A, Brackett S, Garg S, Snell-Bergeon J. Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes. Diabetes Obes Metab. 2020;22(4):583-589. doi: 10.1111/dom.13933\\n\\\\[ [DOI](https://doi.org/10.1111/dom.13933)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/31789447/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Obes%20Metab&title=Long-term%20real-life%20glycaemic%20outcomes%20with%20a%20hybrid%20closed-loop%20system%20compared%20with%20sensor-augmented%20pump%20therapy%20in%20patients%20with%20type%201%20diabetes&author=HK%20Akturk&author=D%20Giordano&author=A%20Champakanath&author=S%20Brackett&author=S%20Garg&volume=22&issue=4&publication_year=2020&pages=583-589&pmid=31789447&doi=10.1111/dom.13933&)\\\\]\\n- 21.\\nMesser LH, Berget C, Vigers T, et al. Real world hybrid closed-loop discontinuation: Predictors and perceptions of youth discontinuing the 670g system in the first 6 months. Pediatr Diabetes. 2020;21(2):319-327. doi: 10.1111/pedi.12971\\n\\\\[ [DOI](https://doi.org/10.1111/pedi.12971)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC7204392/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/31885123/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Pediatr%20Diabetes&title=Real%20world%20hybrid%20closed-loop%20discontinuation:%20Predictors%20and%20perceptions%20of%20youth%20discontinuing%20the%20670g%20system%20in%20the%20first%206%20months&author=LH%20Messer&author=C%20Berget&author=T%20Vigers&volume=21&issue=2&publication_year=2020&pages=319-327&pmid=31885123&doi=10.1111/pedi.12971&)\\\\]\\n- 22.\\nCarlson AL, Sherr JL, Shulman DI, et al. Safety and glycemic outcomes during the minimed™ advanced hybrid closed-loop system pivotal trial in adolescents and adults with type 1 diabetes. Diabetes Technol Ther. 2022;24(3):178-189. doi: 10.1089/dia.2021.0319\\n\\\\[ [DOI](https://doi.org/10.1089/dia.2021.0319)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC8971997/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34694909/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=Safety%20and%20glycemic%20outcomes%20during%20the%20minimed%E2%84%A2%20advanced%20hybrid%20closed-loop%20system%20pivotal%20trial%20in%20adolescents%20and%20adults%20with%20type%201%20diabetes&author=AL%20Carlson&author=JL%20Sherr&author=DI%20Shulman&volume=24&issue=3&publication_year=2022&pages=178-189&pmid=34694909&doi=10.1089/dia.2021.0319&)\\\\]\\n- 23.\\nBergenstal RM, Nimri R, Beck RW, et al. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (flair): A multicentre, randomised, crossover trial. Lancet. 2021;397(10270):208-219. doi: 10.1016/s0140-6736(20)32514-9\\n\\\\[ [DOI](https://doi.org/10.1016/s0140-6736(20)32514-9)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC9194961/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33453783/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet&title=A%20comparison%20of%20two%20hybrid%20closed-loop%20systems%20in%20adolescents%20and%20young%20adults%20with%20type%201%20diabetes%20(flair):%20A%20multicentre,%20randomised,%20crossover%20trial&author=RM%20Bergenstal&author=R%20Nimri&author=RW%20Beck&volume=397&issue=10270&publication_year=2021&pages=208-219&pmid=33453783&doi=10.1016/s0140-6736(20)32514-9&)\\\\]\\n- 24.\\nChoudhary P, Arrieta A, van den Heuvel T, Castañeda J, Smaniotto V, Cohen O. Celebrating the data from 100,000 real-world users of the minimed™ 780g system in Europe, Middle East, and Africa collected over 3 years: From data to clinical evidence. Diabetes Technol Ther. 2024;26(S3):32-37. doi: 10.1089/dia.2023.0433\\n\\\\[ [DOI](https://doi.org/10.1089/dia.2023.0433)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC10890936/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/38377326/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=Celebrating%20the%20data%20from%20100,000%20real-world%20users%20of%20the%20minimed%E2%84%A2%20780g%20system%20in%20Europe,%20Middle%20East,%20and%20Africa%20collected%20over%203%20years:%20From%20data%20to%20clinical%20evidence&author=P%20Choudhary&author=A%20Arrieta&author=T%20van%20den%20Heuvel&author=J%20Casta%C3%B1eda&author=V%20Smaniotto&volume=26&issue=S3&publication_year=2024&pages=32-37&pmid=38377326&doi=10.1089/dia.2023.0433&)\\\\]\\n- 25.\\nArrieta A, Battelino T, Scaramuzza AE, et al. Comparison of minimed 780g system performance in users aged younger and older than 15 years: Evidence from 12 870 real-world users. Diabetes Obes Metab. 2022;24(7):1370-1379. doi: 10.1111/dom.14714\\n\\\\[ [DOI](https://doi.org/10.1111/dom.14714)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC9545031/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/35403792/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Obes%20Metab&title=Comparison%20of%20minimed%20780g%20system%20performance%20in%20users%20aged%20younger%20and%20older%20than%2015%E2%80%89years:%20Evidence%20from%2012%E2%80%89870%20real-world%20users&author=A%20Arrieta&author=T%20Battelino&author=AE%20Scaramuzza&volume=24&issue=7&publication_year=2022&pages=1370-1379&pmid=35403792&doi=10.1111/dom.14714&)\\\\]\\n- 26.\\nBrown SA, Kovatchev BP, Raghinaru D, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med. 2019;381(18):1707-1717. doi: 10.1056/NEJMoa1907863\\n\\\\[ [DOI](https://doi.org/10.1056/NEJMoa1907863)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC7076915/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/31618560/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Six-month%20randomized,%20multicenter%20trial%20of%20closed-loop%20control%20in%20type%201%20diabetes&author=SA%20Brown&author=BP%20Kovatchev&author=D%20Raghinaru&volume=381&issue=18&publication_year=2019&pages=1707-1717&pmid=31618560&doi=10.1056/NEJMoa1907863&)\\\\]\\n- 27.\\nBreton MD, Kanapka LG, Beck RW, et al. A randomized trial of closed-loop control in children with type 1 diabetes. N Engl J Med. 2020;383(9):836-845. doi: 10.1056/NEJMoa2004736\\n\\\\[ [DOI](https://doi.org/10.1056/NEJMoa2004736)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC7920146/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/32846062/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=A%20randomized%20trial%20of%20closed-loop%20control%20in%20children%20with%20type%201%20diabetes&author=MD%20Breton&author=LG%20Kanapka&author=RW%20Beck&volume=383&issue=9&publication_year=2020&pages=836-845&pmid=32846062&doi=10.1056/NEJMoa2004736&)\\\\]\\n- 28.\\nKanapka LG, Wadwa RP, Breton MD, et al. Extended use of the control-IQ closed-loop control system in children with type 1 diabetes. Diabetes Care. 2021;44(2):473-478. doi: 10.2337/dc20-1729\\n\\\\[ [DOI](https://doi.org/10.2337/dc20-1729)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC7818334/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33355258/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&title=Extended%20use%20of%20the%20control-IQ%20closed-loop%20control%20system%20in%20children%20with%20type%201%20diabetes&author=LG%20Kanapka&author=RP%20Wadwa&author=MD%20Breton&volume=44&issue=2&publication_year=2021&pages=473-478&pmid=33355258&doi=10.2337/dc20-1729&)\\\\]\\n- 29.\\nBismuth Tubiana-Rufi ÉN, Rynders CA, et al. Sustained 3-year improvement of glucose control with hybrid closed loop in children with type 1 diabetes while going through puberty. Diabetes Care. 2024;47(9):1696-1703. doi: 10.2337/dc24-0916\\n\\\\[ [DOI](https://doi.org/10.2337/dc24-0916)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/38985499/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&title=Sustained%203-year%20improvement%20of%20glucose%20control%20with%20hybrid%20closed%20loop%20in%20children%20with%20type%201%20diabetes%20while%20going%20through%20puberty&author=%C3%89N%20Bismuth%20Tubiana-Rufi&author=CA%20Rynders&volume=47&issue=9&publication_year=2024&pages=1696-1703&pmid=38985499&doi=10.2337/dc24-0916&)\\\\]\\n- 30.\\nWadwa RP, Reed ZW, Buckingham BA, et al. Trial of hybrid closed-loop control in young children with type 1 diabetes. N Engl J Med. 2023;388(11):991-1001. doi: 10.1056/NEJMoa2210834\\n\\\\[ [DOI](https://doi.org/10.1056/NEJMoa2210834)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC10082994/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/36920756/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Trial%20of%20hybrid%20closed-loop%20control%20in%20young%20children%20with%20type%201%20diabetes&author=RP%20Wadwa&author=ZW%20Reed&author=BA%20Buckingham&volume=388&issue=11&publication_year=2023&pages=991-1001&pmid=36920756&doi=10.1056/NEJMoa2210834&)\\\\]\\n- 31.\\nBeck RW, Kanapka LG, Breton MD, et al. A meta-analysis of randomized trial outcomes for the t:Slim x2 insulin pump with control-IQ technology in youth and adults from age 2 to 72. Diabetes Technol Ther. 2023;25(5):329-342. doi: 10.1089/dia.2022.0558\\n\\\\[ [DOI](https://doi.org/10.1089/dia.2022.0558)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC10171957/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/37067353/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=A%20meta-analysis%20of%20randomized%20trial%20outcomes%20for%20the%20t:Slim%20x2%20insulin%20pump%20with%20control-IQ%20technology%20in%20youth%20and%20adults%20from%20age%202%20to%2072&author=RW%20Beck&author=LG%20Kanapka&author=MD%20Breton&volume=25&issue=5&publication_year=2023&pages=329-342&pmid=37067353&doi=10.1089/dia.2022.0558&)\\\\]\\n- 32.\\nBreton MD, Kovatchev BP. One year real-world use of the control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther. 2021;23(9):601-608. doi: 10.1089/dia.2021.0097\\n\\\\[ [DOI](https://doi.org/10.1089/dia.2021.0097)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC8501470/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33784196/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=One%20year%20real-world%20use%20of%20the%20control-IQ%20advanced%20hybrid%20closed-loop%20technology&author=MD%20Breton&author=BP%20Kovatchev&volume=23&issue=9&publication_year=2021&pages=601-608&pmid=33784196&doi=10.1089/dia.2021.0097&)\\\\]\\n- 33.\\nForlenza GP, Carlson AL, Galindo RJ, et al. Real-world evidence supporting tandem control-IQ hybrid closed-loop success in the medicare and medicaid type 1 and type 2 diabetes populations. Diabetes Technol Ther. 2022;24(11):814-823. doi: 10.1089/dia.2022.0206\\n\\\\[ [DOI](https://doi.org/10.1089/dia.2022.0206)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC9618372/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/35763323/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=Real-world%20evidence%20supporting%20tandem%20control-IQ%20hybrid%20closed-loop%20success%20in%20the%20medicare%20and%20medicaid%20type%201%20and%20type%202%20diabetes%20populations&author=GP%20Forlenza&author=AL%20Carlson&author=RJ%20Galindo&volume=24&issue=11&publication_year=2022&pages=814-823&pmid=35763323&doi=10.1089/dia.2022.0206&)\\\\]\\n- 34.\\nAkturk HK, American Diabetes Association Diabetes Technology Interest Group. Recent advances in diabetes technology and activities of the American diabetes association diabetes technology interest group. Clin Diabetes. 2024;42(2):316-321. doi: 10.2337/cd23-0080\\n\\\\[ [DOI](https://doi.org/10.2337/cd23-0080)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC11060631/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/38694248/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin%20Diabetes&title=Recent%20advances%20in%20diabetes%20technology%20and%20activities%20of%20the%20American%20diabetes%20association%20diabetes%20technology%20interest%20group&volume=42&issue=2&publication_year=2024&pages=316-321&pmid=38694248&doi=10.2337/cd23-0080&)\\\\]\\n- 35.\\nAkturk HK, Karakus KE, D’Souza E, et al. Glycemic and patient-reported outcomes for users of a new, compact automated insulin delivery system: A first report. J Diabetes Sci Technol. 2024;25:19322968241302349. doi: 10.1177/19322968241302349 \\\\[ [DOI](https://doi.org/10.1177/19322968241302349)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC11590071/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/39587715/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Diabetes%20Sci%20Technol&title=Glycemic%20and%20patient-reported%20outcomes%20for%20users%20of%20a%20new,%20compact%20automated%20insulin%20delivery%20system:%20A%20first%20report&author=HK%20Akturk&author=KE%20Karakus&author=E%20D%E2%80%99Souza&volume=25&publication_year=2024&pmid=39587715&doi=10.1177/19322968241302349&)\\\\]\\n- 36.\\nKudva YC, Raghinaru D, Lum JW, et al. A randomized trial of automated insulin delivery in type 2 diabetes \\\\[published online ahead of print September 19, 2025\\\\]. N Engl J Med. doi: 10.1056/NEJMoa2415948 \\\\[ [DOI](https://doi.org/10.1056/NEJMoa2415948)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/40105270/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=A%20randomized%20trial%20of%20automated%20insulin%20delivery%20in%20type%202%20diabetes&author=YC%20Kudva&author=D%20Raghinaru&author=JW%20Lum&pmid=40105270&doi=10.1056/NEJMoa2415948&)\\\\]\\n- 37.\\nBrown SA, Forlenza GP, Bode BW, et al. Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. Diabetes Care. 2021;44(7):1630-1640. doi: 10.2337/dc21-0172\\n\\\\[ [DOI](https://doi.org/10.2337/dc21-0172)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC8323171/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34099518/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&title=Multicenter%20trial%20of%20a%20tubeless,%20on-body%20automated%20insulin%20delivery%20system%20with%20customizable%20glycemic%20targets%20in%20pediatric%20and%20adult%20participants%20with%20type%201%20diabetes&author=SA%20Brown&author=GP%20Forlenza&author=BW%20Bode&volume=44&issue=7&publication_year=2021&pages=1630-1640&pmid=34099518&doi=10.2337/dc21-0172&)\\\\]\\n- 38.\\nCriego AB, Carlson AL, Brown SA, et al. Two years with a tubeless automated insulin delivery system: A single-arm multicenter trial in children, adolescents, and adults with type 1 diabetes. Diabetes Technol Ther. 2024;26(1):11-23. doi: 10.1089/dia.2023.0364\\n\\\\[ [DOI](https://doi.org/10.1089/dia.2023.0364)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC10794844/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/37850941/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=Two%20years%20with%20a%20tubeless%20automated%20insulin%20delivery%20system:%20A%20single-arm%20multicenter%20trial%20in%20children,%20adolescents,%20and%20adults%20with%20type%201%20diabetes&author=AB%20Criego&author=AL%20Carlson&author=SA%20Brown&volume=26&issue=1&publication_year=2024&pages=11-23&pmid=37850941&doi=10.1089/dia.2023.0364&)\\\\]\\n- 39.\\nSherr JL, Bode BW, Forlenza GP, et al. Safety and glycemic outcomes with a tubeless automated insulin delivery system in very young children with type 1 diabetes: A single-arm multicenter clinical trial. Diabetes Care. 2022;45(8):1907-1910. doi: 10.2337/dc21-2359\\n\\\\[ [DOI](https://doi.org/10.2337/dc21-2359)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC9346983/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/35678724/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&title=Safety%20and%20glycemic%20outcomes%20with%20a%20tubeless%20automated%20insulin%20delivery%20system%20in%20very%20young%20children%20with%20type%201%20diabetes:%20A%20single-arm%20multicenter%20clinical%20trial&author=JL%20Sherr&author=BW%20Bode&author=GP%20Forlenza&volume=45&issue=8&publication_year=2022&pages=1907-1910&pmid=35678724&doi=10.2337/dc21-2359&)\\\\]\\n- 40.\\nDeSalvo DJ, Bode BW, Forlenza GP, et al. Glycemic outcomes persist for up to 2 years in very young children with the omnipod(®) 5 automated insulin delivery system. Diabetes Technol Ther. 2024;26(6):383-393. doi: 10.1089/dia.2023.0506\\n\\\\[ [DOI](https://doi.org/10.1089/dia.2023.0506)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/38277156/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=Glycemic%20outcomes%20persist%20for%20up%20to%202%20years%20in%20very%20young%20children%20with%20the%20omnipod(%C2%AE)%205%20automated%20insulin%20delivery%20system&author=DJ%20DeSalvo&author=BW%20Bode&author=GP%20Forlenza&volume=26&issue=6&publication_year=2024&pages=383-393&pmid=38277156&doi=10.1089/dia.2023.0506&)\\\\]\\n- 41.\\nRenard E, Weinstock RS, Aleppo G, et al. Efficacy and safety of a tubeless aid system compared with pump therapy with CGM in the treatment of type 1 diabetes in adults with suboptimal glycemia: A randomized, parallel-group clinical trial. Diabetes Care. 2024;47(12):2248-2257. doi: 10.2337/dc24-1550\\n\\\\[ [DOI](https://doi.org/10.2337/dc24-1550)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC11655411/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/39423118/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&title=Efficacy%20and%20safety%20of%20a%20tubeless%20aid%20system%20compared%20with%20pump%20therapy%20with%20CGM%20in%20the%20treatment%20of%20type%201%20diabetes%20in%20adults%20with%20suboptimal%20glycemia:%20A%20randomized,%20parallel-group%20clinical%20trial&author=E%20Renard&author=RS%20Weinstock&author=G%20Aleppo&volume=47&issue=12&publication_year=2024&pages=2248-2257&pmid=39423118&doi=10.2337/dc24-1550&)\\\\]\\n- 42.\\nForlenza GP, DeSalvo DJ, Aleppo G, et al. Real-world evidence of omnipod(®) 5 automated insulin delivery system use in 69,902 people with type 1 diabetes. Diabetes Technol Ther. 2024;26(8):514-525. doi: 10.1089/dia.2023.0578\\n\\\\[ [DOI](https://doi.org/10.1089/dia.2023.0578)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/38375861/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=Real-world%20evidence%20of%20omnipod(%C2%AE)%205%20automated%20insulin%20delivery%20system%20use%20in%2069,902%20people%20with%20type%201%20diabetes&author=GP%20Forlenza&author=DJ%20DeSalvo&author=G%20Aleppo&volume=26&issue=8&publication_year=2024&pages=514-525&pmid=38375861&doi=10.1089/dia.2023.0578&)\\\\]\\n- 43.\\nDavis GM, Peters AL, Bode BW, et al. Safety and efficacy of the omnipod 5 automated insulin delivery system in adults with type 2 diabetes: From injections to hybrid closed-loop therapy. Diabetes Care. 2023;46(4):742-750. doi: 10.2337/dc22-1915\\n\\\\[ [DOI](https://doi.org/10.2337/dc22-1915)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC10090930/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/36787903/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&title=Safety%20and%20efficacy%20of%20the%20omnipod%205%20automated%20insulin%20delivery%20system%20in%20adults%20with%20type%202%20diabetes:%20From%20injections%20to%20hybrid%20closed-loop%20therapy&author=GM%20Davis&author=AL%20Peters&author=BW%20Bode&volume=46&issue=4&publication_year=2023&pages=742-750&pmid=36787903&doi=10.2337/dc22-1915&)\\\\]\\n- 44.\\nDavis GM, Peters AL, Bode BW, et al. Glycaemic outcomes in adults with type 2 diabetes over 34 weeks with the omnipod® 5 automated insulin delivery system. Diabetes Obes Metab. 2025;27(1):143-154. doi: 10.1111/dom.15993\\n\\\\[ [DOI](https://doi.org/10.1111/dom.15993)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC11618232/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/39382001/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Obes%20Metab&title=Glycaemic%20outcomes%20in%20adults%20with%20type%202%20diabetes%20over%2034%E2%80%89weeks%20with%20the%20omnipod%C2%AE%205%20automated%20insulin%20delivery%20system&author=GM%20Davis&author=AL%20Peters&author=BW%20Bode&volume=27&issue=1&publication_year=2025&pages=143-154&pmid=39382001&doi=10.1111/dom.15993&)\\\\]\\n- 45.\\nPasquel FJ, Davis GM, Huffman DM, et al. Automated insulin delivery in adults with type 2 diabetes: A nonrandomized clinical trial. JAMA Netw Open. 2025;8(2):e2459348. doi: 10.1001/jamanetworkopen.2024.59348 \\\\[ [DOI](https://doi.org/10.1001/jamanetworkopen.2024.59348)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC11829226/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/39951268/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=JAMA%20Netw%20Open&title=Automated%20insulin%20delivery%20in%20adults%20with%20type%202%20diabetes:%20A%20nonrandomized%20clinical%20trial&author=FJ%20Pasquel&author=GM%20Davis&author=DM%20Huffman&volume=8&issue=2&publication_year=2025&pmid=39951268&doi=10.1001/jamanetworkopen.2024.59348&)\\\\]\\n- 46.\\nRussell SJ, Beck RW, Damiano ER, et al. Multicenter, randomized trial of a bionic pancreas in type 1 diabetes. N Engl J Med. 2022;387(13):1161-1172. doi: 10.1056/NEJMoa2205225\\n\\\\[ [DOI](https://doi.org/10.1056/NEJMoa2205225)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC10028490/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/36170500/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Multicenter,%20randomized%20trial%20of%20a%20bionic%20pancreas%20in%20type%201%20diabetes&author=SJ%20Russell&author=RW%20Beck&author=ER%20Damiano&volume=387&issue=13&publication_year=2022&pages=1161-1172&pmid=36170500&doi=10.1056/NEJMoa2205225&)\\\\]\\n- 47.\\nMesser LH, Buckingham BA, Cogen F, et al. Positive impact of the bionic pancreas on diabetes control in youth 6-17 years old with type 1 diabetes: A multicenter randomized trial. Diabetes Technol Ther. 2022;24(10):712-725. doi: 10.1089/dia.2022.0201.pub\\n\\\\[ [DOI](https://doi.org/10.1089/dia.2022.0201.pub)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC9529304/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/36173237/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=Positive%20impact%20of%20the%20bionic%20pancreas%20on%20diabetes%20control%20in%20youth%206-17%20years%20old%20with%20type%201%20diabetes:%20A%20multicenter%20randomized%20trial&author=LH%20Messer&author=BA%20Buckingham&author=F%20Cogen&volume=24&issue=10&publication_year=2022&pages=712-725&pmid=36173237&doi=10.1089/dia.2022.0201.pub&)\\\\]\\n- 48.\\nKruger D, Kass A, Lonier J, et al. A multicenter randomized trial evaluating the insulin-only configuration of the bionic pancreas in adults with type 1 diabetes. Diabetes Technol Ther. 2022;24(10):697-711. doi: 10.1089/dia.2022.0200\\n\\\\[ [DOI](https://doi.org/10.1089/dia.2022.0200)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC9634987/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/36173236/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=A%20multicenter%20randomized%20trial%20evaluating%20the%20insulin-only%20configuration%20of%20the%20bionic%20pancreas%20in%20adults%20with%20type%201%20diabetes&author=D%20Kruger&author=A%20Kass&author=J%20Lonier&volume=24&issue=10&publication_year=2022&pages=697-711&pmid=36173236&doi=10.1089/dia.2022.0200&)\\\\]\\n- 49.\\nLynch J, Kanapka LG, Russell SJ, et al. The insulin-only bionic pancreas pivotal trial extension study: A multi-center single-arm evaluation of the insulin-only configuration of the bionic pancreas in adults and youth with type 1 diabetes. Diabetes Technol Ther. 2022;24(10):726-736. doi: 10.1089/dia.2022.0341\\n\\\\[ [DOI](https://doi.org/10.1089/dia.2022.0341)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC9529297/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/36173238/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=The%20insulin-only%20bionic%20pancreas%20pivotal%20trial%20extension%20study:%20A%20multi-center%20single-arm%20evaluation%20of%20the%20insulin-only%20configuration%20of%20the%20bionic%20pancreas%20in%20adults%20and%20youth%20with%20type%201%20diabetes&author=J%20Lynch&author=LG%20Kanapka&author=SJ%20Russell&volume=24&issue=10&publication_year=2022&pages=726-736&pmid=36173238&doi=10.1089/dia.2022.0341&)\\\\]\\n- 50.\\nGarg SK, Polsky S. Technology use and glycemic outcomes during pregnancy with type 1 diabetes. N Engl J Med. 2023;389(17):1617-1619. doi: 10.1056/NEJMe2310798\\n\\\\[ [DOI](https://doi.org/10.1056/NEJMe2310798)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/37796238/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Technology%20use%20and%20glycemic%20outcomes%20during%20pregnancy%20with%20type%201%20diabetes&author=SK%20Garg&author=S%20Polsky&volume=389&issue=17&publication_year=2023&pages=1617-1619&pmid=37796238&doi=10.1056/NEJMe2310798&)\\\\]\\n- 51.\\nLee TTM, Collett C, Bergford S, et al. Automated insulin delivery in women with pregnancy complicated by type 1 diabetes. N Engl J Med. 2023;389(17):1566-1578. doi: 10.1056/NEJMoa2303911\\n\\\\[ [DOI](https://doi.org/10.1056/NEJMoa2303911)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/37796241/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Automated%20insulin%20delivery%20in%20women%20with%20pregnancy%20complicated%20by%20type%201%20diabetes&author=TTM%20Lee&author=C%20Collett&author=S%20Bergford&volume=389&issue=17&publication_year=2023&pages=1566-1578&pmid=37796241&doi=10.1056/NEJMoa2303911&)\\\\]\\n- 52.\\nPregnancy approval of an automated insulin delivery system in type 1, diabetes. [https://www.fda.gov/news-events/press-announcements/fda-roundup-may-24-2024](https://www.fda.gov/news-events/press-announcements/fda-roundup-may-24-2024)\\n- 53.\\nTauschmann M, Thabit H, Bally L, et al. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: A multicentre, 12-week randomised trial. Lancet. 2018;392(10155):1321-1329. doi: 10.1016/s0140-6736(18)31947-0\\n\\\\[ [DOI](https://doi.org/10.1016/s0140-6736(18)31947-0)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC6182127/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/30292578/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet&title=Closed-loop%20insulin%20delivery%20in%20suboptimally%20controlled%20type%201%20diabetes:%20A%20multicentre,%2012-week%20randomised%20trial&author=M%20Tauschmann&author=H%20Thabit&author=L%20Bally&volume=392&issue=10155&publication_year=2018&pages=1321-1329&pmid=30292578&doi=10.1016/s0140-6736(18)31947-0&)\\\\]\\n- 54.\\nWare J, Boughton CK, Allen JM, et al. Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: A multicentre 6-month randomised controlled trial. Lancet Digit Health. 2022;4(4):e245-e255. doi: 10.1016/s2589-7500(22)00020-6 \\\\[ [DOI](https://doi.org/10.1016/s2589-7500(22)00020-6)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/35272971/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet%20Digit%20Health&title=Cambridge%20hybrid%20closed-loop%20algorithm%20in%20children%20and%20adolescents%20with%20type%201%20diabetes:%20A%20multicentre%206-month%20randomised%20controlled%20trial&author=J%20Ware&author=CK%20Boughton&author=JM%20Allen&volume=4&issue=4&publication_year=2022&pmid=35272971&doi=10.1016/s2589-7500(22)00020-6&)\\\\]\\n- 55.\\nWare J, Allen JM, Boughton CK, et al. Randomized trial of closed-loop control in very young children with type 1 diabetes. N Engl J Med. 2022;386(3):209-219. doi: 10.1056/NEJMoa2111673\\n\\\\[ [DOI](https://doi.org/10.1056/NEJMoa2111673)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/35045227/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Randomized%20trial%20of%20closed-loop%20control%20in%20very%20young%20children%20with%20type%201%20diabetes&author=J%20Ware&author=JM%20Allen&author=CK%20Boughton&volume=386&issue=3&publication_year=2022&pages=209-219&pmid=35045227&doi=10.1056/NEJMoa2111673&)\\\\]\\n- 56.\\nAlwan H, Wilinska ME, Ruan Y, et al. Real-world evidence analysis of a hybrid closed-loop system. J Diabetes Sci Technol. 2023;19:385-389. doi: 10.1177/19322968231185348\\n\\\\[ [DOI](https://doi.org/10.1177/19322968231185348)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC11873883/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/37421250/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Diabetes%20Sci%20Technol&title=Real-world%20evidence%20analysis%20of%20a%20hybrid%20closed-loop%20system&author=H%20Alwan&author=ME%20Wilinska&author=Y%20Ruan&volume=19&publication_year=2023&pages=385-389&pmid=37421250&doi=10.1177/19322968231185348&)\\\\]\\n- 57.Diabetes technology: Standards of care in diabetes-2025. Diabetes Care\\n2025;48(Suppl. 1):s146-s166. doi: 10.2337/dc25-S007 \\\\[ [DOI](https://doi.org/10.2337/dc25-S007)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC11932807/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/39847526/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&title=Diabetes%20technology:%20Standards%20of%20care%20in%20diabetes-2025&volume=48&issue=Suppl.%201&publication_year=2025&pmid=39847526&doi=10.2337/dc25-S007&)\\\\]\\n- 58.\\nLum JW, Bailey RJ, Barnes-Lomen V, et al. A real-world prospective study of the safety and effectiveness of the loop open source automated insulin delivery system. Diabetes Technol Ther. 2021;23(5):367-375. doi: 10.1089/dia.2020.0535\\n\\\\[ [DOI](https://doi.org/10.1089/dia.2020.0535)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC8080906/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33226840/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=A%20real-world%20prospective%20study%20of%20the%20safety%20and%20effectiveness%20of%20the%20loop%20open%20source%20automated%20insulin%20delivery%20system&author=JW%20Lum&author=RJ%20Bailey&author=V%20Barnes-Lomen&volume=23&issue=5&publication_year=2021&pages=367-375&pmid=33226840&doi=10.1089/dia.2020.0535&)\\\\]\\n- 59.\\nRawshani A, Sattar N, Franzén S, et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: A nationwide, register-based cohort study. Lancet. 2018;392(10146):477-486. doi: 10.1016/s0140-6736(18)31506-x\\n\\\\[ [DOI](https://doi.org/10.1016/s0140-6736(18)31506-x)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC6828554/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/30129464/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet&title=Excess%20mortality%20and%20cardiovascular%20disease%20in%20young%20adults%20with%20type%201%20diabetes%20in%20relation%20to%20age%20at%20onset:%20A%20nationwide,%20register-based%20cohort%20study&author=A%20Rawshani&author=N%20Sattar&author=S%20Franz%C3%A9n&volume=392&issue=10146&publication_year=2018&pages=477-486&pmid=30129464&doi=10.1016/s0140-6736(18)31506-x&)\\\\]\\n- 60.\\nRawshani A, Rawshani A, Franzén S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376(15):1407-1418. doi: 10.1056/NEJMoa1608664\\n\\\\[ [DOI](https://doi.org/10.1056/NEJMoa1608664)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/28402770/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Mortality%20and%20cardiovascular%20disease%20in%20type%201%20and%20type%202%20diabetes&author=A%20Rawshani&author=A%20Rawshani&author=S%20Franz%C3%A9n&volume=376&issue=15&publication_year=2017&pages=1407-1418&pmid=28402770&doi=10.1056/NEJMoa1608664&)\\\\]\\n- 61.\\nFang M, Wang D, Selvin E. Prevalence of type 1 diabetes among us children and adults by age, sex, race, and ethnicity. JAMA. 2024;331(16):1411-1413. doi: 10.1001/jama.2024.2103\\n\\\\[ [DOI](https://doi.org/10.1001/jama.2024.2103)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC11040401/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/38573653/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=JAMA&title=Prevalence%20of%20type%201%20diabetes%20among%20us%20children%20and%20adults%20by%20age,%20sex,%20race,%20and%20ethnicity&author=M%20Fang&author=D%20Wang&author=E%20Selvin&volume=331&issue=16&publication_year=2024&pages=1411-1413&pmid=38573653&doi=10.1001/jama.2024.2103&)\\\\]\\n- 62.\\nBailey R, Calhoun P, Garg SK. Weight gain and glycemic control in adults with type 1 diabetes in the T1D exchange registry. Diabetes Technol Ther. 2024;26(3):156-160. doi: 10.1089/dia.2023.0389\\n\\\\[ [DOI](https://doi.org/10.1089/dia.2023.0389)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/38444314/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=Weight%20gain%20and%20glycemic%20control%20in%20adults%20with%20type%201%20diabetes%20in%20the%20T1D%20exchange%20registry&author=R%20Bailey&author=P%20Calhoun&author=SK%20Garg&volume=26&issue=3&publication_year=2024&pages=156-160&pmid=38444314&doi=10.1089/dia.2023.0389&)\\\\]\\n- 63.\\nFoster NC, Beck RW, Miller KM, et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018. Diabetes Technol Ther. 2019;21(2):66-72. doi: 10.1089/dia.2018.0384\\n\\\\[ [DOI](https://doi.org/10.1089/dia.2018.0384)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC7061293/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/30657336/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=State%20of%20type%201%20diabetes%20management%20and%20outcomes%20from%20the%20T1D%20exchange%20in%202016-2018&author=NC%20Foster&author=RW%20Beck&author=KM%20Miller&volume=21&issue=2&publication_year=2019&pages=66-72&pmid=30657336&doi=10.1089/dia.2018.0384&)\\\\]\\n- 64.\\nGarg SK. Cardiovascular and renal biomarkers in overweight and obese adults with type 1 diabetes treated with glp1 analogs in 24 months. Diabetes Technol Ther. 2025;27:152-160.\\n\\\\[ [DOI](https://doi.org/10.1089/dia.2024.0481)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/40098470/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=Cardiovascular%20and%20renal%20biomarkers%20in%20overweight%20and%20obese%20adults%20with%20type%201%20diabetes%20treated%20with%20glp1%20analogs%20in%2024%20months&author=SK%20Garg&volume=27&publication_year=2025&pages=152-160&pmid=40098470&doi=10.1089/dia.2024.0481&)\\\\]\\n- 65.\\nLi P, Li Z, Staton E, et al. GLP-1 receptor agonist and SGLT2 inhibitor prescribing in people with type 1 diabetes. JAMA. 2024;332(19):1667-1669. doi: 10.1001/jama.2024.18581\\n\\\\[ [DOI](https://doi.org/10.1001/jama.2024.18581)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC11500011/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/39441612/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=JAMA&title=GLP-1%20receptor%20agonist%20and%20SGLT2%20inhibitor%20prescribing%20in%20people%20with%20type%201%20diabetes&author=P%20Li&author=Z%20Li&author=E%20Staton&volume=332&issue=19&publication_year=2024&pages=1667-1669&pmid=39441612&doi=10.1001/jama.2024.18581&)\\\\]\\n- 66.\\nAkturk HK, Rewers A, Garg SK. Sglt inhibition: A possible adjunctive treatment for type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2018;25(4):246-250. doi: 10.1097/med.0000000000000423\\n\\\\[ [DOI](https://doi.org/10.1097/med.0000000000000423)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/29794497/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Curr%20Opin%20Endocrinol%20Diabetes%20Obes&title=Sglt%20inhibition:%20A%20possible%20adjunctive%20treatment%20for%20type%201%20diabetes&author=HK%20Akturk&author=A%20Rewers&author=SK%20Garg&volume=25&issue=4&publication_year=2018&pages=246-250&pmid=29794497&doi=10.1097/med.0000000000000423&)\\\\]\\n- 67.\\nAkturk HK, Dong F, Snell-Bergeon JK, et al. Efficacy and safety of tirzepatide in adults with type 1 diabetes: A proof of concept observational study. J Diabetes Sci Technol. 2025;19:292-296. doi: 10.1177/19322968231223991\\n\\\\[ [DOI](https://doi.org/10.1177/19322968231223991)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC11571402/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/38317405/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Diabetes%20Sci%20Technol&title=Efficacy%20and%20safety%20of%20tirzepatide%20in%20adults%20with%20type%201%20diabetes:%20A%20proof%20of%20concept%20observational%20study&author=HK%20Akturk&author=F%20Dong&author=JK%20Snell-Bergeon&volume=19&publication_year=2025&pages=292-296&pmid=38317405&doi=10.1177/19322968231223991&)\\\\]\\n- 68.\\nGarg SK, Akturk HK, Kaur G, Beatson C, Snell-Bergeon J. Efficacy and safety of tirzepatide in overweight and obese adult patients with type 1 diabetes. Diabetes Technol Ther. 2024;26(6):367-374. doi: 10.1089/dia.2024.0050\\n\\\\[ [DOI](https://doi.org/10.1089/dia.2024.0050)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/38512447/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=Efficacy%20and%20safety%20of%20tirzepatide%20in%20overweight%20and%20obese%20adult%20patients%20with%20type%201%20diabetes&author=SK%20Garg&author=HK%20Akturk&author=G%20Kaur&author=C%20Beatson&author=J%20Snell-Bergeon&volume=26&issue=6&publication_year=2024&pages=367-374&pmid=38512447&doi=10.1089/dia.2024.0050&)\\\\]\\n- 69.\\nBaechle C, Rosenbauer J, Stahl-Pehe A, et al. Effectiveness of add-on therapy with SGLT2 inhibitors or GLP-1 receptor agonists in adults with type 1 diabetes: A prospective DPV registry study. Diabetes Obes Metab. 2024;27:1591-1596. doi: 10.1111/dom.16149\\n\\\\[ [DOI](https://doi.org/10.1111/dom.16149)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/39727159/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Obes%20Metab&title=Effectiveness%20of%20add-on%20therapy%20with%20SGLT2%20inhibitors%20or%20GLP-1%20receptor%20agonists%20in%20adults%20with%20type%201%20diabetes:%20A%20prospective%20DPV%20registry%20study&author=C%20Baechle&author=J%20Rosenbauer&author=A%20Stahl-Pehe&volume=27&publication_year=2024&pages=1591-1596&pmid=39727159&doi=10.1111/dom.16149&)\\\\]\\n- 70.\\nGarg SK, Kaur G, Haider Z, Rodriquez E, Beatson C, Snell-Bergeon J. Efficacy of semaglutide in overweight and obese patients with type 1 diabetes. Diabetes Technol Ther. 2024;26(3):184-189. doi: 10.1089/dia.2023.0490\\n\\\\[ [DOI](https://doi.org/10.1089/dia.2023.0490)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/38444317/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=Efficacy%20of%20semaglutide%20in%20overweight%20and%20obese%20patients%20with%20type%201%20diabetes&author=SK%20Garg&author=G%20Kaur&author=Z%20Haider&author=E%20Rodriquez&author=C%20Beatson&volume=26&issue=3&publication_year=2024&pages=184-189&pmid=38444317&doi=10.1089/dia.2023.0490&)\\\\]\\n- 71.\\nSnell-Bergeon JK, Kaur G, Renner D, Akturk HK, Beatson C, Garg SK. Effectiveness of semaglutide and tirzepatide in overweight and obese adults with type 1 diabetes. Diabetes Technol Ther. 2025;27(1):1-9. doi: 10.1089/dia.2024.0328\\n\\\\[ [DOI](https://doi.org/10.1089/dia.2024.0328)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/39745353/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=Effectiveness%20of%20semaglutide%20and%20tirzepatide%20in%20overweight%20and%20obese%20adults%20with%20type%201%20diabetes&author=JK%20Snell-Bergeon&author=G%20Kaur&author=D%20Renner&author=HK%20Akturk&author=C%20Beatson&volume=27&issue=1&publication_year=2025&pages=1-9&pmid=39745353&doi=10.1089/dia.2024.0328&)\\\\]\\n- 72.\\nDandona P, Chaudhuri A, Ghanim H. Semaglutide in early type 1 diabetes. N Engl J Med. 2023;389(10):958-959. doi: 10.1056/NEJMc2302677\\n\\\\[ [DOI](https://doi.org/10.1056/NEJMc2302677)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/37672701/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Semaglutide%20in%20early%20type%201%20diabetes&author=P%20Dandona&author=A%20Chaudhuri&author=H%20Ghanim&volume=389&issue=10&publication_year=2023&pages=958-959&pmid=37672701&doi=10.1056/NEJMc2302677&)\\\\]\\n- 73.\\nShah VN, Peters AL, Umpierrez GE, et al. Consensus report on glucagon-like peptide-1 receptor agonists as adjunctive treatment for individuals with type 1 diabetes using an automated insulin delivery system. J Diabetes Sci Technol. 2025;19(1):191-216. doi: 10.1177/19322968241291512\\n\\\\[ [DOI](https://doi.org/10.1177/19322968241291512)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC11571606/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/39517127/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Diabetes%20Sci%20Technol&title=Consensus%20report%20on%20glucagon-like%20peptide-1%20receptor%20agonists%20as%20adjunctive%20treatment%20for%20individuals%20with%20type%201%20diabetes%20using%20an%20automated%20insulin%20delivery%20system&author=VN%20Shah&author=AL%20Peters&author=GE%20Umpierrez&volume=19&issue=1&publication_year=2025&pages=191-216&pmid=39517127&doi=10.1177/19322968241291512&)\\\\]\\n- 74.\\nGarg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med. 2017;377(24):2337-2348. doi: 10.1056/NEJMoa1708337\\n\\\\[ [DOI](https://doi.org/10.1056/NEJMoa1708337)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/28899222/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Effects%20of%20sotagliflozin%20added%20to%20insulin%20in%20patients%20with%20type%201%20diabetes&author=SK%20Garg&author=RR%20Henry&author=P%20Banks&volume=377&issue=24&publication_year=2017&pages=2337-2348&pmid=28899222&doi=10.1056/NEJMoa1708337&)\\\\]\\n- 75.\\nRosenstock J, Marquard J, Laffel LM, et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: The ease trials. Diabetes Care. 2018;41(12):2560-2569. doi: 10.2337/dc18-1749\\n\\\\[ [DOI](https://doi.org/10.2337/dc18-1749)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/30287422/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&title=Empagliflozin%20as%20adjunctive%20to%20insulin%20therapy%20in%20type%201%20diabetes:%20The%20ease%20trials&author=J%20Rosenstock&author=J%20Marquard&author=LM%20Laffel&volume=41&issue=12&publication_year=2018&pages=2560-2569&pmid=30287422&doi=10.2337/dc18-1749&)\\\\]\\n- 76.\\nDandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (depict-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(11):864-876. doi: 10.1016/s2213-8587(17)30308-x\\n\\\\[ [DOI](https://doi.org/10.1016/s2213-8587(17)30308-x)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/28919061/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet%20Diabetes%20Endocrinol&title=Efficacy%20and%20safety%20of%20dapagliflozin%20in%20patients%20with%20inadequately%20controlled%20type%201%20diabetes%20(depict-1):%2024%20week%20results%20from%20a%20multicentre,%20double-blind,%20phase%203,%20randomised%20controlled%20trial&author=P%20Dandona&author=C%20Mathieu&author=M%20Phillip&volume=5&issue=11&publication_year=2017&pages=864-876&pmid=28919061&doi=10.1016/s2213-8587(17)30308-x&)\\\\]\\n- 77.\\nZhang JY, Shang T, Koliwad SK, Klonoff DC. Continuous ketone monitoring: A new paradigm for physiologic monitoring. J Diabetes Sci Technol. 2021;15(4):775-780. doi: 10.1177/19322968211009860\\n\\\\[ [DOI](https://doi.org/10.1177/19322968211009860)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC8258504/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33834884/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Diabetes%20Sci%20Technol&title=Continuous%20ketone%20monitoring:%20A%20new%20paradigm%20for%20physiologic%20monitoring&author=JY%20Zhang&author=T%20Shang&author=SK%20Koliwad&author=DC%20Klonoff&volume=15&issue=4&publication_year=2021&pages=775-780&pmid=33834884&doi=10.1177/19322968211009860&)\\\\]\\n- 78.\\nKong YW, Morrison D, Lu JC, et al. Continuous ketone monitoring: Exciting implications for clinical practice. Diabetes Obes Metab. 2024;26(Suppl 7):47-58. doi: 10.1111/dom.15921\\n\\\\[ [DOI](https://doi.org/10.1111/dom.15921)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC11646480/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/39314201/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Obes%20Metab&title=Continuous%20ketone%20monitoring:%20Exciting%20implications%20for%20clinical%20practice&author=YW%20Kong&author=D%20Morrison&author=JC%20Lu&volume=26&issue=Suppl%207&publication_year=2024&pages=47-58&pmid=39314201&doi=10.1111/dom.15921&)\\\\]\\n- 79.\\nKarakus KE, Klein MP, Akturk HK, Shah VN. Changes in basal and bolus insulin requirements with tirzepatide as an adjunctive therapy in adults with type 1 diabetes using tandem control-IQ. Diabetes Ther. 2024;15(7):1647-1655. doi: 10.1007/s13300-024-01592-9\\n\\\\[ [DOI](https://doi.org/10.1007/s13300-024-01592-9)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC11211304/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/38743306/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Ther&title=Changes%20in%20basal%20and%20bolus%20insulin%20requirements%20with%20tirzepatide%20as%20an%20adjunctive%20therapy%20in%20adults%20with%20type%201%20diabetes%20using%20tandem%20control-IQ&author=KE%20Karakus&author=MP%20Klein&author=HK%20Akturk&author=VN%20Shah&volume=15&issue=7&publication_year=2024&pages=1647-1655&pmid=38743306&doi=10.1007/s13300-024-01592-9&)\\\\]\\n- 80.\\nKlein MP, Akturk HK, Snell-Bergeon JK, et al. Reduced efficacy of glucagon-like peptide-1 receptor agonists therapy in people with type 1 diabetes and genetic forms of obesity. J Diabetes Sci Technol. 2024;19:297-303. doi: 10.1177/19322968241245680\\n\\\\[ [DOI](https://doi.org/10.1177/19322968241245680)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC11571401/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/38629877/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Diabetes%20Sci%20Technol&title=Reduced%20efficacy%20of%20glucagon-like%20peptide-1%20receptor%20agonists%20therapy%20in%20people%20with%20type%201%20diabetes%20and%20genetic%20forms%20of%20obesity&author=MP%20Klein&author=HK%20Akturk&author=JK%20Snell-Bergeon&volume=19&publication_year=2024&pages=297-303&pmid=38629877&doi=10.1177/19322968241245680&)\\\\]\\n- 81.\\nGarg SK, Snell-Bergeon J, Kaur G, Beatson C. Challenges of GLP analog use for people with type 1 diabetes: Issues with prior approvals and tips for safer use. Diabetes Technol Ther. 2024;26(6):363-366. doi: 10.1089/dia.2024.0023\\n\\\\[ [DOI](https://doi.org/10.1089/dia.2024.0023)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/38517221/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Technol%20Ther&title=Challenges%20of%20GLP%20analog%20use%20for%20people%20with%20type%201%20diabetes:%20Issues%20with%20prior%20approvals%20and%20tips%20for%20safer%20use&author=SK%20Garg&author=J%20Snell-Bergeon&author=G%20Kaur&author=C%20Beatson&volume=26&issue=6&publication_year=2024&pages=363-366&pmid=38517221&doi=10.1089/dia.2024.0023&)\\\\]\\n- 82.\\nSaeed ZI, Akturk HK, Aleppo G, et al. Insulin titration recommendations when using glucagon-like peptide 1 receptor agonist therapy in adults with type 1 diabetes. Clin Diabetes. 2024;43:131-138. doi: 10.2337/cd24-0067\\n\\\\[ [DOI](https://doi.org/10.2337/cd24-0067)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC11739354/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/39829697/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin%20Diabetes&title=Insulin%20titration%20recommendations%20when%20using%20glucagon-like%20peptide%201%20receptor%20agonist%20therapy%20in%20adults%20with%20type%201%20diabetes&author=ZI%20Saeed&author=HK%20Akturk&author=G%20Aleppo&volume=43&publication_year=2024&pages=131-138&pmid=39829697&doi=10.2337/cd24-0067&)\\\\]\",\n      \"summary\": \"{\\\"answer\\\":\\\"This review summarizes registration and real-life studies of US Food and Drug Administration (FDA)-approved AID systems. Real-life studies confirmed the glycemic outcomes of AID systems reported from registration studies. The article mentions the Diabetes Control and Complications Trial (DCCT) and the use of intensive insulin therapy (IIT) via multiple daily injections (MDIs) or insulin pumps. It also mentions continuous glucose monitors (CGMs). The article does not provide information about specific medications like GLP-1 agonists or SGLT2 inhibitors, nor does it specify the latest FDA-approved technologies for diabetes management in 2023-2024.\\\"}\",\n      \"favicon\": \"https://pmc.ncbi.nlm.nih.gov/static/img/favicons/favicon-32x32.png\"\n    }\n  ],\n  \"searchTime\": 2728.1,\n  \"costDollars\": {\n    \"total\": 0.009,\n    \"search\": {\n      \"neural\": 0.005\n    },\n    \"contents\": {\n      \"text\": 0.002,\n      \"summary\": 0.002\n    }\n  }\n}\n---\n**Executive Summary**  \nBetween 2023 and 2025, the FDA has expanded approvals for automated insulin delivery (AID) systems, notably extending their use to type 2 diabetes, and real-world and clinical evidence confirms significant improvements in glycemic control. While AID technologies have rapidly advanced, the use of adjunctive medications—GLP-1 receptor agonists and SGLT2 inhibitors—remains largely off-label in type 1 diabetes, with safety and efficacy still under investigation.\n\n---\n\n**Introduction: Context and Scope**  \nThis synthesis reviews the latest FDA-approved medications and technologies for diabetes management in 2023–2024, focusing on GLP-1 agonists, SGLT2 inhibitors, and automated insulin delivery systems. The analysis integrates FDA announcements and a comprehensive academic review of clinical and real-world data on AID systems, assessing their impact, limitations, and the evolving role of adjunctive pharmacotherapies.\n\n---\n\n**Main Findings by Theme**\n\n**1. Automated Insulin Delivery (AID) Systems: Recent FDA Approvals and Expansions**  \n- **FDA Expansion to Type 2 Diabetes (2024):**  \n  - The Insulet SmartAdjust technology, previously indicated for type 1 diabetes, received FDA clearance in August 2024 for use in adults with type 2 diabetes (FDA, 2024).  \n  - This system automates insulin dosing by integrating with an insulin pump and continuous glucose monitor (CGM), reducing manual intervention and potentially improving quality of life ([FDA Press Release, 2024](https://www.fda.gov/news-events/press-announcements/fda-clears-first-device-enable-automated-insulin-dosing-individuals-type-2-diabetes)).\n\n- **Evidence from Clinical Trials:**  \n  - In a 13-week trial (n=289, adults with type 2 diabetes on insulin), SmartAdjust improved glycemic control across diverse demographic groups, with no serious device-related adverse events. Mild to moderate adverse events included hyperglycemia, hypoglycemia, and skin irritation. Many participants were also on GLP-1 agonists ([FDA, 2024](https://www.fda.gov/news-events/press-announcements/fda-clears-first-device-enable-automated-insulin-dosing-individuals-type-2-diabetes)).\n\n- **Other AID Systems:**  \n  - Multiple systems (Medtronic MiniMed 670G/780G, Tandem Control-IQ, Omnipod 5, iLet Bionic Pancreas, CamAPS FX, Loop) have demonstrated significant reductions in HbA1c and increases in time-in-range (TIR) for type 1 diabetes in both registration and real-world studies ([PMC12213531](https://pmc.ncbi.nlm.nih.gov/articles/PMC12213531/)).\n  - Recent pivotal trials and real-world studies confirm durable glycemic improvements and safety in diverse populations, including children, adults, and those with type 2 diabetes (e.g., Omnipod 5, Control-IQ+).\n\n**2. Adjunctive Medications: GLP-1 Agonists and SGLT2 Inhibitors**  \n- **GLP-1 Receptor Agonists:**  \n  - Widely approved for type 2 diabetes and increasingly prescribed off-label in type 1 diabetes, especially for overweight/obese patients or those with cardiovascular/renal comorbidities ([Li et al., JAMA 2024](https://doi.org/10.1001/jama.2024.18581)).\n  - Small studies show promising improvements in weight and glycemic control, with some patients reducing or eliminating insulin needs. However, these are not FDA-approved for type 1 diabetes, and risks of hypoglycemia and DKA require careful management ([PMC12213531](https://pmc.ncbi.nlm.nih.gov/articles/PMC12213531/)).\n  - Use in type 2 diabetes is well established and often combined with AID systems in clinical practice.\n\n- **SGLT2 Inhibitors:**  \n  - Approved for type 2 diabetes, with demonstrated cardiovascular and renal benefits in this population.\n  - Off-label use in type 1 diabetes is increasing but is not FDA-approved due to elevated risk of diabetic ketoacidosis (DKA), especially in pump users ([PMC12213531](https://pmc.ncbi.nlm.nih.gov/articles/PMC12213531/)).\n  - Safety mitigation strategies (e.g., continuous ketone monitoring) are under investigation.\n\n**3. Real-World Effectiveness and Implementation**  \n- Real-world studies largely confirm the efficacy and safety of AID systems observed in clinical trials, showing sustained improvements in HbA1c and TIR across age groups and socioeconomic strata.\n- Discontinuation and adherence challenges exist, often related to device usability (e.g., calibration demands, alarms).\n- Access, cost, and training remain barriers to broad implementation.\n\n---\n\n**Critical Analysis of Evidence Quality**  \n- **Strengths:**  \n  - Multiple large, randomized controlled trials and real-world studies support the efficacy and safety of AID systems in both type 1 and type 2 diabetes.\n  - FDA clearance is based on robust, diverse clinical trial data, particularly for the recent expansion of AID use to type 2 diabetes.\n\n- **Limitations:**  \n  - Some studies are single-arm or have short durations, limiting direct comparisons.\n  - Real-world studies are often industry-sponsored and may lack standardized outcome measures or control groups.\n  - Evidence for GLP-1 and SGLT2 use in type 1 diabetes is limited to small, off-label studies, with no FDA approval or large-scale safety data.\n\n- **Conflicts of Interest:**  \n  - Several authors and principal investigators have disclosed financial relationships with device and pharmaceutical companies.\n\n---\n\n**Synthesis of Key Insights and Patterns**  \n- AID systems are now the standard of care for type 1 diabetes in developed countries and are rapidly expanding into type 2 diabetes management, with FDA approval for such use as of 2024.\n- These systems consistently improve glycemic outcomes (HbA1c, TIR) and quality of life, with durable effects in real-world practice.\n- Adjunctive use of GLP-1 agonists and SGLT2 inhibitors in type 1 diabetes is growing but remains off-label and requires further research to establish safety and efficacy.\n- The future of diabetes technology includes fully automated systems, integration of additional physiological sensors, and personalized algorithms.\n\n---\n\n**Limitations and Gaps Identified**  \n- Lack of long-term, head-to-head comparative studies among different AID systems.\n- Limited FDA-approved adjunctive pharmacotherapy for type 1 diabetes.\n- Insufficient data on long-term safety of combining AID systems with GLP-1 or SGLT2 agents in type 1 diabetes.\n- Real-world studies may not fully capture diverse patient experiences or rare adverse events.\n\n---\n\n**Evidence-Based Conclusions**  \n- The FDA’s recent clearances mark a significant advance in diabetes technology, with automated insulin delivery now available to a broader patient population, including adults with type 2 diabetes.\n- AID systems offer substantial, durable improvements in glycemic control and patient-reported outcomes.\n- Adjunctive medications like GLP-1 agonists and SGLT2 inhibitors are promising but not yet FDA-approved for type 1 diabetes; their use should be individualized and closely monitored.\n- Barriers to implementation include device complexity, cost, and access disparities.\n\n---\n\n**Future Research Directions**  \n- Large-scale, long-term comparative effectiveness studies of AID systems in both type 1 and type 2 diabetes.\n- Rigorous trials of GLP-1 and SGLT2 agents as adjuncts to insulin and AID systems in type 1 diabetes, focusing on safety (DKA risk) and efficacy.\n- Development and validation of fully automated, user-friendly AID systems incorporating multiple physiological data streams.\n- Research into strategies to improve access, training, and adherence, especially in underserved populations.\n\n---\n\n**References**  \n- [FDA Press Release, 2024](https://www.fda.gov/news-events/press-announcements/fda-clears-first-device-enable-automated-insulin-dosing-individuals-type-2-diabetes)\n- [Comprehensive Review: PMC12213531](https://pmc.ncbi.nlm.nih.gov/articles/PMC12213531/)\n- Li P, et al. JAMA 2024;332(19):1667-1669. doi:10.1001/jama.2024.18581\n\n---\n\n**Errors or Issues Noted**  \n- The academic review (PMC12213531) summary in the tool output erroneously states it does not cover GLP-1 or SGLT2 medications; in reality, these are discussed in the context of off-label use and future directions.\n- No significant data-processing errors detected; however, some summaries may underrepresent the breadth of content in the full articles.\n\n--- Comparative effectiveness of current first-line diabetes treatments based on recent clinical trials and meta-analyses, including HbA1c reduction, cardiovascular outcomes, and quality of life measures\n[{'function': {'arguments': '{\"query\":\"Comparative effectiveness of first-line diabetes treatments: recent clinical trials and meta-analyses on HbA1c reduction, cardiovascular outcomes, and quality of life\"}', 'name': 'exa_search'}, 'id': 'call_H5tdkmtxbCCj1u1w1VaZBOj0', 'type': 'function'}]\nFunction 'exa_search' result:\n{\n  \"requestId\": \"5ba70669a7db59c9d6e11855efbdbd3d\",\n  \"autopromptString\": \"Comparative effectiveness of first-line diabetes treatments: recent clinical trials and meta-analyses on HbA1c reduction, cardiovascular outcomes, and quality of life\",\n  \"autoDate\": \"2025-07-12T00:00:00.000Z\",\n  \"resolvedSearchType\": \"neural\",\n  \"context\": \"Title: Comparison of cardiovascular outcomes of \\n\\nTitle: Causal deep learning reveals the comparat\\n\\n\",\n  \"results\": [\n    {\n      \"id\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC11098653/\",\n      \"title\": \"Comparison of cardiovascular outcomes of new ...\",\n      \"url\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC11098653/\",\n      \"publishedDate\": \"2024-02-28T00:00:00.000Z\",\n      \"author\": \"\",\n      \"text\": \"[Skip to main content](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#main-content)\\n\\n**Official websites use .gov**\\nA\\n**.gov** website belongs to an official\\ngovernment organization in the United States.\\n\\n**Secure .gov websites use HTTPS**\\nA **lock** (\\n\\nLocked padlock icon\\n) or **https://** means you've safely\\nconnected to the .gov website. Share sensitive\\ninformation only on official, secure websites.\\n\\nSearch PMC Full-Text ArchiveSearch in PMC\\n\\n- [Advanced Search](https://www.ncbi.nlm.nih.gov/pmc/advanced/)\\n- [Journal List](https://pmc.ncbi.nlm.nih.gov/journals/)\\n- [User Guide](https://pmc.ncbi.nlm.nih.gov/about/userguide/)\\n\\nNewTry this search in PMC Beta Search\\n\\n- ## PERMALINK\\n\\n\\n\\nCopy\\n\\n\\nAs a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,\\nthe contents by NLM or the National Institutes of Health.\\nLearn more:\\n[PMC Disclaimer](https://pmc.ncbi.nlm.nih.gov/about/disclaimer/)\\n\\\\|\\n[PMC Copyright Notice](https://pmc.ncbi.nlm.nih.gov/about/copyright/)\\n\\nESC Heart Fail\\n\\n. 2024 Feb 28;11(3):1647–1656. doi: [10.1002/ehf2.14726](https://doi.org/10.1002/ehf2.14726)\\n\\n# Comparison of cardiovascular outcomes of new antihyperglycemic agents in Type 2 Diabetes Mellitus: a meta‐analysis\\n\\n[Zijing Zhou](https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhou%20Z%22%5BAuthor%5D)\\n\\n### Zijing Zhou\\n\\n1Department of Cardiovascular Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China\\n\\nFind articles by [Zijing Zhou](https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhou%20Z%22%5BAuthor%5D)\\n\\n1, [Min Zheng](https://pubmed.ncbi.nlm.nih.gov/?term=%22Zheng%20M%22%5BAuthor%5D)\\n\\n### Min Zheng\\n\\n1Department of Cardiovascular Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China\\n\\nFind articles by [Min Zheng](https://pubmed.ncbi.nlm.nih.gov/?term=%22Zheng%20M%22%5BAuthor%5D)\\n\\n1, [Zhihong Zuo](https://pubmed.ncbi.nlm.nih.gov/?term=%22Zuo%20Z%22%5BAuthor%5D)\\n\\n### Zhihong Zuo\\n\\n2Department of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China\\n\\nFind articles by [Zhihong Zuo](https://pubmed.ncbi.nlm.nih.gov/?term=%22Zuo%20Z%22%5BAuthor%5D)\\n\\n2, [Ting Wu](https://pubmed.ncbi.nlm.nih.gov/?term=%22Wu%20T%22%5BAuthor%5D)\\n\\n### Ting Wu\\n\\n1Department of Cardiovascular Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China\\n\\nFind articles by [Ting Wu](https://pubmed.ncbi.nlm.nih.gov/?term=%22Wu%20T%22%5BAuthor%5D)\\n\\n1,✉\\n\\n- Author information\\n- Article notes\\n- Copyright and License information\\n\\n1Department of Cardiovascular Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China\\n\\n2Department of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China\\n\\n\\\\*\\n\\nCorrespondence to: Ting Wu, Department of Cardiovascular Medicine, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Kaifu District, Changsha, Hunan 410008, China. Email: wuting127039@163.com\\n\\n✉\\n\\nCorresponding author.\\n\\nReceived 2023 Nov 3; Accepted 2024 Jan 29; Collection date 2024 Jun.\\n\\n© 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.\\n\\nThis is an open access article under the terms of the [http://creativecommons.org/licenses/by-nc-nd/4.0/](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.\\n\\n[PMC Copyright notice](https://pmc.ncbi.nlm.nih.gov/about/copyright/)\\n\\nPMCID: PMC11098653  PMID: [38419382](https://pubmed.ncbi.nlm.nih.gov/38419382/)\\n\\n## Abstract\\n\\n### Aims\\n\\nThe study aims to provide comprehensive evidence for the selection of agents in type 2 diabetes mellitus (T2DM) patients with cardiovascular risk and summarize the lasted evidence for the cardiovascular effects of sodium glucose cotransporter‐2 inhibitor (SGLT2i) in patients with heart failure (HF).\\n\\n### Methods and results\\n\\nSeveral online databases were searched. All studies that explored the cardiovascular effects of SGLT2i or glucagon‐like peptide 1 receptor agonist (GLP1‐RA) were screened and reviewed. A total of 38 studies were included. Compared with GLP1‐RA, the use of SGLT2i significantly reduced the risk of cardiovascular death \\\\[risk ratio (RR) = 0.59; 95% confidence interval (CI), 0.44–0.58\\\\], hospitalization of heart failure (HHF) (RR = 0.77; 95% CI, 0.74–0.80), death from any cause (RR = 0.64; 95% CI, 0.60–0.68), and myocardial infarction (MI) (RR = 0.81; 95% CI, 0.76–0.87). However, SGLT2i significantly increased the risk of stroke (RR = 1.10; 95% CI, 1.04–1.17). Compared with the control group, SGLT2i treatment reduced the risk of cardiovascular death by 14% (RR = 0.86; 95% CI, 0.79–0.94), HHF by 25%, and death from any cause by 9% in patients with HF, regardless of diabetes status.\\n\\n### Conclusions\\n\\nSGLT2i is associated with a lower risk of cardiovascular death, HHF, death from any cause, and MI in patients with T2DM compared with GLP1‐RA. In addition, SGLT2i brought more benefits with respect to the effects of cardiovascular death, HHF, and death from any cause in patients with HF, regardless of diabetes status.\\n\\n**Keywords:** Cardiovascular outcomes, Sodium glucose cotransporter‐2 inhibitor, Glucagon‐like peptide 1 receptor agonist, Type 2 diabetes, Heart failure\\n\\n## Introduction\\n\\nMajor adverse cardiovascular events (MACE) are the most common morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). [1](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0001) Numerous cardiovascular outcome trials have provided evidence that sodium glucose cotransporter‐2 inhibitor (SGLT2i) reduced MACE rates in T2DM patients. It was reported that SGLT2i exerted protective effects against hospitalization of heart failure (HHF) compared with metformin. [2](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0002) Compared with placebo, SGLT2i presented significant beneficial effects on HHF, death from any cause, and MACE in patients with T2DM. [3](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0003) Compared with dipeptidyl peptidase‐4 inhibitor, SGLT2i brings more benefits with respect to cardiovascular outcomes and risk factors. [4](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0004) Similar to SGLT2i, glucagon‐like peptide 1 receptor agonist (GLP1‐RA) is a new class of glucose‐lowering drug and also presents benefits for MACE and HHF. [5](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0005) However, SGLT2i and GLP1‐RA demonstrated several differences with respect to the types of cardiovascular events they present. According to previous network meta‐analyses, SGLT2i exerts much of its protective effects against HHF, while GLP1‐RA mostly tackles non‐fatal stroke. [6](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0006), [7](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0007) Recently, a head‐to‐head comparison of the effects on cardiovascular outcomes between SGLT2i and GLP1‐RA has been addressed. However, contradictory conclusions were observed. It was revealed that SGLT2i displayed neutral effects on all components of MACE compared with GLP1‐RA. [8](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0008) Another study revealed that SGLT2i was more effective than GLP1‐RA in improving cardiovascular outcomes, [9](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0009) while an Italian cohort study demonstrated that GLP1‐RA was superior to SGLT2i in improving cardiovascular outcomes. [10](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0010) However, the utility of previous meta‐analyses is limited because they indirectly assessed the comparative effects of SGLT2i and GLP1‐RA due to a lack of head‐to‐head trials. In order to provide a more comprehensive conclusion and a basis for the selection of agents for T2DM patients, we firstly collected the latest available data for the meta‐analysis to do a head‐to‐head comparison of the cardiovascular effects between SGLT2i and GLP1‐RA.\\n\\nIn parallel, experimental evidence emerged suggesting that SGLT2i plays a cardioprotective role dependent on blood glucose level. [11](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0011), [12](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0012) Therefore, recent trials have also focused on the cardiovascular effects of SGLT2i in patients with heart failure (HF), regardless of diabetes status. The EMPEROR‐Reduced trial proved that no significant difference in cardiovascular death was found between the SGLT2i and placebo groups in patients with HF, but SGLT2i treatment was closely associated with a lower incidence of HHF. [13](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0013) In contrast, the DAPA‐HF trial demonstrated that SGLT2i significantly reduced the risk of cardiovascular death among patients with HF. [14](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0014) Thus, based on previous contradictory conclusions, we present the meta‐analysis to explore the pooled overall effectiveness of SGLT2i in patients with HF, aiming to provide further insight into the data on SGLT2i's cardiovascular benefits.\\n\\n## Methods\\n\\nThe study was registered in PROSPERO, with Registration No. CRD42023423524.\\n\\n### Search strategy\\n\\nStudies published in the PubMed, Web of Science, EMBASE, the Cochrane Library, and China National Knowledge Infrastructure before or on 13 August 2023 were searched using the following search terms: ‘diabetes’, ‘diabetes mellitus’, ‘heart failure’, ‘sodium glucose co‐transporter 2 inhibitor’, ‘SGLT‐2 inhibitor’, ‘dapaliflozin’, ‘empagliflozin’, ‘ipragliflozin’, ‘canagliflozin’, ‘glucagon‐like peptide‐1 receptor agonists’, ‘GLP‐1RA’, ‘liraglutide’, ‘dulaglutide’, ‘exenatide’, ‘lixisenatide’, ‘semaglutide’, and ‘albiglutide’, alone or in combination, without language restriction.\\n\\n### Inclusion and exclusion criteria\\n\\nThe following inclusion criteria were applied: (i) type of participants: patients (≥18 years old) in each study who were diagnosed with HF or T2DM and (ii) type of study: all studies that compared the effects of SGLT2i and GLP1‐RA as monotherapy or combination therapy with other hypoglycaemic drugs on cardiovascular outcomes and all studies that provide information with respect to cardiovascular outcomes of HF patients divided into the SGLT2i and placebo groups. Exclusion criteria include (i) study design: reviews, comments, letters, case reports, and abstracts; (ii) type of participants: animals, patients <18 years old, and pregnant women; and (iii) insufficient information concerning evaluation rates.\\n\\n### Outcomes\\n\\nThe primary outcomes evaluated in this study were cardiovascular death, HHF, death from any cause, myocardial infarction (MI), and stroke. The secondary outcome included a change in the level (relative to baseline) of haemoglobin A1c (HbA1c), systolic blood pressure (SBP), diastolic blood pressure (DBP), lipid indices \\\\[high‐density lipoprotein cholesterol (HDL‐C), low‐density lipoprotein cholesterol (LDL‐C), and triglycerides\\\\], and body mass index (BMI).\\n\\n### Study selection\\n\\nAfter eliminating duplicates, the remaining identified trials were reviewed by two independent investigators to confirm that they fulfilled the inclusion criteria. The full text of articles would be retrieved and carefully reviewed by three investigators if they thought the titles or abstracts were potentially useful. When discrepancies occurred between investigators, all authors would evaluate the results and reach the final decision. Finally, the relevant studies in the reference lists were screened and assessed in the same manner.\\n\\n### Data extraction\\n\\nA predefined data extraction form was applied, and two authors independently extracted data. The extracted data included the last name of the first author, geographical region, sample size ( _N_), percentage of male patients (%), mean age (years), portion of different drug use, primary outcomes, and research type. The Newcastle–Ottawa scale (NOS) was employed to assess the quality of the included retrospective studies. The NOS score of 1–3, 4–6, and 7–9 presented low, intermediate, and high quality, respectively. We used the Cochrane risk of bias tools to assess the quality of randomized controlled trials (RCTs). All disagreements were resolved through discussion.\\n\\n### Statistical analysis\\n\\nWe employed risk ratio (RR) and weighted mean difference (WMD) to compare dichotomous variables and continuous variables, respectively. All results are reported with 95% confidence intervals (CIs). Fixed‐effect models were conducted to pool the effect estimates of the outcomes, while random‐effect models were used if significant heterogeneity was detected. _I_ 2 was used to estimate heterogeneity, and _I_ 2 > 50% was considered significant. The possible publication bias of outcome was presented by Egger's test and Begg's test ( _P_ < 0.10). The sensitivity analyses were conducted by removing one study at a time to observe the effect estimate of the outcomes. We completed all statistical analysis with STATA 12.0 statistical software (STATA Corporation, College Station, Texas, USA).\\n\\n## Results\\n\\n### Selection of included studies and study characteristics\\n\\nA total of 1578 relevant articles were screened by searching several online databases. The review and selection process of the included trials in the study is presented in _Figure_ [_1_](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-fig-0001). Finally, 38 studies were identified in the meta‐analysis, whose characteristics are summarized in Supporting Information, _Tables_ [_S1_](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-supitem-0001) and [_S2_](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-supitem-0001). [8](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0008), [9](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0009), [10](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0010), [13](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0013), [14](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0014), [15](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0015), [16](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0016), [17](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0017), [18](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0018), [19](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0019), [20](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0020), [21](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0021), [22](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0022), [23](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0023), [24](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0024), [25](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0025), [26](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0026), [27](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0027), [28](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0028), [29](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0029), [30](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0030), [31](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0031), [32](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0032), [33](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0033), [34](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0034), [35](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0035), [36](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0036), [37](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0037), [38](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0038), [39](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0039), [40](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0040), [41](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0041), [42](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0042), [43](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0043), [44](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0044), [45](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0045), [46](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0046), [47](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0047) Among these studies, 19 were RCTs, 18 were retrospective studies, and the last one was a prospective study. Twenty‐four trials focused on the comparison of SGLT2i with GLP1‐RA in patients with T2DM, while 14 studies discussed the effect of SGLT2i on cardiovascular outcomes in patients with HF. The results of the quality assessment are estimated in Supporting Information, _Tables_ [_S1_](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-supitem-0001) and [_S3_](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-supitem-0001).\\n\\n#### Figure 1.\\n\\n[Open in a new tab](https://pmc.ncbi.nlm.nih.gov/figure/ehf214726-fig-0001/)\\n\\nPRISMA diagram of study selection.\\n\\n### Effects of sodium glucose cotransporter‐2 inhibitor and glucagon‐like peptide 1 receptor agonist on cardiovascular outcomes in type 2 diabetes mellitus patients\\n\\nThe use of SGLT2i significantly reduced the risk of cardiovascular death compared with GLP1‐RA (RR = 0.59; 95% CI, 0.53–0.65). The SGLT2i group also lowered the risk of HHF by 23% (RR = 0.77; 95% CI, 0.74–0.80). As high heterogeneity was detected in these two outcomes, subgroup analyses were undertaken based on sample size. Heterogeneity was significantly decreased in ‘small size’ subgroups, and results were consistent between different groups ( _Figure_ [_2_](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-fig-0002)). Furthermore, SGLT2i significantly reduced the risks of death from any cause (RR = 0.64; 95% CI, 0.60–0.68) and MI (RR = 0.81; 95% CI, 0.76–0.87) ( _Figure_ [_2_](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-fig-0002)). A significant difference was observed in the risk of stroke (RR = 1.10; 95% CI, 1.04–1.17) among patients treated with SGLT2i and GLP1‐RA ( _Figure_ [_3_](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-fig-0003)). The pooled result showed that the effect of SGLT2i and GLP1‐RA treatments on HbA1c is similar (WMD = 0.33%; 95% CI, −0.03% to 0.69%). However, SGLT2i brought benefits with respect to the SBP (WMD = −2.0 mmHg; 95% CI, −2.08 to −1.92 mmHg) and DBP (WMD = −2.00 mmHg; 95% CI, −2.07 to −1.93 mmHg) ( _Figure_ [_3_](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-fig-0003)). No significant difference was observed in BMI or blood lipids, including HDL‐C, LDL‐C, and triglycerides, between the SGLT2i and GLP1‐RA treatments (Supporting Information, _Figure_ [_S1_](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-supitem-0001)).\\n\\n#### Figure 2.\\n\\n[Open in a new tab](https://pmc.ncbi.nlm.nih.gov/figure/ehf214726-fig-0002/)\\n\\nMeta‐analysis of cardiovascular effects on (A) cardiovascular death, (B) hospitalization of heart failure (HHF), (C) death from any cause, and (D) myocardial infarction (MI) of sodium glucose cotransporter‐2 inhibitor and glucagon‐like peptide 1 receptor agonist in type 2 diabetes mellitus patients. CI, confidence interval; RR, risk ratio.\\n\\n#### Figure 3.\\n\\n[Open in a new tab](https://pmc.ncbi.nlm.nih.gov/figure/ehf214726-fig-0003/)\\n\\nMeta‐analysis of cardiovascular effects on (A) stroke, (B) haemoglobin A1c (HbA1c), (C) systolic blood pressure (SBP), and (D) diastolic blood pressure (DBP) of sodium glucose cotransporter‐2 inhibitor and glucagon‐like peptide 1 receptor agonist in type 2 diabetes mellitus patients. CI, confidence interval; RR, risk ratio; WMD, weighted mean difference.\\n\\n### Effects of sodium glucose cotransporter‐2 inhibitor on cardiovascular outcomes in patients with heart failure\\n\\nCompared with the control group, SGLT2i treatment reduced the risk of cardiovascular death by 14% (RR = 0.86; 95% CI, 0.79–0.94) in patients with HF. The use of SGLT2i was closely associated with a lower incidence of HHF (RR = 0.75; 95% CI, 0.70–0.80). A significantly lower incidence of death from any cause (RR = 0.91; 95% CI, 0.86–0.97) was observed among HF patients treated with SGLT2i ( _Figure_ [_4_](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-fig-0004)).\\n\\n#### Figure 4.\\n\\n[Open in a new tab](https://pmc.ncbi.nlm.nih.gov/figure/ehf214726-fig-0004/)\\n\\nMeta‐analysis of cardiovascular effects on (A, D) cardiovascular death, (B, E) hospitalization of heart failure (HHF), and (C, F) death from any cause of sodium glucose cotransporter‐2 inhibitor and placebo in heart failure (HF) patients. CI, confidence interval; RR, risk ratio.\\n\\nFurthermore, we assessed the cardiovascular effects of SGLT2i in HF patients with or without diabetes. Similar results were found in HF patients with diabetes ( _Figure_ [_4_](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-fig-0004)). SGLT2i treatment lowered the risk of cardiovascular death by 14% (RR = 0.86; 95% CI, 0.76–0.97). Patients treated with SGLT2i were more likely to have a low risk of HHF (RR = 0.71; 95% CI, 0.66–0.76). In addition, the use of SGLT2i was closely associated with a lower incidence of death from any cause (RR = 0.78; 95% CI, 0.68–0.91). The effects of SGLT2i on cardiovascular outcomes in HF patients without diabetes are presented in Supporting Information, _Figure_ [_S2_](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-supitem-0001).\\n\\n### Publication bias and sensitivity analysis\\n\\nNo significant publication bias was noted in the study (Supporting Information, _Table_ [_S4_](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-supitem-0001)). Sensitivity analysis revealed no meaningful differences in the outcomes except for the pooled results of cardiovascular death in patients with HF and diabetes.\\n\\n## Discussion\\n\\nIn the meta‐analysis, data from 38 trials were assessed, and we draw the following conclusions. Compared with GLP1‐RA, SGLT2i was more likely to reduce the risk of cardiovascular death, HHF, death from any cause, and MI in patients with T2DM. SGLT2i brought more benefits with respect to the control of SBP and DBP. However, the incidence of stroke was increased in the SGLT2i treatment group. In addition, compared with the control group, SGLT2i treatment reduced the risk of cardiovascular death, HHF, and death from any cause in patients with HF, regardless of glucose level.\\n\\nSGLT2 works in the proximal renal tubule, reabsorbing the majority of filtered glucose. An enhanced expression of SGLT is noticed in T2DM patients; therefore, SGLT2i enhances glycosuria and reduces hyperglycaemia by inhibiting SGLT2 independently of insulin. [48](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0048) Cardiovascular benefits of SGLT2i in patients with T2DM have been demonstrated in large clinical trials comparing SGLT2i with placebo. EMPA‐REG displayed that the SGLT2i group had a lower rate of cardiovascular death, HHF, and death from any cause. [3](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0003) The CANVAS trial also demonstrated that the rate of cardiovascular causes, HHF, non‐fatal MI, and non‐fatal stroke, was lower with SGLT2i treatment. [49](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0049) However, the DECLARE‐TIMI 58 trial posted opposite results. [50](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0050) No significant difference in the MACE in the SGLT2i group was observed except for HHF. The consistent evidence led us to hypothesize that SGLT2i may be effective as an HF treatment regardless of T2DM status. The DAPA‐HF trail demonstrated that treatment with SGLT2i was associated with a lower risk of cardiovascular death, HHF, and death from any cause. [14](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0014) The EMPEROR‐Reduced trial proved that SGLT2i markedly reduced the risk of HHF and cardiovascular death. No significant beneficial effects on death from any cause were detected. [13](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0013) The DELIVER trial [38](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0038) and the EMPEROR‐Preserved trial [51](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0051) also reached contradictory conclusions due to the HF subtype.\\n\\nGLP1‐RA mimics the function of GLP‐1 and binds G‐protein receptors expressed on the pancreatic beta cells, suppressing the release of glucagon from the pancreatic beta cells in a glucose‐dependent manner. [52](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0052) Cardiovascular efficacy of GLP1‐RA has been explored in several large clinical trials among T2DM patients. In the ELIXA trial, GLP1‐RA did not significantly alter the rate of MACE of GLP1‐RA compared with placebo, [53](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0053) and consistent results were observed in the SUSTAIN‐6 trial. [54](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0054) However, the LEADER trial suggests that GLP1‐RA was superior to placebo for reducing the risk of cardiovascular death and all‐cause death, with no significant difference in HHF. [55](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0055) Similar results were detected in the Harmony Outcomes trial [56](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0056) and the REWIND trial. [57](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0057) A meta‐analysis summarized the comprehensive results of RCTs and the significant reduction of MACE, cardiovascular death, stroke, MI, all‐cause death, and HF. [5](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0005) Based on previous comprehensive evidence, GLP1‐RA was recommended as a first‐line treatment in T2DM patients with high‐risk or established cardiovascular disease.\\n\\nRecently, a head‐to‐head comparison of the effects on cardiovascular outcomes between SGLT2i and GLP1‐RA has been addressed. However, contradictory conclusions were observed. It is still unclear whether using one drug over the other yields differences in cardiovascular outcomes, and comprehensive conclusions are necessary. A previous meta‐analysis evaluated the effects of SGLT2i and GLP1‐RA, but the study just compared the absolute benefits of these drugs with placebo, respectively. SGLT2i brought more benefits with respect to HHF in the study, which was consistent with our study and another meta‐analysis. [6](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0006), [7](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0007) Zelniker _et al_. [7](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0007) also compared the effects of SGLT2i and GLP1‐RA for the prevention of MACE in T2DM patients. Similarly, no direct comparison was performed. Therefore, our meta‐analysis firstly and directly compares the effects of SGLT2i and GLP1‐RA on cardiovascular outcomes.\\n\\nAccording to the pooled results of our meta‐analysis, SGLT2i was superior to GLP1‐RA for reducing the rate of cardiovascular death, HHF, and MI in patients with T2DM. In addition, compared with the control group, SGLT2i treatment reduced the risk of cardiovascular death, HHF, and death from any cause in patients with HF. All these results suggested the significant cardiovascular benefits of SGLT2i in patients with HF, regardless of T2DM status. Mechanisms explaining the cardiovascular efficacy of SGLT2i are not completely understood but are a topic of intensive investigation. SGLT2i treatment was associated with a reduction in extracellular volume, explaining the reduction in SBP and DBP, [58](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0058) which was consistent with our study. SGLT2i activates voltage‐gated potassium channels and protein kinase G and induces vasodilatation, resulting in improved endothelial function and arterial stiffness. [59](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0059) Improvements in cardiac energy metabolism and bioenergetics are another hypothesis. β‐Hydroxybutyrate induced by SGLT2i is an energy‐efficient ‘superfuel’, and it offers an alternative and less expensive myocardial fuel source, resulting in improved cardiac metabolism. [60](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0060) SGLT2i also mediates a reduction in plasma uric acid level, which is associated with cardiovascular complications. [61](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0061) Another postulated mechanism is decreasing myocardial intracellular sodium concentration by inhibiting the Na+/H+ exchanger 1 isoform in the cardiomyocyte, leading to a decrease in intracellular calcium and an increase in mitochondrial calcium. [62](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0062) Increased myocardial intracellular sodium is an early hallmark of HF, while increased mitochondrial calcium prevents HF. [63](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#ehf214726-bib-0063)\\n\\n### Limitations\\n\\nThere are several potential limitations to address. First, there was a difference in the duration of follow‐up between trials. Second, most trials comparing the effects of SGLT2i and GLP1‐RA are retrospective studies, but the quality of these trials is high. Finally, the effects of other agents cannot be excluded.\\n\\n## Conclusions\\n\\nSGLT2i is associated with a lower risk of cardiovascular death, HHF, death from any cause, and MI in patients with T2DM compared with GLP1‐RA. In addition, SGLT2i brought more benefits with respect to the effects of cardiovascular death, HHF, and death from any cause in patients with HF, regardless of diabetes status. Our findings provide comprehensive evidence for the selection of agents in T2DM patients with cardiovascular risk and summarize the lasted evidence for the cardiovascular effects of SGLT2i in patients with HF.\\n\\n## Conflict of interest\\n\\nNone declared.\\n\\n## Funding\\n\\nThis work was supported by the China Postdoctoral Science Foundation (2023M733963), the Youth Science Foundation of Xiangya Hospital (2022Q01), the Natural Science Foundation of Changsha (kq2208369), the Natural Science Foundation of Hunan Province (2023JJ40996), and the National Nature Science Foundation of China (82300490).\\n\\n## Supporting information\\n\\n**Table S1.** Study characteristics of included studies comparing SGLT2i and GLP1‐RA in patients with T2DM.\\n\\n**Table S2.** Study characteristics of included studies comparing SGLT2i and placebo in HF patients regardless of diabetes status.\\n\\n**Table S3.** Quality assessment of included RCTs.\\n\\n**Table S4.** Publication bias of cardiovascular outcomes.\\n\\n**Figure S1.** Supporting information.\\n\\n**Figure S2.** Supporting information.\\n\\n[EHF2-11-1647-s001.docx](https://pmc.ncbi.nlm.nih.gov/articles/instance/11098653/bin/EHF2-11-1647-s001.docx) (299.4KB, docx)\\n\\n## Acknowledgements\\n\\nWe thank Drs Ruizheng Shi, Zhaoya Liu, and Chan Li for scientific discussions concerning this work.\\n\\nZhou, Z.\\n,\\nZheng, M.\\n,\\nZuo, Z.\\n, and\\nWu, T.\\n(2024) Comparison of cardiovascular outcomes of new antihyperglycemic agents in Type 2 Diabetes Mellitus: a meta‐analysis. ESC Heart Failure, 11: 1647–1656. 10.1002/ehf2.14726.\\n\\n## References\\n\\n- 1.\\nAmerican Diabetes Association\\n. 10\\\\. Cardiovascular disease and risk management: Standards of medical care in diabetes—2019. Diabetes Care\\n2019;42:S103‐S123. doi: 10.2337/dc19-S002\\n\\\\[ [DOI](https://doi.org/10.2337/dc19-S002)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/30559236/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&title=10.%20Cardiovascular%20disease%20and%20risk%20management:%20Standards%20of%20medical%20care%20in%20diabetes%E2%80%942019&volume=42&publication_year=2019&pages=S103-S123&pmid=30559236&doi=10.2337/dc19-S002&)\\\\]\\n- 2.\\nShin H, Schneeweiss S, Glynn RJ, _et al_. Cardiovascular outcomes in patients initiating first‐line treatment of type 2 diabetes with sodium‐glucose cotransporter‐2 inhibitors versus metformin: A cohort study. Ann Intern Med\\n2022;175:927‐937. doi: 10.7326/M21-4012\\n\\\\[ [DOI](https://doi.org/10.7326/M21-4012)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/35605236/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Ann%20Intern%20Med&title=Cardiovascular%20outcomes%20in%20patients%20initiating%20first%E2%80%90line%20treatment%20of%20type%202%20diabetes%20with%20sodium%E2%80%90glucose%20cotransporter%E2%80%902%20inhibitors%20versus%20metformin:%20A%20cohort%20study&author=H%20Shin&author=S%20Schneeweiss&author=RJ%20Glynn&volume=175&publication_year=2022&pages=927-937&pmid=35605236&doi=10.7326/M21-4012&)\\\\]\\n- 3.\\nZinman B, Wanner C, Lachin JM, _et al_. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med\\n2015;373:2117‐2128. doi: 10.1056/NEJMoa1504720\\n\\\\[ [DOI](https://doi.org/10.1056/NEJMoa1504720)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/26378978/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Empagliflozin,%20cardiovascular%20outcomes,%20and%20mortality%20in%20type%202%20diabetes&author=B%20Zinman&author=C%20Wanner&author=JM%20Lachin&volume=373&publication_year=2015&pages=2117-2128&pmid=26378978&doi=10.1056/NEJMoa1504720&)\\\\]\\n- 4.\\nWang S, Wu T, Zou Z, _et al_. Comparison of cardiovascular outcomes and cardiometabolic risk factors between patients with type 2 diabetes treated with sodium‐glucose cotransporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors: A meta‐analysis. Eur J Prev Cardiol\\n2022;28:1840‐1849. doi: 10.1093/eurjpc/zwab099\\n\\\\[ [DOI](https://doi.org/10.1093/eurjpc/zwab099)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34136913/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Prev%20Cardiol&title=Comparison%20of%20cardiovascular%20outcomes%20and%20cardiometabolic%20risk%20factors%20between%20patients%20with%20type%202%20diabetes%20treated%20with%20sodium%E2%80%90glucose%20cotransporter%E2%80%902%20inhibitors%20and%20dipeptidyl%20peptidase%E2%80%904%20inhibitors:%20A%20meta%E2%80%90analysis&author=S%20Wang&author=T%20Wu&author=Z%20Zou&volume=28&publication_year=2022&pages=1840-1849&pmid=34136913&doi=10.1093/eurjpc/zwab099&)\\\\]\\n- 5.\\nKristensen SL, Rorth R, Jhund PS, _et al_. Cardiovascular, mortality, and kidney outcomes with GLP‐1 receptor agonists in patients with type 2 diabetes: A systematic review and meta‐analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol\\n2019;7:776‐785. doi: 10.1016/S2213-8587(19)30249-9\\n\\\\[ [DOI](https://doi.org/10.1016/S2213-8587(19)30249-9)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/31422062/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet%20Diabetes%20Endocrinol&title=Cardiovascular,%20mortality,%20and%20kidney%20outcomes%20with%20GLP%E2%80%901%20receptor%20agonists%20in%20patients%20with%20type%202%20diabetes:%20A%20systematic%20review%20and%20meta%E2%80%90analysis%20of%20cardiovascular%20outcome%20trials&author=SL%20Kristensen&author=R%20Rorth&author=PS%20Jhund&volume=7&publication_year=2019&pages=776-785&pmid=31422062&doi=10.1016/S2213-8587(19)30249-9&)\\\\]\\n- 6.\\nPalmer SC, Tendal B, Mustafa RA, _et al_. Sodium‐glucose cotransporter protein‐2 (SGLT‐2) inhibitors and glucagon‐like peptide‐1 (GLP‐1) receptor agonists for type 2 diabetes: Systematic review and network meta‐analysis of randomised controlled trials. BMJ\\n2021;372:m4573. doi: 10.1136/bmj.m4573.\\n\\\\[ [DOI](https://doi.org/10.1136/bmj.m4573.)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC7804890/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33441402/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=BMJ&title=Sodium%E2%80%90glucose%20cotransporter%20protein%E2%80%902%20(SGLT%E2%80%902)%20inhibitors%20and%20glucagon%E2%80%90like%20peptide%E2%80%901%20(GLP%E2%80%901)%20receptor%20agonists%20for%20type%202%20diabetes:%20Systematic%20review%20and%20network%20meta%E2%80%90analysis%20of%20randomised%20controlled%20trials&author=SC%20Palmer&author=B%20Tendal&author=RA%20Mustafa&volume=372&publication_year=2021&pages=m4573&pmid=33441402&doi=10.1136/bmj.m4573.&)\\\\]\\n- 7.\\nZelniker TA, Wiviott SD, Raz I, _et al_. Comparison of the effects of glucagon‐like peptide receptor agonists and sodium‐glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation\\n2019;139:2022‐2031. doi: 10.1161/CIRCULATIONAHA.118.038868\\n\\\\[ [DOI](https://doi.org/10.1161/CIRCULATIONAHA.118.038868)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/30786725/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Circulation&title=Comparison%20of%20the%20effects%20of%20glucagon%E2%80%90like%20peptide%20receptor%20agonists%20and%20sodium%E2%80%90glucose%20cotransporter%202%20inhibitors%20for%20prevention%20of%20major%20adverse%20cardiovascular%20and%20renal%20outcomes%20in%20type%202%20diabetes%20mellitus&author=TA%20Zelniker&author=SD%20Wiviott&author=I%20Raz&volume=139&publication_year=2019&pages=2022-2031&pmid=30786725&doi=10.1161/CIRCULATIONAHA.118.038868&)\\\\]\\n- 8.\\nLugner M, Sattar N, Miftaraj M, _et al_. Cardiorenal and other diabetes related outcomes with SGLT‐2 inhibitors compared to GLP‐1 receptor agonists in type 2 diabetes: Nationwide observational study. Cardiovasc Diabetol\\n2021;20:67. doi: 10.1186/s12933-021-01258-x\\n\\\\[ [DOI](https://doi.org/10.1186/s12933-021-01258-x)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC7983265/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33752680/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cardiovasc%20Diabetol&title=Cardiorenal%20and%20other%20diabetes%20related%20outcomes%20with%20SGLT%E2%80%902%20inhibitors%20compared%20to%20GLP%E2%80%901%20receptor%20agonists%20in%20type%202%20diabetes:%20Nationwide%20observational%20study&author=M%20Lugner&author=N%20Sattar&author=M%20Miftaraj&volume=20&publication_year=2021&pages=67&pmid=33752680&doi=10.1186/s12933-021-01258-x&)\\\\]\\n- 9.\\nLongato E, Di Camillo B, Sparacino G, _et al_. Cardiovascular outcomes of type 2 diabetic patients treated with SGLT‐2 inhibitors versus GLP‐1 receptor agonists in real‐life. BMJ Open Diabetes Res Care\\n2020;8:e001451. doi: 10.1136/bmjdrc-2020-001451\\n\\\\[ [DOI](https://doi.org/10.1136/bmjdrc-2020-001451)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC7319723/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/32591373/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=BMJ%20Open%20Diabetes%20Res%20Care&title=Cardiovascular%20outcomes%20of%20type%202%20diabetic%20patients%20treated%20with%20SGLT%E2%80%902%20inhibitors%20versus%20GLP%E2%80%901%20receptor%20agonists%20in%20real%E2%80%90life&author=E%20Longato&author=B%20Di%20Camillo&author=G%20Sparacino&volume=8&publication_year=2020&pages=e001451&pmid=32591373&doi=10.1136/bmjdrc-2020-001451&)\\\\]\\n- 10.\\nBaviera M, Foresta A, Colacioppo P, _et al_. Effectiveness and safety of GLP‐1 receptor agonists versus SGLT‐2 inhibitors in type 2 diabetes: An Italian cohort study. Cardiovasc Diabetol\\n2022;21:162. doi: 10.1186/s12933-022-01572-y\\n\\\\[ [DOI](https://doi.org/10.1186/s12933-022-01572-y)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC9400295/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/35999556/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cardiovasc%20Diabetol&title=Effectiveness%20and%20safety%20of%20GLP%E2%80%901%20receptor%20agonists%20versus%20SGLT%E2%80%902%20inhibitors%20in%20type%202%20diabetes:%20An%20Italian%20cohort%20study&author=M%20Baviera&author=A%20Foresta&author=P%20Colacioppo&volume=21&publication_year=2022&pages=162&pmid=35999556&doi=10.1186/s12933-022-01572-y&)\\\\]\\n- 11.\\nYurista SR, Sille HHW, Ooberdorf‐Maass SU, _et al_. Sodium‐glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail\\n2019;21:862‐873. doi: 10.1002/ejhf.1473\\n\\\\[ [DOI](https://doi.org/10.1002/ejhf.1473)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/31033127/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Heart%20Fail&title=Sodium%E2%80%90glucose%20co%E2%80%90transporter%202%20inhibition%20with%20empagliflozin%20improves%20cardiac%20function%20in%20non%E2%80%90diabetic%20rats%20with%20left%20ventricular%20dysfunction%20after%20myocardial%20infarction&author=SR%20Yurista&author=HHW%20Sille&author=SU%20Ooberdorf%E2%80%90Maass&volume=21&publication_year=2019&pages=862-873&pmid=31033127&doi=10.1002/ejhf.1473&)\\\\]\\n- 12.\\nSantos‐Gallego CG, Requena‐Ibanez JA, San Antonio R, _et al_. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol\\n2019;73:1931‐1944. doi: 10.1016/j.jacc.2019.01.056\\n\\\\[ [DOI](https://doi.org/10.1016/j.jacc.2019.01.056)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/30999996/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&title=Empagliflozin%20ameliorates%20adverse%20left%20ventricular%20remodeling%20in%20nondiabetic%20heart%20failure%20by%20enhancing%20myocardial%20energetics&author=CG%20Santos%E2%80%90Gallego&author=JA%20Requena%E2%80%90Ibanez&author=R%20San%20Antonio&volume=73&publication_year=2019&pages=1931-1944&pmid=30999996&doi=10.1016/j.jacc.2019.01.056&)\\\\]\\n- 13.\\nPacker M, Anker SD, Butler J, _et al_. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med\\n2020;383:1413‐1424. doi: 10.1056/NEJMoa2022190\\n\\\\[ [DOI](https://doi.org/10.1056/NEJMoa2022190)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/32865377/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Cardiovascular%20and%20renal%20outcomes%20with%20empagliflozin%20in%20heart%20failure&author=M%20Packer&author=SD%20Anker&author=J%20Butler&volume=383&publication_year=2020&pages=1413-1424&pmid=32865377&doi=10.1056/NEJMoa2022190&)\\\\]\\n- 14.\\nMcMurray JJV, Solomon SD, Inzucchi SE, _et al_. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med\\n2019;381:1995‐2008. doi: 10.1056/NEJMoa1911303\\n\\\\[ [DOI](https://doi.org/10.1056/NEJMoa1911303)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/31535829/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Dapagliflozin%20in%20patients%20with%20heart%20failure%20and%20reduced%20ejection%20fraction&author=JJV%20McMurray&author=SD%20Solomon&author=SE%20Inzucchi&volume=381&publication_year=2019&pages=1995-2008&pmid=31535829&doi=10.1056/NEJMoa1911303&)\\\\]\\n- 15.\\nNauck M, Weinstock RS, Umpierrez GE, _et al_. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD‐5). Diabetes Care\\n2014;37:2149‐2158. doi: 10.2337/dc13-2761\\n\\\\[ [DOI](https://doi.org/10.2337/dc13-2761)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC4113177/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/24742660/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&title=Efficacy%20and%20safety%20of%20dulaglutide%20versus%20sitagliptin%20after%2052%20weeks%20in%20type%202%20diabetes%20in%20a%20randomized%20controlled%20trial%20(AWARD%E2%80%905)&author=M%20Nauck&author=RS%20Weinstock&author=GE%20Umpierrez&volume=37&publication_year=2014&pages=2149-2158&pmid=24742660&doi=10.2337/dc13-2761&)\\\\]\\n- 16.\\nAl‐Mashhadi ZK, Viggers R, Starup‐Linde J, _et al_. SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP‐1 receptor agonists: A nationwide cohort study. Front Endocrinol (Lausanne)\\n2022;13:861422. doi: 10.3389/fendo.2022.861422\\n\\\\[ [DOI](https://doi.org/10.3389/fendo.2022.861422)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC9437938/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/36060970/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Front%20Endocrinol%20(Lausanne)&title=SGLT2%20inhibitor%20treatment%20is%20not%20associated%20with%20an%20increased%20risk%20of%20osteoporotic%20fractures%20when%20compared%20to%20GLP%E2%80%901%20receptor%20agonists:%20A%20nationwide%20cohort%20study&author=ZK%20Al%E2%80%90Mashhadi&author=R%20Viggers&author=J%20Starup%E2%80%90Linde&volume=13&publication_year=2022&pages=861422&pmid=36060970&doi=10.3389/fendo.2022.861422&)\\\\]\\n- 17.\\nNorgaard CH, Starkofp L, Gerds TA, _et al_. Cardiovascular outcomes with GLP‐1 receptor agonists vs. SGLT‐2 inhibitors in patients with type 2 diabetes. Eur Heart J Cardiovasc Pharmacother\\n2022;8:549‐556. doi: 10.1093/ehjcvp/pvab053\\n\\\\[ [DOI](https://doi.org/10.1093/ehjcvp/pvab053)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34215881/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J%20Cardiovasc%20Pharmacother&title=Cardiovascular%20outcomes%20with%20GLP%E2%80%901%20receptor%20agonists%20vs.%20SGLT%E2%80%902%20inhibitors%20in%20patients%20with%20type%202%20diabetes&author=CH%20Norgaard&author=L%20Starkofp&author=TA%20Gerds&volume=8&publication_year=2022&pages=549-556&pmid=34215881&doi=10.1093/ehjcvp/pvab053&)\\\\]\\n- 18.\\nDong YH, Chang CH, Lin JW, _et al_. Comparative cardiovascular effectiveness of glucagon‐like peptide‐1 receptor agonists versus sodium‐glucose cotransporter‐2 inhibitors in patients with type 2 diabetes: A population‐based cohort study. Diabetes Obes Metab\\n2022;24:1623‐1637. doi: 10.1111/dom.14741\\n\\\\[ [DOI](https://doi.org/10.1111/dom.14741)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/35491533/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Obes%20Metab&title=Comparative%20cardiovascular%20effectiveness%20of%20glucagon%E2%80%90like%20peptide%E2%80%901%20receptor%20agonists%20versus%20sodium%E2%80%90glucose%20cotransporter%E2%80%902%20inhibitors%20in%20patients%20with%20type%202%20diabetes:%20A%20population%E2%80%90based%20cohort%20study&author=YH%20Dong&author=CH%20Chang&author=JW%20Lin&volume=24&publication_year=2022&pages=1623-1637&pmid=35491533&doi=10.1111/dom.14741&)\\\\]\\n- 19.\\nKim CH, Hwang IC, Choi HM, _et al_. Differential cardiovascular and renal benefits of SGLT2 inhibitors and GLP1 receptor agonists in patients with type 2 diabetes mellitus. Int J Cardiol\\n2022;364:104‐111. doi: 10.1016/j.ijcard.2022.06.027\\n\\\\[ [DOI](https://doi.org/10.1016/j.ijcard.2022.06.027)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/35716949/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Int%20J%20Cardiol&title=Differential%20cardiovascular%20and%20renal%20benefits%20of%20SGLT2%20inhibitors%20and%20GLP1%20receptor%20agonists%20in%20patients%20with%20type%202%20diabetes%20mellitus&author=CH%20Kim&author=IC%20Hwang&author=HM%20Choi&volume=364&publication_year=2022&pages=104-111&pmid=35716949&doi=10.1016/j.ijcard.2022.06.027&)\\\\]\\n- 20.\\nHiramatsu T, Ito H, Okumura S, _et al_. Impact of glucagon like peptide‐1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment. Diab Vasc Dis Res\\n2020;17:1479164120971220. doi: 10.1177/1479164120971220\\n\\\\[ [DOI](https://doi.org/10.1177/1479164120971220)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC7919219/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33371732/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diab%20Vasc%20Dis%20Res&title=Impact%20of%20glucagon%20like%20peptide%E2%80%901%20receptor%20agonist%20and%20sodium%20glucose%20cotransporter%202%20inhibitors%20on%20type%202%20diabetes%20patients%20with%20renal%20impairment&author=T%20Hiramatsu&author=H%20Ito&author=S%20Okumura&volume=17&publication_year=2020&pages=1479164120971220&pmid=33371732&doi=10.1177/1479164120971220&)\\\\]\\n- 21.\\nPatorno E, Htoo PT, Glynn RJ, _et al_. Sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease. Ann Intern Med\\n2021;174:1528‐1541. doi: 10.7326/M21-0893\\n\\\\[ [DOI](https://doi.org/10.7326/M21-0893)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC8969214/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34570599/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Ann%20Intern%20Med&title=Sodium%E2%80%90glucose%20cotransporter%E2%80%902%20inhibitors%20versus%20glucagon%E2%80%90like%20peptide%E2%80%901%20receptor%20agonists%20and%20the%20risk%20for%20cardiovascular%20outcomes%20in%20routine%20care%20patients%20with%20diabetes%20across%20categories%20of%20cardiovascular%20disease&author=E%20Patorno&author=PT%20Htoo&author=RJ%20Glynn&volume=174&publication_year=2021&pages=1528-1541&pmid=34570599&doi=10.7326/M21-0893&)\\\\]\\n- 22.\\nLyu B, Grams ME, Chang A, _et al_. Sodium‐glucose cotransporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists, and dipeptidyl peptidase‐4 inhibitors, and risk of hospitalization. Am J Cardiol\\n2022;165:124‐130. doi: 10.1016/j.amjcard.2021.11.013\\n\\\\[ [DOI](https://doi.org/10.1016/j.amjcard.2021.11.013)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC8766913/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34937658/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Am%20J%20Cardiol&title=Sodium%E2%80%90glucose%20cotransporter%202%20inhibitors,%20glucagon%E2%80%90like%20peptide%E2%80%901%20receptor%20agonists,%20and%20dipeptidyl%20peptidase%E2%80%904%20inhibitors,%20and%20risk%20of%20hospitalization&author=B%20Lyu&author=ME%20Grams&author=A%20Chang&volume=165&publication_year=2022&pages=124-130&pmid=34937658&doi=10.1016/j.amjcard.2021.11.013&)\\\\]\\n- 23.\\nUeda P, Wintzell V, Dalhqwist E, _et al_. The comparative cardiovascular and renal effectiveness of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A Scandinavian cohort study. Diabetes Obes Metab\\n2022;24:473‐485. doi: 10.1111/dom.14598\\n\\\\[ [DOI](https://doi.org/10.1111/dom.14598)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34738703/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Obes%20Metab&title=The%20comparative%20cardiovascular%20and%20renal%20effectiveness%20of%20sodium%E2%80%90glucose%20co%E2%80%90transporter%E2%80%902%20inhibitors%20and%20glucagon%E2%80%90like%20peptide%E2%80%901%20receptor%20agonists:%20A%20Scandinavian%20cohort%20study&author=P%20Ueda&author=V%20Wintzell&author=E%20Dalhqwist&volume=24&publication_year=2022&pages=473-485&pmid=34738703&doi=10.1111/dom.14598&)\\\\]\\n- 24.\\nGonzalez J, Bates BA, Setoguchi S, _et al_. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP‐1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction. Cardiovasc Diabetol\\n2023;22:54. doi: 10.1186/s12933-023-01784-w\\n\\\\[ [DOI](https://doi.org/10.1186/s12933-023-01784-w)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC9999503/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/36899387/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cardiovasc%20Diabetol&title=Cardiovascular%20outcomes%20with%20SGLT2%20inhibitors%20versus%20DPP4%20inhibitors%20and%20GLP%E2%80%901%20receptor%20agonists%20in%20patients%20with%20heart%20failure%20with%20reduced%20and%20preserved%20ejection%20fraction&author=J%20Gonzalez&author=BA%20Bates&author=S%20Setoguchi&volume=22&publication_year=2023&pages=54&pmid=36899387&doi=10.1186/s12933-023-01784-w&)\\\\]\\n- 25.\\nLui DTW, Tang EHM, Wu T, _et al_. Risks of stroke, its subtypes and atrial fibrillation associated with glucagon‐like peptide 1 receptor agonists versus sodium‐glucose cotransporter 2 inhibitors: A real‐world population‐based cohort study in Hong Kong. Cardiovasc Diabetol\\n2023;22:40. doi: 10.1186/s12933-023-01772-0\\n\\\\[ [DOI](https://doi.org/10.1186/s12933-023-01772-0)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC9960638/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/36829226/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cardiovasc%20Diabetol&title=Risks%20of%20stroke,%20its%20subtypes%20and%20atrial%20fibrillation%20associated%20with%20glucagon%E2%80%90like%20peptide%201%20receptor%20agonists%20versus%20sodium%E2%80%90glucose%20cotransporter%202%20inhibitors:%20A%20real%E2%80%90world%20population%E2%80%90based%20cohort%20study%20in%20Hong%20Kong&author=DTW%20Lui&author=EHM%20Tang&author=T%20Wu&volume=22&publication_year=2023&pages=40&pmid=36829226&doi=10.1186/s12933-023-01772-0&)\\\\]\\n- 26.\\nFu EL, Clase CM, Janse RJ, _et al_. Comparative effectiveness of SGLT2i versus GLP1‐RA on cardiovascular outcomes in routine clinical practice. Int J Cardiol\\n2022;352:172‐179. doi: 10.1016/j.ijcard.2022.01.042\\n\\\\[ [DOI](https://doi.org/10.1016/j.ijcard.2022.01.042)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/35074492/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Int%20J%20Cardiol&title=Comparative%20effectiveness%20of%20SGLT2i%20versus%20GLP1%E2%80%90RA%20on%20cardiovascular%20outcomes%20in%20routine%20clinical%20practice&author=EL%20Fu&author=CM%20Clase&author=RJ%20Janse&volume=352&publication_year=2022&pages=172-179&pmid=35074492&doi=10.1016/j.ijcard.2022.01.042&)\\\\]\\n- 27.\\nPatorno E, Goldfine AB, Schneeweiss S, _et al_. Cardiovascular outcomes associated with canagliflozin versus other non‐gliflozin antidiabetic drugs: Population based cohort study. BMJ\\n2018;360:k119. doi: 10.1136/bmj.k119\\n\\\\[ [DOI](https://doi.org/10.1136/bmj.k119)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC5799855/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/29437648/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=BMJ&title=Cardiovascular%20outcomes%20associated%20with%20canagliflozin%20versus%20other%20non%E2%80%90gliflozin%20antidiabetic%20drugs:%20Population%20based%20cohort%20study&author=E%20Patorno&author=AB%20Goldfine&author=S%20Schneeweiss&volume=360&publication_year=2018&pages=k119&pmid=29437648&doi=10.1136/bmj.k119&)\\\\]\\n- 28.\\nThomsen RW, Knudsen JS, Kahlert J, _et al_. Cardiovascular events, acute hospitalizations, and mortality in patients with type 2 diabetes mellitus who initiate empagliflozin versus liraglutide: A comparative effectiveness study. J Am Heart Assoc\\n2021;10:e019356. doi: 10.1161/JAHA.120.019356\\n\\\\[ [DOI](https://doi.org/10.1161/JAHA.120.019356)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC8483550/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34032121/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Am%20Heart%20Assoc&title=Cardiovascular%20events,%20acute%20hospitalizations,%20and%20mortality%20in%20patients%20with%20type%202%20diabetes%20mellitus%20who%20initiate%20empagliflozin%20versus%20liraglutide:%20A%20comparative%20effectiveness%20study&author=RW%20Thomsen&author=JS%20Knudsen&author=J%20Kahlert&volume=10&publication_year=2021&pages=e019356&pmid=34032121&doi=10.1161/JAHA.120.019356&)\\\\]\\n- 29.\\nTang EHM, Wong CKH, Lau KTK, _et al_. Cardio‐renal outcomes and the direct medical cost of type 2 diabetes patients treated with sodium glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A population‐based cohort study. Diabetes Res Clin Pract\\n2021;180:109071. doi: 10.1016/j.diabres.2021.109071\\n\\\\[ [DOI](https://doi.org/10.1016/j.diabres.2021.109071)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34592391/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Res%20Clin%20Pract&title=Cardio%E2%80%90renal%20outcomes%20and%20the%20direct%20medical%20cost%20of%20type%202%20diabetes%20patients%20treated%20with%20sodium%20glucose%20cotransporter%E2%80%902%20inhibitors%20and%20glucagon%E2%80%90like%20peptide%E2%80%901%20receptor%20agonists:%20A%20population%E2%80%90based%20cohort%20study&author=EHM%20Tang&author=CKH%20Wong&author=KTK%20Lau&volume=180&publication_year=2021&pages=109071&pmid=34592391&doi=10.1016/j.diabres.2021.109071&)\\\\]\\n- 30.\\nD'Onofrio L, Mignogna C, Carlone A, _et al_. Decrease of coronary heart disease risk with GLP1‐receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: A 24 months follow‐up study. Diabetes Res Clin Pract\\n2021;173:108681. doi: 10.1016/j.diabres.2021.108681\\n\\\\[ [DOI](https://doi.org/10.1016/j.diabres.2021.108681)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33516784/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Res%20Clin%20Pract&title=Decrease%20of%20coronary%20heart%20disease%20risk%20with%20GLP1%E2%80%90receptor%20agonists%20or%20SGLT2%20inhibitors%20therapy%20in%20patients%20with%20type%202%20diabetes%20in%20primary%20cardiovascular%20prevention:%20A%2024%C2%A0months%20follow%E2%80%90up%20study&author=L%20D'Onofrio&author=C%20Mignogna&author=A%20Carlone&volume=173&publication_year=2021&pages=108681&pmid=33516784&doi=10.1016/j.diabres.2021.108681&)\\\\]\\n- 31.\\nVan Ruiten CC, van der Aart‐van der Beek AB, IJzerman RG, _et al_. Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial. Diabetes Obes Metab\\n2021;23:1851‐1858. doi: 10.1111/dom.14410\\n\\\\[ [DOI](https://doi.org/10.1111/dom.14410)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC8360098/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33908691/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Obes%20Metab&title=Effect%20of%20exenatide%20twice%20daily%20and%20dapagliflozin,%20alone%20and%20in%20combination,%20on%20markers%20of%20kidney%20function%20in%20obese%20patients%20with%20type%202%20diabetes:%20A%20prespecified%20secondary%20analysis%20of%20a%20randomized%20controlled%20clinical%20trial&author=CC%20Van%20Ruiten&author=AB%20van%20der%20Aart%E2%80%90van%20der%20Beek&author=RG%20IJzerman&volume=23&publication_year=2021&pages=1851-1858&pmid=33908691&doi=10.1111/dom.14410&)\\\\]\\n- 32.\\nLingvay I, Catarig AM, Frias JP, _et al_. Efficacy and safety of once‐weekly semaglutide versus daily canagliflozin as add‐on to metformin in patients with type 2 diabetes (SUSTAIN 8): A double‐blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol\\n2019;7:834‐844. doi: 10.1016/S2213-8587(19)30311-0\\n\\\\[ [DOI](https://doi.org/10.1016/S2213-8587(19)30311-0)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/31540867/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet%20Diabetes%20Endocrinol&title=Efficacy%20and%20safety%20of%20once%E2%80%90weekly%20semaglutide%20versus%20daily%20canagliflozin%20as%20add%E2%80%90on%20to%20metformin%20in%20patients%20with%20type%202%20diabetes%20(SUSTAIN%208):%20A%20double%E2%80%90blind,%20phase%203b,%20randomised%20controlled%20trial&author=I%20Lingvay&author=AM%20Catarig&author=JP%20Frias&volume=7&publication_year=2019&pages=834-844&pmid=31540867&doi=10.1016/S2213-8587(19)30311-0&)\\\\]\\n- 33.\\nJabbour SA, Frias JP, Hardy E, _et al_. Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 52‐week results of the DURATION‐8 randomized controlled trial. Diabetes Care\\n2018;41:2136‐2146. doi: 10.2337/dc18-0680\\n\\\\[ [DOI](https://doi.org/10.2337/dc18-0680)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC6150435/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/30082326/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&title=Safety%20and%20efficacy%20of%20exenatide%20once%20weekly%20plus%20dapagliflozin%20once%20daily%20versus%20exenatide%20or%20dapagliflozin%20alone%20in%20patients%20with%20type%202%20diabetes%20inadequately%20controlled%20with%20metformin%20monotherapy:%2052%E2%80%90week%20results%20of%20the%20DURATION%E2%80%908%20randomized%20controlled%20trial&author=SA%20Jabbour&author=JP%20Frias&author=E%20Hardy&volume=41&publication_year=2018&pages=2136-2146&pmid=30082326&doi=10.2337/dc18-0680&)\\\\]\\n- 34.\\nZhaohu H, Xiao H, Hailin S, _et al_. Efficacy and safety of dapagliflozin versus liraglutide in patients with overweight or obesity and type 2 diabetes mellitus: A randomised controlled clinical trial in Tianjin, China. J Diabetes Res\\n2022;2022:4126995. doi: 10.1155/2022/4126995\\n\\\\[ [DOI](https://doi.org/10.1155/2022/4126995)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC9381852/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/35990242/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Diabetes%20Res&title=Efficacy%20and%20safety%20of%20dapagliflozin%20versus%20liraglutide%20in%20patients%20with%20overweight%20or%20obesity%20and%20type%202%20diabetes%20mellitus:%20A%20randomised%20controlled%20clinical%20trial%20in%20Tianjin,%20China&author=H%20Zhaohu&author=H%20Xiao&author=S%20Hailin&volume=2022&publication_year=2022&pages=4126995&pmid=35990242&doi=10.1155/2022/4126995&)\\\\]\\n- 35.\\nIkonomidis I, Pavlidis G, Thymis J, _et al_. Effects of glucagon‐like peptide‐1 receptor agonists, sodium‐glucose cotransporter‐2 inhibitors, and their combination on endothelial glycocalyx, arterial function, and myocardial work index in patients with type 2 diabetes mellitus after 12‐month treatment. J Am Heart Assoc\\n2020;9:e015716. doi: 10.1161/JAHA.119.015716\\n\\\\[ [DOI](https://doi.org/10.1161/JAHA.119.015716)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC7428590/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/32326806/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Am%20Heart%20Assoc&title=Effects%20of%20glucagon%E2%80%90like%20peptide%E2%80%901%20receptor%20agonists,%20sodium%E2%80%90glucose%20cotransporter%E2%80%902%20inhibitors,%20and%20their%20combination%20on%20endothelial%20glycocalyx,%20arterial%20function,%20and%20myocardial%20work%20index%20in%20patients%20with%20type%202%20diabetes%20mellitus%20after%2012%E2%80%90month%20treatment&author=I%20Ikonomidis&author=G%20Pavlidis&author=J%20Thymis&volume=9&publication_year=2020&pages=e015716&pmid=32326806&doi=10.1161/JAHA.119.015716&)\\\\]\\n- 36.\\nNassif ME, Windsor SL, Tang F, _et al_. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: The DEFINE‐HF trial. Circulation\\n2019;140:1463‐1476. doi: 10.1161/CIRCULATIONAHA.119.042929\\n\\\\[ [DOI](https://doi.org/10.1161/CIRCULATIONAHA.119.042929)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/31524498/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Circulation&title=Dapagliflozin%20effects%20on%20biomarkers,%20symptoms,%20and%20functional%20status%20in%20patients%20with%20heart%20failure%20with%20reduced%20ejection%20fraction:%20The%20DEFINE%E2%80%90HF%20trial&author=ME%20Nassif&author=SL%20Windsor&author=F%20Tang&volume=140&publication_year=2019&pages=1463-1476&pmid=31524498&doi=10.1161/CIRCULATIONAHA.119.042929&)\\\\]\\n- 37.\\nNassif ME, Windsor SL, Borlaug BA, _et al_. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: A multicenter randomized trial. Nat Med\\n2021;27:1954‐1960. doi: 10.1038/s41591-021-01536-x\\n\\\\[ [DOI](https://doi.org/10.1038/s41591-021-01536-x)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC8604725/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34711976/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Nat%20Med&title=The%20SGLT2%20inhibitor%20dapagliflozin%20in%20heart%20failure%20with%20preserved%20ejection%20fraction:%20A%20multicenter%20randomized%20trial&author=ME%20Nassif&author=SL%20Windsor&author=BA%20Borlaug&volume=27&publication_year=2021&pages=1954-1960&pmid=34711976&doi=10.1038/s41591-021-01536-x&)\\\\]\\n- 38.\\nSolomon SD, McMurray JJV, Claggett B, _et al_. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med\\n2022;387:1089‐1098. doi: 10.1056/NEJMoa2206286\\n\\\\[ [DOI](https://doi.org/10.1056/NEJMoa2206286)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/36027570/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Dapagliflozin%20in%20heart%20failure%20with%20mildly%20reduced%20or%20preserved%20ejection%20fraction&author=SD%20Solomon&author=JJV%20McMurray&author=B%20Claggett&volume=387&publication_year=2022&pages=1089-1098&pmid=36027570&doi=10.1056/NEJMoa2206286&)\\\\]\\n- 39.\\nSavarese G, Uijl A, Lund LH, _et al_. Empagliflozin in heart failure with predicted preserved versus reduced ejection fraction: Data from the EMPA‐REG OUTCOME trial. J Card Fail\\n2021;27:888‐895. doi: 10.1016/j.cardfail.2021.05.012\\n\\\\[ [DOI](https://doi.org/10.1016/j.cardfail.2021.05.012)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34364665/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Card%20Fail&title=Empagliflozin%20in%20heart%20failure%20with%20predicted%20preserved%20versus%20reduced%20ejection%20fraction:%20Data%20from%20the%20EMPA%E2%80%90REG%20OUTCOME%20trial&author=G%20Savarese&author=A%20Uijl&author=LH%20Lund&volume=27&publication_year=2021&pages=888-895&pmid=34364665&doi=10.1016/j.cardfail.2021.05.012&)\\\\]\\n- 40.\\nVoors AA, Angermann CE, Teerlink JR, _et al_. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial. Nat Med\\n2022;28:568‐574. doi: 10.1038/s41591-021-01659-1\\n\\\\[ [DOI](https://doi.org/10.1038/s41591-021-01659-1)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC8938265/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/35228754/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Nat%20Med&title=The%20SGLT2%20inhibitor%20empagliflozin%20in%20patients%20hospitalized%20for%20acute%20heart%20failure:%20A%20multinational%20randomized%20trial&author=AA%20Voors&author=CE%20Angermann&author=JR%20Teerlink&volume=28&publication_year=2022&pages=568-574&pmid=35228754&doi=10.1038/s41591-021-01659-1&)\\\\]\\n- 41.\\nPetrie MC, Verma S, Docherty KF, _et al_. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA\\n2020;323:1353‐1368. doi: 10.1001/jama.2020.1906\\n\\\\[ [DOI](https://doi.org/10.1001/jama.2020.1906)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC7157181/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/32219386/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=JAMA&title=Effect%20of%20dapagliflozin%20on%20worsening%20heart%20failure%20and%20cardiovascular%20death%20in%20patients%20with%20heart%20failure%20with%20and%20without%20diabetes&author=MC%20Petrie&author=S%20Verma&author=KF%20Docherty&volume=323&publication_year=2020&pages=1353-1368&pmid=32219386&doi=10.1001/jama.2020.1906&)\\\\]\\n- 42.\\nKato ET, Silverman MG, Mosenzon O, _et al_. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation\\n2019;139:2528‐2536. doi: 10.1161/CIRCULATIONAHA.119.040130\\n\\\\[ [DOI](https://doi.org/10.1161/CIRCULATIONAHA.119.040130)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/30882238/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Circulation&title=Effect%20of%20dapagliflozin%20on%20heart%20failure%20and%20mortality%20in%20type%202%20diabetes%20mellitus&author=ET%20Kato&author=MG%20Silverman&author=O%20Mosenzon&volume=139&publication_year=2019&pages=2528-2536&pmid=30882238&doi=10.1161/CIRCULATIONAHA.119.040130&)\\\\]\\n- 43.\\nKosiborod M, Gause‐Nilsson I, Xu J, _et al_. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure. J Diabetes Complications\\n2017;31:1215‐1221. doi: 10.1016/j.jdiacomp.2017.02.001\\n\\\\[ [DOI](https://doi.org/10.1016/j.jdiacomp.2017.02.001)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/28284707/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Diabetes%20Complications&title=Efficacy%20and%20safety%20of%20dapagliflozin%20in%20patients%20with%20type%202%20diabetes%20and%20concomitant%20heart%20failure&author=M%20Kosiborod&author=I%20Gause%E2%80%90Nilsson&author=J%20Xu&volume=31&publication_year=2017&pages=1215-1221&pmid=28284707&doi=10.1016/j.jdiacomp.2017.02.001&)\\\\]\\n- 44.\\nAnker SD, Butler J, Filippatos G, _et al_. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: Results from the EMPEROR‐Reduced trial. Circulation\\n2021;143:337‐349. doi: 10.1161/CIRCULATIONAHA.120.051824\\n\\\\[ [DOI](https://doi.org/10.1161/CIRCULATIONAHA.120.051824)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC7834911/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33175585/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Circulation&title=Effect%20of%20empagliflozin%20on%20cardiovascular%20and%20renal%20outcomes%20in%20patients%20with%20heart%20failure%20by%20baseline%20diabetes%20status:%20Results%20from%20the%20EMPEROR%E2%80%90Reduced%20trial&author=SD%20Anker&author=J%20Butler&author=G%20Filippatos&volume=143&publication_year=2021&pages=337-349&pmid=33175585&doi=10.1161/CIRCULATIONAHA.120.051824&)\\\\]\\n- 45.\\nFitchett D, Zinman B, Wanner C, _et al_. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: Results of the EMPA‐REG OUTCOME® trial. Eur Heart J\\n2016;37:1526‐1534. doi: 10.1093/eurheartj/ehv728\\n\\\\[ [DOI](https://doi.org/10.1093/eurheartj/ehv728)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC4872285/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/26819227/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&title=Heart%20failure%20outcomes%20with%20empagliflozin%20in%20patients%20with%20type%202%20diabetes%20at%20high%20cardiovascular%20risk:%20Results%20of%20the%20EMPA%E2%80%90REG%20OUTCOME%C2%AE%20trial&author=D%20Fitchett&author=B%20Zinman&author=C%20Wanner&volume=37&publication_year=2016&pages=1526-1534&pmid=26819227&doi=10.1093/eurheartj/ehv728&)\\\\]\\n- 46.\\nFilippatos G, Butler J, Farmakis D, _et al_. Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes. Circulation\\n2022;146:676‐686. doi: 10.1161/CIRCULATIONAHA.122.059785\\n\\\\[ [DOI](https://doi.org/10.1161/CIRCULATIONAHA.122.059785)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC9422757/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/35762322/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Circulation&title=Empagliflozin%20for%20heart%20failure%20with%20preserved%20left%20ventricular%20ejection%20fraction%20with%20and%20without%20diabetes&author=G%20Filippatos&author=J%20Butler&author=D%20Farmakis&volume=146&publication_year=2022&pages=676-686&pmid=35762322&doi=10.1161/CIRCULATIONAHA.122.059785&)\\\\]\\n- 47.\\nBhatt DL, Szarek M, Steg PG, _et al_. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med\\n2021;384:117‐128. doi: 10.1056/NEJMoa2030183\\n\\\\[ [DOI](https://doi.org/10.1056/NEJMoa2030183)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33200892/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Sotagliflozin%20in%20patients%20with%20diabetes%20and%20recent%20worsening%20heart%20failure&author=DL%20Bhatt&author=M%20Szarek&author=PG%20Steg&volume=384&publication_year=2021&pages=117-128&pmid=33200892&doi=10.1056/NEJMoa2030183&)\\\\]\\n- 48.\\nConsoli A, Formoso G, Baldassarre MPA, _et al_. A comparative safety review between GLP‐1 receptor agonists and SGLT2 inhibitors for diabetes treatment. Expert Opin Drug Saf\\n2018;17:293‐302. doi: 10.1080/14740338.2018.1428305\\n\\\\[ [DOI](https://doi.org/10.1080/14740338.2018.1428305)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/29334278/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Expert%20Opin%20Drug%20Saf&title=A%20comparative%20safety%20review%20between%20GLP%E2%80%901%20receptor%20agonists%20and%20SGLT2%20inhibitors%20for%20diabetes%20treatment&author=A%20Consoli&author=G%20Formoso&author=MPA%20Baldassarre&volume=17&publication_year=2018&pages=293-302&pmid=29334278&doi=10.1080/14740338.2018.1428305&)\\\\]\\n- 49.\\nNeal B, Perkovic V, Mahaffey KW, _et al_. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med\\n2017;377:644‐657. doi: 10.1056/NEJMoa1611925\\n\\\\[ [DOI](https://doi.org/10.1056/NEJMoa1611925)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/28605608/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Canagliflozin%20and%20cardiovascular%20and%20renal%20events%20in%20type%202%20diabetes&author=B%20Neal&author=V%20Perkovic&author=KW%20Mahaffey&volume=377&publication_year=2017&pages=644-657&pmid=28605608&doi=10.1056/NEJMoa1611925&)\\\\]\\n- 50.\\nWiviott SD, Raz I, Bonaca MP, _et al_. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med\\n2019;380:347‐357. doi: 10.1056/NEJMoa1812389\\n\\\\[ [DOI](https://doi.org/10.1056/NEJMoa1812389)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/30415602/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Dapagliflozin%20and%20cardiovascular%20outcomes%20in%20type%202%20diabetes&author=SD%20Wiviott&author=I%20Raz&author=MP%20Bonaca&volume=380&publication_year=2019&pages=347-357&pmid=30415602&doi=10.1056/NEJMoa1812389&)\\\\]\\n- 51.\\nAnker SD, Butler J, Filippatos G, _et al_. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med\\n2021;385:1451‐1461. doi: 10.1056/NEJMoa2107038\\n\\\\[ [DOI](https://doi.org/10.1056/NEJMoa2107038)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34449189/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Empagliflozin%20in%20heart%20failure%20with%20a%20preserved%20ejection%20fraction&author=SD%20Anker&author=J%20Butler&author=G%20Filippatos&volume=385&publication_year=2021&pages=1451-1461&pmid=34449189&doi=10.1056/NEJMoa2107038&)\\\\]\\n- 52.\\nSavarese G, Butler J, Lund LH, _et al_. Cardiovascular effects of non‐insulin glucose‐lowering agents: A comprehensive review of trial evidence and potential cardioprotective mechanisms. Cardiovasc Res\\n2022;118:2231‐2252. doi: 10.1093/cvr/cvab271\\n\\\\[ [DOI](https://doi.org/10.1093/cvr/cvab271)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34390570/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cardiovasc%20Res&title=Cardiovascular%20effects%20of%20non%E2%80%90insulin%20glucose%E2%80%90lowering%20agents:%20A%20comprehensive%20review%20of%20trial%20evidence%20and%20potential%20cardioprotective%20mechanisms&author=G%20Savarese&author=J%20Butler&author=LH%20Lund&volume=118&publication_year=2022&pages=2231-2252&pmid=34390570&doi=10.1093/cvr/cvab271&)\\\\]\\n- 53.\\nPfeffer MA, Claggett B, Diaz R, _et al_. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med\\n2015;373:2247‐2257. doi: 10.1056/NEJMoa1509225\\n\\\\[ [DOI](https://doi.org/10.1056/NEJMoa1509225)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/26630143/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Lixisenatide%20in%20patients%20with%20type%202%20diabetes%20and%20acute%20coronary%20syndrome&author=MA%20Pfeffer&author=B%20Claggett&author=R%20Diaz&volume=373&publication_year=2015&pages=2247-2257&pmid=26630143&doi=10.1056/NEJMoa1509225&)\\\\]\\n- 54.\\nMarso SP, Bain SC, Consoli A, _et al_. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med\\n2016;375:1834‐1844. doi: 10.1056/NEJMoa1607141\\n\\\\[ [DOI](https://doi.org/10.1056/NEJMoa1607141)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/27633186/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Semaglutide%20and%20cardiovascular%20outcomes%20in%20patients%20with%20type%202%20diabetes&author=SP%20Marso&author=SC%20Bain&author=A%20Consoli&volume=375&publication_year=2016&pages=1834-1844&pmid=27633186&doi=10.1056/NEJMoa1607141&)\\\\]\\n- 55.\\nVerma S, Bain SC, Buse JB, _et al_. Occurence of first and recurrent major adverse cardiovascular events with liraglutide treatment among patients with type 2 diabetes and high risk of cardiovascular events: A post hoc analysis of a randomized clinical trial. JAMA Cardiol\\n2019;4:1214‐1220. doi: 10.1001/jamacardio.2019.3080\\n\\\\[ [DOI](https://doi.org/10.1001/jamacardio.2019.3080)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC6865601/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/31721979/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=JAMA%20Cardiol&title=Occurence%20of%20first%20and%20recurrent%20major%20adverse%20cardiovascular%20events%20with%20liraglutide%20treatment%20among%20patients%20with%20type%202%20diabetes%20and%20high%20risk%20of%20cardiovascular%20events:%20A%20post%20hoc%20analysis%20of%20a%20randomized%20clinical%20trial&author=S%20Verma&author=SC%20Bain&author=JB%20Buse&volume=4&publication_year=2019&pages=1214-1220&pmid=31721979&doi=10.1001/jamacardio.2019.3080&)\\\\]\\n- 56.\\nHernandez AF, Green JB, Janmohamed S, _et al_. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double‐blind, randomised placebo‐controlled trial. Lancet\\n2018;392:1519‐1529. doi: 10.1016/S0140-6736(18)32261-X\\n\\\\[ [DOI](https://doi.org/10.1016/S0140-6736(18)32261-X)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/30291013/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet&title=Albiglutide%20and%20cardiovascular%20outcomes%20in%20patients%20with%20type%202%20diabetes%20and%20cardiovascular%20disease%20(Harmony%20Outcomes):%20A%20double%E2%80%90blind,%20randomised%20placebo%E2%80%90controlled%20trial&author=AF%20Hernandez&author=JB%20Green&author=S%20Janmohamed&volume=392&publication_year=2018&pages=1519-1529&pmid=30291013&doi=10.1016/S0140-6736(18)32261-X&)\\\\]\\n- 57.\\nGerstein HC, Colhoun HM, Dagenais GR, _et al_. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double‐blind, randomised placebo‐controlled trial. Lancet\\n2019;394:121‐130. doi: 10.1016/S0140-6736(19)31149-3\\n\\\\[ [DOI](https://doi.org/10.1016/S0140-6736(19)31149-3)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/31189511/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet&title=Dulaglutide%20and%20cardiovascular%20outcomes%20in%20type%202%20diabetes%20(REWIND):%20A%20double%E2%80%90blind,%20randomised%20placebo%E2%80%90controlled%20trial&author=HC%20Gerstein&author=HM%20Colhoun&author=GR%20Dagenais&volume=394&publication_year=2019&pages=121-130&pmid=31189511&doi=10.1016/S0140-6736(19)31149-3&)\\\\]\\n- 58.\\nPhrommintikul A, Wongcharoen W, Kumfu S, _et al_. Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: A randomised study. Br J Clin Pharmacol\\n2019;85:1337‐1347. doi: 10.1111/bcp.13903\\n\\\\[ [DOI](https://doi.org/10.1111/bcp.13903)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC6533436/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/30767253/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Br%20J%20Clin%20Pharmacol&title=Effects%20of%20dapagliflozin%20vs%20vildagliptin%20on%20cardiometabolic%20parameters%20in%20diabetic%20patients%20with%20coronary%20artery%20disease:%20A%20randomised%20study&author=A%20Phrommintikul&author=W%20Wongcharoen&author=S%20Kumfu&volume=85&publication_year=2019&pages=1337-1347&pmid=30767253&doi=10.1111/bcp.13903&)\\\\]\\n- 59.\\nChilton R, Tikkanen I, Cannon CP, _et al_. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab\\n2015;17:1180‐1193. doi: 10.1111/dom.12572\\n\\\\[ [DOI](https://doi.org/10.1111/dom.12572)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC5057299/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/26343814/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Obes%20Metab&title=Effects%20of%20empagliflozin%20on%20blood%20pressure%20and%20markers%20of%20arterial%20stiffness%20and%20vascular%20resistance%20in%20patients%20with%20type%202%20diabetes&author=R%20Chilton&author=I%20Tikkanen&author=CP%20Cannon&volume=17&publication_year=2015&pages=1180-1193&pmid=26343814&doi=10.1111/dom.12572&)\\\\]\\n- 60.\\nFerrannini E, Mark M, Mayoux E. CV protection in the EMPA‐REG OUTCOME trial: A “thrifty substrate” hypothesis. Diabetes Care\\n2016;39:1108‐1114. doi: 10.2337/dc16-0330\\n\\\\[ [DOI](https://doi.org/10.2337/dc16-0330)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/27289126/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&title=CV%20protection%20in%20the%20EMPA%E2%80%90REG%20OUTCOME%20trial:%20A%20%E2%80%9Cthrifty%20substrate%E2%80%9D%20hypothesis&author=E%20Ferrannini&author=M%20Mark&author=E%20Mayoux&volume=39&publication_year=2016&pages=1108-1114&pmid=27289126&doi=10.2337/dc16-0330&)\\\\]\\n- 61.\\nLytvyn Y, Škrtic M, Yang GK, _et al_. Glycosuria‐mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol\\n2015;308:F77‐F83. doi: 10.1152/ajprenal.00555.2014\\n\\\\[ [DOI](https://doi.org/10.1152/ajprenal.00555.2014)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/25377916/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Am%20J%20Physiol%20Renal%20Physiol&title=Glycosuria%E2%80%90mediated%20urinary%20uric%20acid%20excretion%20in%20patients%20with%20uncomplicated%20type%201%20diabetes%20mellitus&author=Y%20Lytvyn&author=M%20%C5%A0krtic&author=GK%20Yang&volume=308&publication_year=2015&pages=F77-F83&pmid=25377916&doi=10.1152/ajprenal.00555.2014&)\\\\]\\n- 62.\\nBaartscheer A, Schumacher CA, Wust RC, _et al_. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia\\n2017;60:568‐573. doi: 10.1007/s00125-016-4134-x\\n\\\\[ [DOI](https://doi.org/10.1007/s00125-016-4134-x)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC6518059/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/27752710/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetologia&title=Empagliflozin%20decreases%20myocardial%20cytoplasmic%20Na+%20through%20inhibition%20of%20the%20cardiac%20Na+/H+%20exchanger%20in%20rats%20and%20rabbits&author=A%20Baartscheer&author=CA%20Schumacher&author=RC%20Wust&volume=60&publication_year=2017&pages=568-573&pmid=27752710&doi=10.1007/s00125-016-4134-x&)\\\\]\\n- 63.\\nLiu T, Takimoto E, Dimaano VL, _et al_. Inhibiting mitochondrial Na+/Ca2+ exchange prevents sudden death in a guinea pig model of heart failure. Circ Res\\n2014;115:44‐54. doi: 10.1161/CIRCRESAHA.115.303062\\n\\\\[ [DOI](https://doi.org/10.1161/CIRCRESAHA.115.303062)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC4219273/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/24780171/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Circ%20Res&title=Inhibiting%20mitochondrial%20Na+/Ca2+%20exchange%20prevents%20sudden%20death%20in%20a%20guinea%20pig%20model%20of%20heart%20failure&author=T%20Liu&author=E%20Takimoto&author=VL%20Dimaano&volume=115&publication_year=2014&pages=44-54&pmid=24780171&doi=10.1161/CIRCRESAHA.115.303062&)\\\\]\\n\\n## Associated Data\\n\\n_This section collects any data citations, data availability statements, or supplementary materials included in this article._\\n\\n### Supplementary Materials\\n\\n**Table S1.** Study characteristics of included studies comparing SGLT2i and GLP1‐RA in patients with T2DM.\\n\\n**Table S2.** Study characteristics of included studies comparing SGLT2i and placebo in HF patients regardless of diabetes status.\\n\\n**Table S3.** Quality assessment of included RCTs.\\n\\n**Table S4.** Publication bias of cardiovascular outcomes.\\n\\n**Figure S1.** Supporting information.\\n\\n**Figure S2.** Supporting information.\\n\\n[EHF2-11-1647-s001.docx](https://pmc.ncbi.nlm.nih.gov/articles/instance/11098653/bin/EHF2-11-1647-s001.docx) (299.4KB, docx)\\n\\n## ACTIONS\\n\\n- [View on publisher site](https://doi.org/10.1002/ehf2.14726)\\n- [PDF (1.2 MB)](https://pmc.ncbi.nlm.nih.gov/pdf/EHF2-11-1647.pdf)\\n- Cite\\n- Collections\\n- Permalink\\n\\n\\n## PERMALINK\\n\\n\\n\\nCopy\\n\\n\\n## RESOURCES\\n\\n### Similar articles\\n\\n### Cited by other articles\\n\\n### Links to NCBI Databases\\n\\nBack to Top\",\n      \"summary\": \"{\\\"answer\\\":\\\"The study is a meta-analysis comparing cardiovascular outcomes of new antihyperglycemic agents in Type 2 Diabetes Mellitus. It includes authors Zijing Zhou, Min Zheng, Zhihong Zuo, and Ting Wu. The article was published in ESC Heart Fail in 2024. The abstract aims to provide evidence for the selection of agents in T2DM patients with cardiovascular risk and summarize the latest evidence for the cardiovascular effects of SGLT2i in patients with heart failure.\\\"}\",\n      \"favicon\": \"https://pmc.ncbi.nlm.nih.gov/static/img/favicons/favicon-32x32.png\"\n    },\n    {\n      \"id\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC9663714/\",\n      \"title\": \"Causal deep learning reveals the comparative ...\",\n      \"url\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC9663714/\",\n      \"publishedDate\": \"2022-11-14T00:00:00.000Z\",\n      \"author\": \"\",\n      \"text\": \"[Skip to main content](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#main-content)\\n\\n**Official websites use .gov**\\nA\\n**.gov** website belongs to an official\\ngovernment organization in the United States.\\n\\n**Secure .gov websites use HTTPS**\\nA **lock** (\\n\\nLocked padlock icon\\n) or **https://** means you've safely\\nconnected to the .gov website. Share sensitive\\ninformation only on official, secure websites.\\n\\nSearch PMC Full-Text ArchiveSearch in PMC\\n\\n- [Advanced Search](https://www.ncbi.nlm.nih.gov/pmc/advanced/)\\n- [Journal List](https://pmc.ncbi.nlm.nih.gov/journals/)\\n- [User Guide](https://pmc.ncbi.nlm.nih.gov/about/userguide/)\\n\\nNewTry this search in PMC Beta Search\\n\\n- ## PERMALINK\\n\\n\\n\\nCopy\\n\\n\\nAs a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,\\nthe contents by NLM or the National Institutes of Health.\\nLearn more:\\n[PMC Disclaimer](https://pmc.ncbi.nlm.nih.gov/about/disclaimer/)\\n\\\\|\\n[PMC Copyright Notice](https://pmc.ncbi.nlm.nih.gov/about/copyright/)\\n\\nNat Commun\\n\\n. 2022 Nov 14;13:6921. doi: [10.1038/s41467-022-33732-9](https://doi.org/10.1038/s41467-022-33732-9)\\n\\n# Causal deep learning reveals the comparative effectiveness of antihyperglycemic treatments in poorly controlled diabetes\\n\\n[Chinmay Belthangady](https://pubmed.ncbi.nlm.nih.gov/?term=%22Belthangady%20C%22%5BAuthor%5D)\\n\\n### Chinmay Belthangady\\n\\n1Elevance Health Palo Alto, California, US\\n\\nFind articles by [Chinmay Belthangady](https://pubmed.ncbi.nlm.nih.gov/?term=%22Belthangady%20C%22%5BAuthor%5D)\\n\\n1,#, [Stefanos Giampanis](https://pubmed.ncbi.nlm.nih.gov/?term=%22Giampanis%20S%22%5BAuthor%5D)\\n\\n### Stefanos Giampanis\\n\\n1Elevance Health Palo Alto, California, US\\n\\nFind articles by [Stefanos Giampanis](https://pubmed.ncbi.nlm.nih.gov/?term=%22Giampanis%20S%22%5BAuthor%5D)\\n\\n1,#, [Ivana Jankovic](https://pubmed.ncbi.nlm.nih.gov/?term=%22Jankovic%20I%22%5BAuthor%5D)\\n\\n### Ivana Jankovic\\n\\n1Elevance Health Palo Alto, California, US\\n\\nFind articles by [Ivana Jankovic](https://pubmed.ncbi.nlm.nih.gov/?term=%22Jankovic%20I%22%5BAuthor%5D)\\n\\n1,#, [Will Stedden](https://pubmed.ncbi.nlm.nih.gov/?term=%22Stedden%20W%22%5BAuthor%5D)\\n\\n### Will Stedden\\n\\n1Elevance Health Palo Alto, California, US\\n\\nFind articles by [Will Stedden](https://pubmed.ncbi.nlm.nih.gov/?term=%22Stedden%20W%22%5BAuthor%5D)\\n\\n1, [Paula Alves](https://pubmed.ncbi.nlm.nih.gov/?term=%22Alves%20P%22%5BAuthor%5D)\\n\\n### Paula Alves\\n\\n1Elevance Health Palo Alto, California, US\\n\\nFind articles by [Paula Alves](https://pubmed.ncbi.nlm.nih.gov/?term=%22Alves%20P%22%5BAuthor%5D)\\n\\n1, [Stephanie Chong](https://pubmed.ncbi.nlm.nih.gov/?term=%22Chong%20S%22%5BAuthor%5D)\\n\\n### Stephanie Chong\\n\\n1Elevance Health Palo Alto, California, US\\n\\nFind articles by [Stephanie Chong](https://pubmed.ncbi.nlm.nih.gov/?term=%22Chong%20S%22%5BAuthor%5D)\\n\\n1, [Charlotte Knott](https://pubmed.ncbi.nlm.nih.gov/?term=%22Knott%20C%22%5BAuthor%5D)\\n\\n### Charlotte Knott\\n\\n1Elevance Health Palo Alto, California, US\\n\\nFind articles by [Charlotte Knott](https://pubmed.ncbi.nlm.nih.gov/?term=%22Knott%20C%22%5BAuthor%5D)\\n\\n1, [Beau Norgeot](https://pubmed.ncbi.nlm.nih.gov/?term=%22Norgeot%20B%22%5BAuthor%5D)\\n\\n### Beau Norgeot\\n\\n1Elevance Health Palo Alto, California, US\\n\\nFind articles by [Beau Norgeot](https://pubmed.ncbi.nlm.nih.gov/?term=%22Norgeot%20B%22%5BAuthor%5D)\\n\\n1,✉\\n\\n- Author information\\n- Article notes\\n- Copyright and License information\\n\\n1Elevance Health Palo Alto, California, US\\n\\n✉\\n\\nCorresponding author.\\n\\n#\\n\\nContributed equally.\\n\\nReceived 2021 Jul 9; Accepted 2022 Sep 30; Collection date 2022.\\n\\n© The Author(s) 2022\\n\\n**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/).\\n\\n[PMC Copyright notice](https://pmc.ncbi.nlm.nih.gov/about/copyright/)\\n\\nPMCID: PMC9663714  PMID: [36376286](https://pubmed.ncbi.nlm.nih.gov/36376286/)\\n\\n## Abstract\\n\\nType-2 diabetes is associated with severe health outcomes, the effects of which are responsible for approximately 1/4th of the total healthcare spending in the United States (US). Current treatment guidelines endorse a massive number of potential anti-hyperglycemic treatment options in various combinations. Strategies for optimizing treatment selection are lacking. Real-world data from a nationwide population of over one million high-risk diabetic patients (HbA1c ≥ 9%) in the US is analyzed to evaluate the comparative effectiveness for HbA1c reduction in this population of more than 80 different treatment strategies ranging from monotherapy up to combinations of five concomitant classes of drugs across each of 10 clinical cohorts defined by age, insulin dependence, and a number of other chronic conditions. A causal deep learning approach developed on such data allows for more personalized evaluation of treatment selection. An average confounder-adjusted reduction in HbA1c of 0.69% \\\\[−0.75, −0.65\\\\] is observed between patients receiving high vs low ranked treatments across cohorts for which the difference was significant. This method can be extended to explore treatment optimization for other chronic conditions.\\n\\n**Subject terms:** Machine learning, Endocrinology, Type 2 diabetes\\n\\nCurrent treatment guidelines for Type-2 diabetes endorse a massive number of potential anti-hyper-glycemic treatment options in various permutations and combinations. Here, the authors present a causal deep learning approach for more personalized recommendations of treatment selection.\\n\\n## Introduction\\n\\nRecent data from the Centers for Disease Control and Prevention estimates that ~13% of the adult population of the United States (US), or about 34 million people, have been diagnosed with diabetes mellitus[1](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR1). When insufficiently managed, diabetes leads to complications including cardiovascular disease, kidney disease, neuropathy, and blindness, any of which can dramatically impair an individual’s quality of life. The high prevalence of diabetes and concomitant complications put a major burden on the US healthcare system in terms of care utilization and costs, with one recent report estimating that one of every four healthcare spending dollars in the US can be directly attributed to diabetes[2](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR2).\\n\\nDiabetes is typically managed by a combination of lifestyle interventions and pharmacological treatments. For the latter, current guidelines stipulate that unless otherwise contraindicated, initial therapy for type-2 diabetes mellitus (T2DM) should be metformin[3](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR3). If this first-line therapy is insufficient, combination therapy with antihyperglycemic drugs from two or more classes is suggested. There are multiple second-line choices with various risks and benefits, and a clinician may therefore need to attempt multiple treatment combinations before finding one that works for their patient. There have been efforts to determine sequential treatment of diabetes, both with data-driven informatics methods[4](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR4) and with expert-curated guidelines;[5](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR5) however, both of these approaches take into account a few patient-specific characteristics and can be ambiguous in suggesting the next best option for an individual patient. Even when glycemic control is achieved, there is currently no simple way to know whether a different combination might be superior for a given patient, either by providing greater glycemic control, by simultaneously managing comorbidities, or by providing equivalent control at a lower cost, or with fewer total drugs or with fewer side effects. Indeed, the enormous heterogeneity of treatment decisions observed in daily clinical practice is indicative that optimal treatment regimens have not been identified[6](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR6). Given the complexity of diabetes treatment, patients can often benefit from focused subspecialist insights, such as referral to an endocrinologist[7](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR7). However, subspecialist care is resource-intensive and the current shortage of endocrinologists is only projected to grow[8](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR8), thus offering an opportunity for a data-driven understanding of the real-world comparative effectiveness of pharmacological diabetes treatment strategies to help guide T2DM management.\\n\\nResearch on the comparative efficacy and effectiveness of antihyperglycemic drugs has been expanding. The ADOPT trial examined the relative efficacies of three monotherapies using a randomized, double-blind study examining the time to monotherapy failure over multiple years on 4,360 relatively healthy patients between the ages of 30 and 75[9](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR9). Causal analysis methods, such as the frameworks developed by Rosenbaum and Rubin[10](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR10) for observational data are now robust and widespread in clinical research. Meta-analysis[11](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR11) and Network Meta-Analysis[12](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR12) have made it possible to combine results from multiple trials to respectively gain effect insights from a combined pool of patients and leverage both direct and indirect comparisons between treatment arms to reduce measurement uncertainty. These approaches have been applied to a growing body of literature on the effects of T2DM pharmacological interventions, for example to randomized controlled trials (RCTs) and real-world data[4](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR4), [13](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR13). Although such studies have contributed substantially to clinical knowledge, a comprehensive understanding that reflects the realities of daily practice including diverse patients who may be on more than two classes of antihyperglycemics is still missing.\\n\\nIn recent years, there has been a rapid trend toward digitization in the healthcare industry. Patient medical histories are increasingly recorded in electronic format and claim adjudication systems have become streamlined and more automated. This digitization has led to an explosion in the amount of medical data available to learn from. Concurrently, there have been major advances in the fields of artificial intelligence and machine learning[14](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR14), allowing algorithms to extract complex signals from increasingly larger amounts of data. In medicine, artificial intelligence models have demonstrated human-level performance in interpreting dermatology[15](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR15) and ophthalmology[16](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR16) images. Deep neural networks trained on electronic health records (EHR) have been used to estimate the risk of disease onset[17](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR17), the risk of hospital readmissions[18](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR18), and to forecast the future health state of individuals with complex diseases[19](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR19). It is now possible to use artificial intelligence to extract meaningful insights from large-scale observational studies, which can be extended to potentially infer causal relationships.\\n\\nHere, an approach is demonstrated that combines deep learning, causal inference, and network meta-analysis[12](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR12) (NMA) to estimate the real-word comparative effectiveness of combination therapies for T2DM in clinically stratified high-risk sub-populations. Using the change in levels of glycated hemoglobin (HbA1c) as the primary outcome of interest, effectiveness was measured by estimating confounder-adjusted average treatment effects (ATE) of each treatment strategy relative to other treatments, at the level of drug classes, observed using a nationwide cohort of patients with poorly controlled T2DM. This work departs from previous research in several important ways: (i) it is, to our knowledge, the first study to extend beyond single or dual therapies and compares all treatment regimens observed in the data without imposing restrictions on the number of drug classes; results on combinations of up to five drug classes are reported here; (ii) the analysis was performed on 10 cohorts stratified based on clinical variables to make the rankings more personalized; (iii) a recently developed deep-learning-based propensity score model was used for causal analysis that scales well to large multi-arm observational studies; and (iv) a sensitivity analysis was performed on held-out test data in order to assess the extent to which the comparative effectiveness rankings were meaningful and broadly generalizable. With further development and prospective validation, these rankings for combination therapies could form the basis of a tool to complement/enhance guideline-based practice and help clinicians make personalized data-driven decisions when deciding the next step in treatment for their high-risk patients.\\n\\n## Results\\n\\n### Inclusion criteria\\n\\nThe data for this study came from health insurance claims of 56.4 million individuals collected over a 5-year period (see Methods). The claims contain records of diagnoses made during doctor visits, procedures performed in in-patient or out-patient medical centers, lab tests ordered and their results, and drug prescriptions including dosage and refill information. The set of claims for an individual, therefore, serves as a succinct historical record of that individual’s state of health. Clinical filters (Fig. [1a](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#Fig1)) were used to identify a subpopulation of 1.2 million patients with T2DM. Temporal “snapshots” (Fig. [1b](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#Fig1)) of patient health histories, beginning with a given HbA1c event and ending with the next subsequent HbA1c lab measurement for each pair of HbA1c events in a patient’s timeline, were generated for each person in this subpopulation from their available history of medications, diagnoses, procedures, and relevant laboratory values to assess the treatment strategies and resulting causal effect calculations (Fig. [1](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#Fig1)). The combinations of medications, at the level of drug class, that a patient was filling during the time of interest was considered a treatment. We evaluated changes in HbA1c regardless of whether the treatment regimen changed during the snapshot. If a regimen did change during a snapshot, the change in A1c was attributed to the new regimen. Snapshots were filtered for those with an initial HbA1c ≥9% to target high-risk patients who were clearly above goal[20](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR20) and could most benefit from treatment insights. Causal inference analyses were conducted on a final study population of 141,625 patient snapshots.\\n\\n#### Fig. 1. Study cohort definition and data preparation.\\n\\n[Open in a new tab](https://pmc.ncbi.nlm.nih.gov/figure/Fig1/)\\n\\n**a** Clinical filters were designed to identify patients with T2DM (1.2 million individuals) and retain only those with well-established, high-risk disease. **b** Each patient’s health history was split into a series of temporal snapshots, determined by an HbA1c ≥9% lab measurement and ending at the subsequent HbA1c for each patient. A snapshot consisted of a pair of HbA1c lab events. The first of these is referred to as the index HbA1c lab event and the period between the two lab events is the observation period. Only snapshots where the duration between the lab pairs was between 90 and 365 days were retained and the rest were excluded, resulting in a final study population of 141,625 patient snapshots. All further analyses were conducted at the level of patient snapshots. **c** A patient was considered to have been treated by a particular antihyperglycemic drug at the time of a given HbA1c lab event if it was prescribed prior to the lab and if the number of days’ supply (blue arrows) extended past the lab date. When multiple such drugs existed, the individual was considered treated by the combination of these drugs. Prior treatment was the regimen used to treat the individual in the period prior to the observation window between the two labs.\\n\\n### Clinical cohort definition\\n\\nBecause target HbA1c varies by a patient’s age and health status[20](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR20), patient snapshots were assigned to 1 of 10 clinical cohorts on the basis of each patient’s age and a number of additional chronic health conditions at the time of the HbA1c index event, as well as by insulin status at the time of the index HbA1c. Cohorts by age/comorbidities were chosen to prevent the algorithm from inappropriately optimizing low HbA1c in groups for which sub-target HbA1c may be due to dangerous hypoglycemia, and cohorts by insulin status at the time of index HbA1c were chosen as a proxy for hypoinsulinemia, which would be dangerous to misclassify but is not otherwise well-captured in the available data. The number of snapshots present as well as the number of treatment strategies that cohorts were exposed to tended to decrease with age and disease burden (Table [1](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#Tab1)) though these trends did not decrease monotonically. There were 81 unique treatment regimens identified across all clinical cohorts. The number of distinct treatment strategies observed in a cohort was correlated to the number of patient snapshots present; the larger the population, the more unique treatment strategies were observed.\\n\\n#### Table 1.\\n\\nDefinitions and characteristics of T2DM patient cohorts\\n\\n| Cohort | Insulin status | Age | CCI | Number of snapshots | Number of patients | Number of treatments |\\n| --- | --- | --- | --- | --- | --- | --- |\\n| A | Non-user | <65 years | ≤2 | 54415 | 42676 | 69 |\\n| B | Non-user | <65 years | >2 & <5 | 21342 | 16570 | 50 |\\n| C | Non-user | <65 years | ≥5 | 9164 | 7121 | 37 |\\n| D | Non-user | ≥65 years | <5 | 8971 | 7163 | 30 |\\n| E | Non-user | ≥65 years | ≥5 | 4339 | 3504 | 18 |\\n| F | User | <65 years | ≤2 | 13422 | 7025 | 43 |\\n| G | User | <65 years | >2 & <5 | 13057 | 9356 | 43 |\\n| H | User | <65 years | ≥5 | 8973 | 5878 | 35 |\\n| I | User | ≥65 years | <5 | 3661 | 2681 | 15 |\\n| J | User | ≥65 years | ≥5 | 4281 | 3018 | 19 |\\n\\n[Open in a new tab](https://pmc.ncbi.nlm.nih.gov/table/Tab1/)\\n\\nCCI (unweighted) Charleson Comorbidity Index; Snapshots divided into cohorts by the patient’s history at the time of the index HbA1c laboratory event as defined in Fig. [1b](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#Fig1). Number of treatments refers to the number of unique treatment strategies (including combinations of drugs) observed in the cohort as detailed in Fig. [1c](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#Fig1). Also shown is the number of patients in each cohort. Bolding of cohort names and headers for clarity.\\n\\n### Characteristics of the study population\\n\\nTable [S1](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#MOESM1) summarizes variable values for the study population at the snapshot level.\\n\\nThe snapshot population had a mean age of 55 years, with baseline HbA1c, estimated glomerular filtration rate (EGFR), and creatinine lab values of 10.5%, 94 mL/min/1.72m2, and 0.9 mg/dL respectively. Data on race and ethnicity was available for only 28% and 16% of the patients, respectively, and no income data was available. Since these variables can act as confounders, information on the racial makeup and income levels in the patient’s zip code tabulation area (ZCTA) were used as proxies. This demographic data came from the 2017 American Community Survey published by the US Census Bureau[21](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR21). Neighborhood median incomes ranged significantly with a median value of fifty-five thousand dollars annually. White, Black, and Asian populations were well represented with Whites being in the majority. As expected, within a population of patients with significantly elevated blood sugar, a wide range of comorbid conditions were present, with obesity, heart disease, COPD, and renal disease being most prevalent. For model training and validation purposes, patient snapshots were divided into training (80%) and test (20%) sets that matched statistically on all variables.\\n\\n### Causal modeling of optimized treatment ranking by subpopulation\\n\\nA schematic of the modeling approach to generate treatment rankings is shown in Fig. [2](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#Fig2) and described in Methods. Significant differences existed in the underlying covariate distributions between treatment and comparator arms in the observational data but were successfully balanced through the BCAUS[22](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR22) methodology (Supplementary Fig. [1](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#MOESM1)). The confounder-adjusted causal relative effect (see Supplement) of each treatment strategy compared to other treatments was calculated independently for each cohort (Fig. [2](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#Fig2)). Network Meta-Analysis was performed and treatment strategies were ranked based on network-synthesized causal reduction in HbA1c.\\n\\n#### Fig. 2. Schematic of ranking generation and analysis.\\n\\n[Open in a new tab](https://pmc.ncbi.nlm.nih.gov/figure/Fig2/)\\n\\nSnapshots were split into training (80%) and test (20%) datasets. Snapshots were stratified into 10 clinical cohorts based on age, number of comorbidities, and prior insulin use (Supplementary Table [1](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#MOESM1)). For each clinical cohort, all treatments with cohort size >35 were selected and case-comparator observational studies were performed comparing every treatment with every other treatment using BCAUS, a neural-network-based propensity score model for causal inference. A densely connected network graph was constructed with treatments as nodes and edges connecting treatments via measured Average Treatment Effect (ATE) values. Bayesian Network Meta-Analysis (NMA) was performed to compute network-synthesized ATEs compared against a baseline treatment which was set to Metformin (the first-line therapy for T2DM). Treatments were sorted by their Surface Under the Cumulative RAnking curve (SUCRA) scores[42](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR42) to generate a ranked list of treatment strategies for the cohort. To gauge the effectiveness of the ranking procedure, each cohort in the test set was divided into a concordant group consisting of patient snapshots where the prescribed treatment was one of the top-three ranked treatments and a non-concordant group where the prescribed treatment did not match any of the top-three ranked treatments. The difference in HbA1c between the concordant group and the non-concordant group was used to estimate the confounder-adjusted ATE of the comparative effectiveness treatment rankings.\\n\\nThe top-10 most effective treatment strategies for each cohort (Supplementary Tables [4](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#MOESM1) and [5](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#MOESM1)), revealed that the highest-ranked treatment strategy was unique to each cohort (see Supplementary Fig. [14](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#MOESM1)). Note that a change in treatments that occurs between the two HbA1c lab events is attributed to the new regimen (at the time of the terminal HbA1c) and not to the prior one (from the time of the index HbA1c), which is why non-insulin regimens may appear in the insulin-using groups (which are defined by insulin status at the time of index HbA1c). Also note that these rankings are by point estimates, which may have overlapping uncertainty intervals (Supplementary Figs. [2](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#MOESM1)– [11](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#MOESM1)). GLP-1s and metformin, both known to be highly efficacious for blood glucose control[23](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR23), are the only classes to appear as monotherapies in any group’s top ten ranked treatments, though they only appear for half of the cohorts and never higher than position five. A complete listing of the rankings for all treatment strategies across all cohorts can be found in the Supplement (Supplementary Fig. [12](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#MOESM1)) as well as the measured causal effects, confidence intervals, and sample sizes for all treatment strategies in each cohort (Supplementary Figs. [2](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#MOESM1)– [21](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#MOESM1)).\\n\\n### Causal effect of treatment rankings on HbA1c reduction\\n\\nSignificant differences in patient outcomes were observed between the top-three treatments (representing 2.4% of all snapshots) and all other choices (Fig. [3](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#Fig3)), with an average confounder-adjusted reduction in HbA1c across cohorts of 0.69%. The differences were significant clinically as well as statistically, persisted even after controlling for differences between patients that received highly ranked choices versus others, and generalized extraordinarily well to the test cohorts. A sensitivity analysis revealed a consistent relationship between top three, ranks 4–10, and 11 and below treatment strategies (Supplementary Fig. [13](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#MOESM1)).\\n\\n#### Fig. 3. Causal effect of treatment rankings on HbA1c reduction.\\n\\n[Open in a new tab](https://pmc.ncbi.nlm.nih.gov/figure/Fig3/)\\n\\nEvaluations for concordant (blue) and non-concordant (red) groups for all clinical cohorts. An individual is considered concordant if their current treatment matches one of the top-three recommendations for their clinical cohort and non-concordant otherwise. Training and test set results are shown. The \\\\* denotes that the confounder-adjusted Average Treatment Effect (ATE) of the comparative effectiveness treatment rankings between concordant and non-concordant groups is statistically significant ( _p_ < 0.05) by independent two-sample _t_ test (see Ranking Validation Procedure section of the Methods). Diamonds show ATE values for cases that are statistically significant (asterisk). Error bars represent 95% confidence intervals. Numbers on the bars denote the number of patient snapshots in each group. CCI (unweighted) Charlson Comorbidity Index.\\n\\n### Ranking group prescription patterns in real-world observational data\\n\\nThe distribution of high-ranked treatment strategies provided to patients in each clinical cohort in the study population of patients with poorly controlled diabetes (Supplementary Table [2](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#MOESM1)) was evaluated. Across all cohorts, the average treatment rank per snapshot was 28. The lowest rates of concordance were observed among the younger or relatively healthier cohorts. In 62% of cases where a single patient had multiple associated snapshots, differences in treatment strategies were analyzed between consecutive snapshots. The overall incidence of these patients switching treatments between snapshots was 35 percent. When patients switched treatments, 51 percent of those switches led to a new treatment with a better rank (with an average improvement of 13 positions of rank), while 49 percent of switches led to treatments with a worse rank for the patient (with an average decrease in rank of 12). The mean change in treatment rank across all changes was an improvement of 1 position.\\n\\n## Discussion\\n\\nIn this study, antihyperglycemic treatment strategies for patients with an HbA1c ≥9% were examined over a five-year period in a nationwide cohort of US patients with T2DM. Over 80 different strategies of drug class combination were observed, ranging from monotherapy to combinations of five distinct drug classes. This enormous heterogeneity persisted even after accounting for age, a number of comorbidities, and status of insulin dependence. A network meta-analysis using deep causal models was performed on the cohort’s observational data to rank treatment strategies for ten clinical cohorts based on effectiveness in lowering HbA1C in the high-risk population. The rankings differed between each of the cohorts and they generalized well to snapshots in the held-out test set. Top-three ranked treatments were clinically and statistically better at lowering HbA1c than other choices for most cohorts. There were considerable differences between which treatments were best for each of the clinical cohorts (Supplementary Fig. [14](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#MOESM1)), though the specific class and combination were cohort dependent. Therapeutic classes known to provide secondary cardioprotective benefits, such as SGLT2’s and GLP-1’s, feature prominently in the top ten choices for each cohort. Although cardioprotection was not evaluated in this study, this finding may indicate that there is no need for a trade-off between glucose control and cardioprotection. Additionally, although no monotherapy was the top-ranked treatment for any cohort, the rankings clearly show that simply adding more drug classes[24](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR24) to a patient’s regimen is not uniformly best for HbA1c reduction, consistent with prior literature showing decreasing adherence and worse outcomes with the increasing complexity of medication regimens[25](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR25), [26](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR26), as well as the lack of association between polypharmacy (>4 drugs) and improved A1c control[27](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR27), [28](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR28) in patients with diabetes. In our data, treatment switches, when they occurred, moved patients into lower-ranked strategies as often as they resulted in higher-ranked strategies. Interestingly, in the insulin non-user groups, insulin-containing regimens tend to rank poorly, suggesting poor real-world effectiveness[29](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR29) of a medication known to have high efficacy in Randomized Controlled Trials[20](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR20).\\n\\nThat treatment strategies for T2DM are massively heterogeneous is well known. While Hripcsak et al.[6](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR6) observed that 10% of diabetic patients in their international study had treatment pathways that were unique specifically to that individual, the authors hazard that the variability was not a sign of personalization but rather that “it may point to a failure of the field to converge on an effective treatment”. To our knowledge, this is the first study to examine comparative effectiveness between all observed treatment strategies in multiple clinically-relevant real-world cohorts. The monotherapy[9](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR9) and dual-therapy[30](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR30) results found in this work are reasonably consistent with prior published results, which were limited to those two options. However, differences in cohort sizes and inclusion criteria make direct comparisons difficult. For example, the ADOPT trial[9](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR9) contained fewer than 5,000 participants and excluded patients with more advanced diseases that would not be eligible for monotherapy. Mearns et al.[30](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR30). combined all patients from dual-therapy trials, regardless of age, disease severity, or comorbid conditions, making it impossible to directly compare results to the clinically stratified cohorts examined here. Rosenstock et al.[31](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR31). evaluated the effectiveness of linagliptin vs glimepiride as second or third-line therapy in achieving goal HbA1c as a secondary outcome of a randomized trial, but the other medications in the combination were not evaluated.\\n\\nAlthough no treatments were censored, no treatment strategies were found to be in violation of current standard-of-care guidelines[32](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR32). While it is reassuring that guidelines are generally followed, it also reinforces the concern that guidelines may be insufficient at guiding treatment choices for blood sugar reduction. Instead of contradicting current best practices, the findings provide clarity on which strategies may be best when the guidelines allow many to choose from. It is perhaps not surprising that few patients were on a treatment that may be most effective for them. Patients with highly elevated HbA1c are, by definition, those who have not yet found a treatment strategy that works within their circumstances to control their blood sugar. Additionally, since the current guidelines unilaterally suggest a progressive approach from mono to dual therapy, followed by experimentation within dual-therapy before adding more drug classes, there is a diffusion effect that necessitates a long time until sufficient experimentation has occurred to identify a good strategy for many patients.\\n\\nImportantly, the results of network meta analyses (NMA) must be interpreted with care. Mbaugbaw et al.[33](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR33). specifically review common pitfalls with the clinical interpretation of NMA results, especially SUCRA rankings. For example, they note the tendency to interpret a ranked list of treatments as a definitive hierarchy of best options, without contextualizing the quality of the underlying data, the inherent uncertainty surrounding each rank position, or that the NMA evaluates treatments only based on one component of an often multifaceted treatment decision. In our study, our major clinical finding is that the average treatment effect of a top-three treatment choice is significantly greater than a lower-ranked treatment choice in multiple cohorts. The absolute rankings by point estimate are provided for examination in Supplementary Table [4](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#MOESM1), with contextual uncertainty metrics for each treatment by cohort additionally provided in the supplement. As noted by Mgbaugbaw et al.[33](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR33), our NMA is limited to one component of treatment decisions- the potential change in A1c- and does not evaluate other aspects of clinical treatment decisions such as side effects, secondary benefits, or patient preferences; the rankings provided here should not be interpreted as definitive treatment recommendations.\\n\\nAlthough this work has potentially significant clinical value for developing a clinical decision support tool, and may even provide the signal necessary for the field to identify effective treatments that Hripcsak et al. have called for[8](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR8), there are several important limitations. As with any observational trial, unobserved confounding may affect results and so the results will need to be validated prospectively. Also, the inverse probability weighting method creates pseudo-populations in case and comparator arms that are balanced in observed confounders. While this method decouples case-comparator observational studies that (prior to weight adjustment) may share a common cohort, it is possible that residual correlations exist and the variances in the network-synthesized ATEs are underestimated. Additionally, effectiveness was defined exclusively on the grounds of HbA1c reduction. This choice is reasonable given that HbA1c as a surrogate endpoint is the most used outcome for clinical trials and that our study population is comprised of patients with highly elevated blood sugar, however, there are additional clinical endpoints, particularly those related to cardiovascular outcomes, that are relevant for patients with diabetes. For example, the low concordance with a top-ranked treatment could potentially be due to physicians prioritizing cardioprotective or nephroprotective medications at the expense of glucose-lowering medications. However, the strong presence of treatments with secondary protective effects (i.e., SGLT2 inhibitors, GLP-1 agonists) in the top-ranked choices may indicate that while the effects on cardiovascular and renal outcomes are not captured here, the treatment choices that are most effective for glycemic control are top choices for secondary protective effects as well. Nonetheless, conclusions about how treatment protocols that utilized the rankings derived here would impact these endpoints cannot be drawn from this work. A second limitation is that impact on HbA1c was only calculated at the follow-up measurement after treatment was assigned (a 6-month median window). This time period is sufficient to see the effects of medication changes considering the half-life of hemoglobin, including the slower-acting thiazolidinediones[20](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR20), but may not be perfectly indicative of long-term trends and tolerability. We also do not consider treatments prior to the time period surrounding a given snapshot. Given the length of time it takes for diabetes-related complications to develop, causal attribution to specific treatment strategies is clouded by the many patient-related factors that can change over such a length of time, such as the course of treatment. However, a longer study period that tracks clinical endpoints as well as laboratory endpoints is desirable and could be feasible as datasets such as this grow over time. Future studies could leverage our methodology to define effectiveness by distance from a specified HbA1c value for each clinical subpopulation, instead of absolute HbA1c reduction. Alternatively, maximal risk reduction for microvascular or macrovascular outcomes could be used as the endpoint instead of HbA1c. However, such investigations would be most robustly served by a prospective study tracking the impact on multiple clinical endpoints from prescribing high-ranked treatment strategies to achieving cohort-specific targets.\\n\\nWe envision that this work can be the basis for the development of a clinical decision-support tool for choosing or augmenting diabetes treatments in patients with T2DM. Although the treatment rankings presented in this work are fixed to the clinical population defined above, the method used to identify top treatment regimens could be applied in validated populations to supplement guidelines to support many different approaches to decision-making. For example, based on patient needs and clinician preferences, some may choose not to prescribe the highest-ranked treatment but instead the highest-ranked option that involves the smallest change from the current regimen. Alternatively, for patients for whom compliance may be a concern, selecting a treatment that optimizes the rank with the fewest number of total drugs would be an option. Findings could also be filtered to avoid contraindications (e.g., based on most recent EGFR, hypoglycemia risk, or patient allergies), minimize costs, or avoid injections. For every highly ranked strategy in our study that contained many different drug classes, there was usually a simpler combination with nearby rank. Additionally, clinicians likely have access to information that the model does not, such as BMI or duration of diabetes, and thus a non-prescriptive, filterable decision support tool will allow them to overcome this limitation. The enormous variety of ways in which these comparative effectiveness rankings could be utilized may be best leveraged by software with a performant, intuitive user interface to return the optimized results for a given patient target. Such software could also provide additional metrics captured in this study, like the number of patients observed on each treatment strategy and the clinical and demographic parameters associated with each person, which are not possible to display in the context of individual patients within a manuscript like this. Additional convenience functions, such as the removal of contraindicated treatments from the rankings list for each individual patient may be desired. As with any clinical decision support tool, evaluation and optimization will be an ongoing process to ensure no undesirable effects[34](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR34).\\n\\nTaken together, these findings have important implications for personalizing care for chronic health conditions. The approach outlined here represents a concrete step towards a functional learning healthcare system, and it is immediately extensible to other conditions beyond diabetes mellitus that have complex pharmacological treatment patterns such as hypertension, asthma, chronic obstructive pulmonary disease, depression, and congestive heart failure. By forestalling adverse events that arise from unmanaged chronic diseases, such learning systems could greatly reduce patient suffering and lead to significant reductions in healthcare costs.\\n\\n## Methods\\n\\n### Study cohort definition and data preparation\\n\\nThis manuscript reports findings that were obtained as a part of healthcare operations quality improvement using only aggregated results of the analysis; no individually identifiable information (protected health information or otherwise) was used in the development of the manuscript and the work was deemed not human subjects research by the Anthem Office of General Counsel (OGC). Electronic health records were analyzed for 56.4 million members from a healthcare plan population between 1 December 2014 and 1 January 2020 to determine the average treatment effect of diabetes medications on HbA1c. The records included approximately five billion insurance claims (for diagnoses, procedures, and drug prescriptions or refills) as well as lab test results for the associated patients. Not all patient records spanned the entire five years. Clinical filters were designed to distinguish between major sub-types of diabetes, and patients with Type I diabetes, anyone under 18 years of age, or gestational diabetes were excluded from the study (Fig. [1a](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#Fig1)). Individuals with histories of diabetes ketoacidosis, cystic fibrosis, or solid-organ transplants were also excluded as a safety precaution because they are highly complex patients who would clearly benefit from subspecialist care and the rankings developed herein are targeted towards PCPs managing typical patients with T2DM. Snapshots with HbA1c’s below 9% at the initial HbA1c were also removed to focus on high-risk patients who were clearly eligible for treatment strategies beyond first-line based on the Center for Medicare and Medicaid Services definition[35](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR35) of poor glycemic control as well as because an HbA1c > 9% is clearly above goal for almost all patients[20](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR20). This filtering resulted in a study population of 104,992 unique individuals.\\n\\nThe health status of any individual evolves with time. Since the study period in our work spanned several years, to properly account for this evolution, each individual’s health history was split into a series of temporal snapshots as shown in Fig. [1b](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#Fig1). Each snapshot was determined by an index HbA1c ≥9% lab measurement and terminated at the subsequent HbA1c for each patient, with a lookback period to the patient’s first healthcare event on record. The time period between the two labs was considered the observation period. The age of the individual in a particular snapshot and any clinical covariates that were treated as confounders were measured as of the date of the first lab of the pair. Individuals with only a single HbA1c lab report were excluded. Only snapshots where the observation period was between 90 and 365 days were retained, and the rest were excluded, resulting in a final study population of 141,625 patient snapshots, with each patient contributing on average 1.3 snapshots for analysis. Snapshot duration was not otherwise considered in the model. As shown in Fig. [1c](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#Fig1), an individual was considered as treated by a particular antihyperglycemic drug at the time of an HbA1c lab event if it was prescribed prior to that lab and if the number of days of supply plus a grace period of 30 days (for non-adherence) extended past the lab date. If a regimen changed during a snapshot, the change in HbA1c was attributed to the new regimen. Because HbA1c reflects glycemic control over a period of approximately 90 days[36](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR36) and the half-lives of anti glycemic medications are on the order of hours to days[37](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR37), only current treatments were considered in the model. Given that metformin is the consensus first-line therapy and as our goal was to compare efficacy between treatment regimens, patients on no treatment were excluded. Medications taken prior to the pre-snapshot period were not included in the model. When multiple drugs existed within the inclusive dates, treatment was considered the combination of these drugs. Diabetes drugs were identified only by their class names (e.g., SGLT2 inhibitors, sulfonylureas, etc.) and non-diabetes drugs were excluded. All further analysis was performed on the pseudo-population of patient snapshots.\\n\\nMany clinical and social factors are known to be associated with diabetic treatment selection and HbA1c outcomes. For example, kidney function as well as the presence of various comorbid conditions may result in contraindications for certain antihyperglycemic drug classes and may also influence the HbA1c value that the prescribing clinician targets for an individual. Additionally, social determinants of health (SDoH) such as patient race, income, and location are known to influence both treatment selection and health outcomes. In order to control for these confounding factors so that an accurate estimate of the causal effect of treatment strategies could be obtained, all comorbidities present in the history of each patient were included using diagnostic definitions defined by the Charlson Comorbidity Index (CCI)[38](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR38), as well as the most recent EGFR and creatinine values at the time of each snapshot. Race is known to be reported at very low levels both within EHRs and claims data. Accordingly, census-derived data on the racial and economic profiles of each patient’s neighborhood using zip codes was used. These are weak surrogates for true SDoH markers, but we believe that including them is still significantly better than ignoring SDoH completely from large-scale clinical studies. Missing data were imputed to the mean (Supplementary Table [3](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#MOESM1)); no age or sex data were missing. Supplementary Table [1](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#MOESM1) provides the summary statistics of all covariates that were treated as confounders for causal inference.\\n\\n#### Causal inference modeling\\n\\nSeveral methods for the causal inference analysis were considered for use. Because there are multiple possible combinations of treatments, the number of head-to-head comparisons that need to be performed is extremely large. Propensity score matching[11](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR11) or weighting[39](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR39) methods are widely used for observational studies but are considered “do-it-yourself,”[40](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR40) in that the propensity score model must be checked for correct specification after it is trained, and, when incorrectly specified, it has to be retrained by modifying model parametrization or feature engineering. Automated methods like Bayesian Additive Regression Trees[41](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR41) have yielded good performance on benchmark datasets[40](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR40), but rely on Monte Carlo sampling and are therefore prohibitively slow for the number of comparisons necessary in this study. Recently, a technique was introduced[22](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR22) called BCAUS (Balancing Covariates Automatically Using Supervision) that scales well to massive multi-arm studies. BCAUS consists of a neural-network propensity model that is trained using a joint loss given by\\n\\n| |\\n| --- |\\n| LTOTAL=LBCE+νμLBIAS. |\\n\\nThe first term, LBCE, is a binary cross-entropy loss which penalizes incorrect treatment prediction, while the second, LBIAS, is a loss term which explicitly tries to minimize imbalance between inverse probability weighted covariates. Details of the training process are described in Supplementary Materials and a comparison with other state-of-the-art neural-network-based methods on benchmark datasets has been described elsewhere[22](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR22). For each pairwise comparison between diabetes treatments, a separate BCAUS model was trained. The propensity score outputs of trained models were used to estimate average treatment effects using Inverse Probability of Treatment Weighting (IPTW). A bootstrapping procedure was used to compute standard errors and confidence intervals (see Supplement). The input data for NMA consisted of the estimated ATEs and standard errors.\\n\\n#### Network meta-analysis\\n\\nAn ATE value measured via a direct causal comparison between two treatments has to be consistent with values that are indirectly estimated by comparing each treatment of the pair with intermediary treatments and then computing differences. Separate network graphs were constructed for the 10 clinical cohorts where every treatment node was connected with every other treatment node. Edges representing observational studies where all confounding covariates were not balanced were trimmed and Bayesian NMA was performed over the resultant graph. We used a random-effects model, set uninformative priors, and used a Markov Chain Monte Carlo (MCMC) sampling procedure to construct posterior distributions of ATE values for all treatment pairs. To determine relative ranks, samples were drawn from the posterior predictive distributions of ATE values of all treatments compared against metformin, which was set as the baseline treatment. For each draw, treatments were ranked in ascending order of ATE values (i.e., higher ranks for more negative values), and a mean rank was computed for each treatment across all draws. This mean rank was normalized to compute the Surface Under the Cumulative RAnking curve (SUCRA) score[42](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#CR42). Treatments were ranked in descending order of SUCRA scores such that the treatment that reduced HbA1c by the largest amount relative to metformin had the highest rank. This ranked list of treatments applies to all members of a given cohort; within-cohort treatment heterogeneity is not further accounted for by the model. Further details of the training procedure are available in Supplementary Materials.\\n\\n#### Ranking validation procedure\\n\\nTo investigate the degree to which the rankings generalized to new patients while generating an estimate of the improvement to HbA1c over existing practices if rankings were used to guide treatment decisions, outcomes between patients whose physicians happened to have prescribed a top-3 ranked treatment choice for them versus selecting any other treatment option were compared retrospectively. Snapshots in each clinical cohort were divided into concordant cohorts (where the actual prescribed treatment matched one of the top-3 recommendations) and non-concordant cohorts (where a patient was provided any treatment ranked four or lower). Differences in the mean change in HbA1c between the concordant and non-concordant groups were calculated for all cohorts for both training and test datasets. If the difference in means was found to be statistically significant (using an independent two-sample _t_ test), an additional confounder-adjusted case-comparator study was performed between the cohorts to measure whether the differences in means were directly attributable to the differences in treatment strategy ranks.\\n\\nTo further investigate if the rankings demonstrate an internally consistent effect, a sensitivity analysis was performed by splitting patient snapshots of each cohort in the training dataset into three concordance cohorts: (i) the “top” cohort is concordant with treatments ranked 1–3; (ii) the “middle” cohort is concordant with treatments ranked 4–10, and (iii) the “bottom” cohort is concordant with treatments ranked 11 and below. Confounder-adjusted ATE values were estimated, comparing the top versus bottom groups and the middle versus bottom groups. If the ranks are internally consistent, an effect where-in the top outperforms the middle and the middle outperforms the bottom would be expected. The ranks were internally consistent as shown in Supplementary Fig. [13](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#MOESM1).\\n\\n### Reporting summary\\n\\nFurther information on research design is available in the [Nature Research Reporting Summary](https://pmc.ncbi.nlm.nih.gov/pmc.ncbi.nlm.nih.gov#MOESM2) linked to this article.\\n\\n## Supplementary information\\n\\n[Supplementary Information](https://pmc.ncbi.nlm.nih.gov/articles/instance/9663714/bin/41467_2022_33732_MOESM1_ESM.pdf) (2.5MB, pdf)\\n\\n[Reporting Summary](https://pmc.ncbi.nlm.nih.gov/articles/instance/9663714/bin/41467_2022_33732_MOESM2_ESM.pdf) (1.1MB, pdf)\\n\\n## Acknowledgements\\n\\nAll research was funded by Elevance Health. The authors gratefully acknowledge Chris Jensen for his assistance in preparing and submitting the manuscript.\\n\\n## Author contributions\\n\\nB.N. conceived of the study, supervised the project, and designed the analyses. C.B., S.G., and W.S. developed the methodology and the software implementation. P.A., S.C., and C.K. collected and prepared the data. P.A. and I.J. contributed to subgroup design and confounding variable selection. C.B and S.G. ran the experiments. C.B, I.J., and B.N. interpreted the results. All authors performed the analysis. All authors wrote and edited the manuscript.\\n\\n## Peer review\\n\\n### Peer review information\\n\\n_Nature Communications_ thanks Zhengping Che, Jodi Segal, Jonathan Shaw, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.\\n\\n## Data availability\\n\\nThe raw data are protected and are not available due to data privacy laws and commercial interests. Investigators with an academic affiliation may contact the corresponding author for data access for the purposes of validating the above findings. Requests will be processed within 60 days.\\n\\n## Code availability\\n\\nThe code for the method used in this study is freely available at [https://github.com/gstef80/bcaus\\\\_nma](https://github.com/gstef80/bcaus_nma).\\n\\n## Competing interests\\n\\nAll authors were full-time employees at Elevance Health and received no compensation outside of the regular compensation of their respective employers.\\n\\n## Footnotes\\n\\n**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\\n\\nThese authors contributed equally: Chinmay Belthangady, Stefanos Giampanis, Ivana Jankovic.\\n\\n## Supplementary information\\n\\nThe online version contains supplementary material available at 10.1038/s41467-022-33732-9.\\n\\n## References\\n\\n- 1.Centers for Disease Control and Prevention. National Diabetes Statistics Report, A., GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2020.\\n- 2.American Diabetes, A. Economic Costs of Diabetes in the U.S. in 2017. _Diabetes Care_ **41**, 917–928, (2018). \\\\[ [DOI](https://doi.org/10.2337/dci18-0007)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC5911784/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/29567642/)\\\\]\\n- 3.Davies MJ, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2018;41:2669–2701. doi: 10.2337/dci18-0033. \\\\[ [DOI](https://doi.org/10.2337/dci18-0033)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC6245208/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/30291106/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&title=Management%20of%20Hyperglycemia%20in%20Type%202%20Diabetes,%202018.%20A%20consensus%20report%20by%20the%20American%20Diabetes%20Association%20(ADA)%20and%20the%20European%20Association%20for%20the%20Study%20of%20Diabetes%20(EASD)&author=MJ%20Davies&volume=41&publication_year=2018&pages=2669-2701&pmid=30291106&doi=10.2337/dci18-0033&)\\\\]\\n- 4.Vashisht R, et al. Association of hemoglobin A1c levels with use of sulfonylureas, dipeptidyl peptidase 4 inhibitors, and thiazolidinediones in patients with type 2 diabetes treated with metformin: analysis from the observational health data sciences and informatics initiative. JAMA Netw. Open. 2018;1:e181755. doi: 10.1001/jamanetworkopen.2018.1755. \\\\[ [DOI](https://doi.org/10.1001/jamanetworkopen.2018.1755)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC6324274/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/30646124/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=JAMA%20Netw.%20Open&title=Association%20of%20hemoglobin%20A1c%20levels%20with%20use%20of%20sulfonylureas,%20dipeptidyl%20peptidase%204%20inhibitors,%20and%20thiazolidinediones%20in%20patients%20with%20type%202%20diabetes%20treated%20with%20metformin:%20analysis%20from%20the%20observational%20health%20data%20sciences%20and%20informatics%20initiative&author=R%20Vashisht&volume=1&publication_year=2018&pages=e181755&pmid=30646124&doi=10.1001/jamanetworkopen.2018.1755&)\\\\]\\n- 5.American Diabetes, A. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. _Diabetes Care_ **42**, S90-S102, (2019). \\\\[ [DOI](https://doi.org/10.2337/dc19-S009)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/30559235/)\\\\]\\n- 6.Hripcsak G, et al. Characterizing treatment pathways at scale using the OHDSI network. Proc. Natl. Acad. Sci. USA. 2016;113:7329–7336. doi: 10.1073/pnas.1510502113. \\\\[ [DOI](https://doi.org/10.1073/pnas.1510502113)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC4941483/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/27274072/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Proc.%20Natl.%20Acad.%20Sci.%20USA&title=Characterizing%20treatment%20pathways%20at%20scale%20using%20the%20OHDSI%20network&author=G%20Hripcsak&volume=113&publication_year=2016&pages=7329-7336&pmid=27274072&doi=10.1073/pnas.1510502113&)\\\\]\\n- 7.Setji TL, Page C, Pagidipati N, Goldstein BA. Differences in achieving Hba1c goals among patients seen by endocrinologists and primary care providers. Endocr. Pract. 2019;25:461–469. doi: 10.4158/EP-2018-0405. \\\\[ [DOI](https://doi.org/10.4158/EP-2018-0405)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/30720349/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Endocr.%20Pract.&title=Differences%20in%20achieving%20Hba1c%20goals%20among%20patients%20seen%20by%20endocrinologists%20and%20primary%20care%20providers&author=TL%20Setji&author=C%20Page&author=N%20Pagidipati&author=BA%20Goldstein&volume=25&publication_year=2019&pages=461-469&pmid=30720349&doi=10.4158/EP-2018-0405&)\\\\]\\n- 8.Romeo, G. R., Hirsch, I. B., Lash, R. W. & Gabbay, R. A. Trends in the endocrinology fellowship recruitment: reasons for concern and possible interventions. _J. Clin. Endocrinol. Metab._ **105**, 1701–1706 (2020). \\\\[ [DOI](https://doi.org/10.1210/clinem/dgaa134)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC7150610/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/32188983/)\\\\]\\n- 9.Kahn SE, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 2006;355:2427–2443. doi: 10.1056/NEJMoa066224. \\\\[ [DOI](https://doi.org/10.1056/NEJMoa066224)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/17145742/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N.%20Engl.%20J.%20Med.&title=Glycemic%20durability%20of%20rosiglitazone,%20metformin,%20or%20glyburide%20monotherapy&author=SE%20Kahn&volume=355&publication_year=2006&pages=2427-2443&pmid=17145742&doi=10.1056/NEJMoa066224&)\\\\]\\n- 10.Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55. doi: 10.1093/biomet/70.1.41. \\\\[ [DOI](https://doi.org/10.1093/biomet/70.1.41)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Biometrika&title=The%20central%20role%20of%20the%20propensity%20score%20in%20observational%20studies%20for%20causal%20effects&author=PR%20Rosenbaum&author=DB%20Rubin&volume=70&publication_year=1983&pages=41-55&doi=10.1093/biomet/70.1.41&)\\\\]\\n- 11.Chalmers TC, Matta RJ, Smith H, Jr., Kunzler AM. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N. Engl. J. Med. 1977;297:1091–1096. doi: 10.1056/NEJM197711172972004. \\\\[ [DOI](https://doi.org/10.1056/NEJM197711172972004)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/909566/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N.%20Engl.%20J.%20Med.&title=Evidence%20favoring%20the%20use%20of%20anticoagulants%20in%20the%20hospital%20phase%20of%20acute%20myocardial%20infarction&author=TC%20Chalmers&author=RJ%20Matta&author=H%20Smith&author=AM%20Kunzler&volume=297&publication_year=1977&pages=1091-1096&pmid=909566&doi=10.1056/NEJM197711172972004&)\\\\]\\n- 12.Lumley T. Network meta-analysis for indirect treatment comparisons. Stat. Med. 2002;21:2313–2324. doi: 10.1002/sim.1201. \\\\[ [DOI](https://doi.org/10.1002/sim.1201)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/12210616/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Stat.%20Med.&title=Network%20meta-analysis%20for%20indirect%20treatment%20comparisons&author=T%20Lumley&volume=21&publication_year=2002&pages=2313-2324&pmid=12210616&doi=10.1002/sim.1201&)\\\\]\\n- 13.Ryan PB, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D) Diabetes Obes. Metab. 2018;20:2585–2597. doi: 10.1111/dom.13424. \\\\[ [DOI](https://doi.org/10.1111/dom.13424)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC6220807/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/29938883/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Obes.%20Metab.&title=Comparative%20effectiveness%20of%20canagliflozin,%20SGLT2%20inhibitors%20and%20non-SGLT2%20inhibitors%20on%20the%20risk%20of%20hospitalization%20for%20heart%20failure%20and%20amputation%20in%20patients%20with%20type%202%20diabetes%20mellitus:%20a%20real-world%20meta-analysis%20of%204%20observational%20databases%20(OBSERVE-4D)&author=PB%20Ryan&volume=20&publication_year=2018&pages=2585-2597&pmid=29938883&doi=10.1111/dom.13424&)\\\\]\\n- 14.LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015;521:436–444. doi: 10.1038/nature14539. \\\\[ [DOI](https://doi.org/10.1038/nature14539)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/26017442/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Nature&title=Deep%20learning&author=Y%20LeCun&author=Y%20Bengio&author=G%20Hinton&volume=521&publication_year=2015&pages=436-444&pmid=26017442&doi=10.1038/nature14539&)\\\\]\\n- 15.Esteva A, et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017;542:115–118. doi: 10.1038/nature21056. \\\\[ [DOI](https://doi.org/10.1038/nature21056)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC8382232/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/28117445/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Nature&title=Dermatologist-level%20classification%20of%20skin%20cancer%20with%20deep%20neural%20networks&author=A%20Esteva&volume=542&publication_year=2017&pages=115-118&pmid=28117445&doi=10.1038/nature21056&)\\\\]\\n- 16.Gulshan V, et al. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. JAMA. 2016;316:2402–2410. doi: 10.1001/jama.2016.17216. \\\\[ [DOI](https://doi.org/10.1001/jama.2016.17216)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/27898976/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=JAMA&title=Development%20and%20validation%20of%20a%20deep%20learning%20algorithm%20for%20detection%20of%20diabetic%20retinopathy%20in%20retinal%20fundus%20photographs&author=V%20Gulshan&volume=316&publication_year=2016&pages=2402-2410&pmid=27898976&doi=10.1001/jama.2016.17216&)\\\\]\\n- 17.Li L, et al. Disease risk factors identified through shared genetic architecture and electronic medical records. Sci. Transl. Med. 2014;6:234ra257. doi: 10.1126/scitranslmed.3007191. \\\\[ [DOI](https://doi.org/10.1126/scitranslmed.3007191)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC4323098/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/24786325/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Sci.%20Transl.%20Med.&title=Disease%20risk%20factors%20identified%20through%20shared%20genetic%20architecture%20and%20electronic%20medical%20records&author=L%20Li&volume=6&publication_year=2014&pages=234ra257&pmid=24786325&doi=10.1126/scitranslmed.3007191&)\\\\]\\n- 18.Rajkomar A, et al. Scalable and accurate deep learning with electronic health records. NPJ Digit Med. 2018;1:18. doi: 10.1038/s41746-018-0029-1. \\\\[ [DOI](https://doi.org/10.1038/s41746-018-0029-1)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC6550175/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/31304302/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=NPJ%20Digit%20Med.&title=Scalable%20and%20accurate%20deep%20learning%20with%20electronic%20health%20records&author=A%20Rajkomar&volume=1&publication_year=2018&pages=18&pmid=31304302&doi=10.1038/s41746-018-0029-1&)\\\\]\\n- 19.Norgeot B, et al. Assessment of a deep learning model based on electronic health record data to forecast clinical outcomes in patients with rheumatoid arthritis. JAMA Netw. Open. 2019;2:e190606. doi: 10.1001/jamanetworkopen.2019.0606. \\\\[ [DOI](https://doi.org/10.1001/jamanetworkopen.2019.0606)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC6484652/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/30874779/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=JAMA%20Netw.%20Open&title=Assessment%20of%20a%20deep%20learning%20model%20based%20on%20electronic%20health%20record%20data%20to%20forecast%20clinical%20outcomes%20in%20patients%20with%20rheumatoid%20arthritis&author=B%20Norgeot&volume=2&publication_year=2019&pages=e190606&pmid=30874779&doi=10.1001/jamanetworkopen.2019.0606&)\\\\]\\n- 20.American Diabetes, A. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:S73–S84. doi: 10.2337/dc21-S006. \\\\[ [DOI](https://doi.org/10.2337/dc21-S006)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33298417/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&title=6.%20Glycemic%20Targets:%20Standards%20of%20Medical%20Care%20in%20Diabetes-2021&volume=44&publication_year=2021&pages=S73-S84&pmid=33298417&doi=10.2337/dc21-S006&)\\\\]\\n- 21.Explore Census Data. Accessed 1 March 2022. [https://data.census.gov/cedsci/](https://data.census.gov/cedsci/).\\n- 22.Belthangady C, Stedden W, Norgeot B. Minimizing bias in massive multi-arm observational studies with BCAUS: balancing covariates automatically using supervision. BMC Med. Res. Methodol. 2021;21:190. doi: 10.1186/s12874-021-01383-x. \\\\[ [DOI](https://doi.org/10.1186/s12874-021-01383-x)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC8454087/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/34544367/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=BMC%20Med.%20Res.%20Methodol.&title=Minimizing%20bias%20in%20massive%20multi-arm%20observational%20studies%20with%20BCAUS:%20balancing%20covariates%20automatically%20using%20supervision&author=C%20Belthangady&author=W%20Stedden&author=B%20Norgeot&volume=21&publication_year=2021&pages=190&pmid=34544367&doi=10.1186/s12874-021-01383-x&)\\\\]\\n- 23.Noble J, Baerlocher MO, Silverberg J. Management of type 2 diabetes mellitus. Role thiazolidinediones. Can. Fam. Physician. 2005;51:683–687. \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC1472920/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/15934272/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Role%20thiazolidinediones.%20Can.%20Fam.%20Physician&title=Management%20of%20type%202%20diabetes%20mellitus&author=J%20Noble&author=MO%20Baerlocher&author=J%20Silverberg&volume=51&publication_year=2005&pages=683-687&pmid=15934272&)\\\\]\\n- 24.Coutinho DF, et al. Association between control of diabetes mellitus and polypharmacy at the Brazilian Longitudinal Study of Adult Health (ELSA‐Brasil) Pharmacoepidemiol. Drug Saf. 2021;30:749–757. doi: 10.1002/pds.5236. \\\\[ [DOI](https://doi.org/10.1002/pds.5236)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33772928/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Pharmacoepidemiol.%20Drug%20Saf.&title=Association%20between%20control%20of%20diabetes%20mellitus%20and%20polypharmacy%20at%20the%20Brazilian%20Longitudinal%20Study%20of%20Adult%20Health%20(ELSA%E2%80%90Brasil)&author=DF%20Coutinho&volume=30&publication_year=2021&pages=749-757&pmid=33772928&doi=10.1002/pds.5236&)\\\\]\\n- 25.Elnaem MH, et al. Impact of medication regimen simplification on medication adherence and clinical outcomes in patients with long-term medical conditions. Patient Prefer. Adherence. 2020;14:2135–2145. doi: 10.2147/PPA.S268499. \\\\[ [DOI](https://doi.org/10.2147/PPA.S268499)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC7646472/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/33173282/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Patient%20Prefer.%20Adherence&title=Impact%20of%20medication%20regimen%20simplification%20on%20medication%20adherence%20and%20clinical%20outcomes%20in%20patients%20with%20long-term%20medical%20conditions&author=MH%20Elnaem&volume=14&publication_year=2020&pages=2135-2145&pmid=33173282&doi=10.2147/PPA.S268499&)\\\\]\\n- 26.Davies LE, et al. Adverse outcomes of polypharmacy in older people: systematic review of reviews. J. Am. Med. Dir. Assoc. 2020;21:181–187. doi: 10.1016/j.jamda.2019.10.022. \\\\[ [DOI](https://doi.org/10.1016/j.jamda.2019.10.022)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/31926797/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J.%20Am.%20Med.%20Dir.%20Assoc.&title=Adverse%20outcomes%20of%20polypharmacy%20in%20older%20people:%20systematic%20review%20of%20reviews&author=LE%20Davies&volume=21&publication_year=2020&pages=181-187&pmid=31926797&doi=10.1016/j.jamda.2019.10.022&)\\\\]\\n- 27.Labib AM, Martins AP, Raposo JF, Torre C. The association between polypharmacy and adverse health consequences in elderly type 2 diabetes mellitus patients; a systematic review and meta-analysis. Diabetes Res. Clin. Pract. 2019;155:107804. doi: 10.1016/j.diabres.2019.107804. \\\\[ [DOI](https://doi.org/10.1016/j.diabres.2019.107804)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/31376400/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Res.%20Clin.%20Pract.&title=The%20association%20between%20polypharmacy%20and%20adverse%20health%20consequences%20in%20elderly%20type%202%20diabetes%20mellitus%20patients;%20a%20systematic%20review%20and%20meta-analysis&author=AM%20Labib&author=AP%20Martins&author=JF%20Raposo&author=C%20Torre&volume=155&publication_year=2019&pages=107804&pmid=31376400&doi=10.1016/j.diabres.2019.107804&)\\\\]\\n- 28.Remelli, F., Ceresini, M.G., Trevisan, C., Noale, M. and Volpato, S. Prevalence and impact of polypharmacy in older patients with type 2 diabetes. _Aging Clin. Exp. Res._ **34**, 1969–1983 (2022). \\\\[ [DOI](https://doi.org/10.1007/s40520-022-02165-1)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC9464133/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/35723858/)\\\\]\\n- 29.Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. JAMA. 1997;278:1663–1669. doi: 10.1001/jama.1997.03550200039029. \\\\[ [DOI](https://doi.org/10.1001/jama.1997.03550200039029)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/9388085/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=JAMA&title=Starting%20insulin%20therapy%20in%20patients%20with%20type%202%20diabetes:%20effectiveness,%20complications,%20and%20resource%20utilization&author=RA%20Hayward&author=WG%20Manning&author=SH%20Kaplan&author=EH%20Wagner&author=S%20Greenfield&volume=278&publication_year=1997&pages=1663-1669&pmid=9388085&doi=10.1001/jama.1997.03550200039029&)\\\\]\\n- 30.Mearns ES, et al. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis. PLoS One. 2015;10:e0125879. doi: 10.1371/journal.pone.0125879. \\\\[ [DOI](https://doi.org/10.1371/journal.pone.0125879)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC4412636/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/25919293/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=PLoS%20One&title=Comparative%20efficacy%20and%20safety%20of%20antidiabetic%20drug%20regimens%20added%20to%20metformin%20monotherapy%20in%20patients%20with%20type%202%20diabetes:%20a%20network%20meta-analysis&author=ES%20Mearns&volume=10&publication_year=2015&pages=e0125879&pmid=25919293&doi=10.1371/journal.pone.0125879&)\\\\]\\n- 31.Rosenstock J, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019;322:1155–1166. doi: 10.1001/jama.2019.13772. \\\\[ [DOI](https://doi.org/10.1001/jama.2019.13772)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC6763993/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/31536101/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=JAMA&title=Effect%20of%20linagliptin%20vs%20glimepiride%20on%20major%20adverse%20cardiovascular%20outcomes%20in%20patients%20with%20type%202%20diabetes:%20the%20CAROLINA%20randomized%20clinical%20trial&author=J%20Rosenstock&volume=322&publication_year=2019&pages=1155-1166&pmid=31536101&doi=10.1001/jama.2019.13772&)\\\\]\\n- 32.Nathan DM, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203. doi: 10.2337/dc08-9025. \\\\[ [DOI](https://doi.org/10.2337/dc08-9025)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC2606813/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/18945920/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&title=Medical%20management%20of%20hyperglycemia%20in%20type%202%20diabetes:%20a%20consensus%20algorithm%20for%20the%20initiation%20and%20adjustment%20of%20therapy:%20a%20consensus%20statement%20of%20the%20American%20Diabetes%20Association%20and%20the%20European%20Association%20for%20the%20Study%20of%20Diabetes&author=DM%20Nathan&volume=32&publication_year=2009&pages=193-203&pmid=18945920&doi=10.2337/dc08-9025&)\\\\]\\n- 33.Mbuagbaw L, et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst. Rev. 2017;6:1–5. doi: 10.1186/s13643-017-0473-z. \\\\[ [DOI](https://doi.org/10.1186/s13643-017-0473-z)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC5389085/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/28403893/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Syst.%20Rev.&title=Approaches%20to%20interpreting%20and%20choosing%20the%20best%20treatments%20in%20network%20meta-analyses&author=L%20Mbuagbaw&volume=6&publication_year=2017&pages=1-5&pmid=28403893&doi=10.1186/s13643-017-0473-z&)\\\\]\\n- 34.Jankovic I, Chen JH. Clinical decision support and implications for the clinician burnout crisis. Yearb. Med Inf. 2020;29:145–154. doi: 10.1055/s-0040-1701986. \\\\[ [DOI](https://doi.org/10.1055/s-0040-1701986)\\\\] \\\\[ [PMC free article](https://pmc.ncbi.nlm.nih.gov/articles/PMC7442505/)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/32823308/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Yearb.%20Med%20Inf.&title=Clinical%20decision%20support%20and%20implications%20for%20the%20clinician%20burnout%20crisis&author=I%20Jankovic&author=JH%20Chen&volume=29&publication_year=2020&pages=145-154&pmid=32823308&doi=10.1055/s-0040-1701986&)\\\\]\\n- 35.Centers for Medicare and Medicaid Services Measures Inventory Tool. _Centers for Medicare and Medicaid Services Measures Inventory Tool_ [https://cmit.cms.gov/cmit/#/FamilyView?familyId=204](https://cmit.cms.gov/cmit/#/FamilyView?familyId=204).\\n- 36.HBA1C - Overview: Hemoglobin A1c, Blood. _HBA1C - Overview: Hemoglobin A1c, Blood_ [https://www.mayocliniclabs.com/test-catalog/overview/82080#Clinical-and-Interpretive](https://www.mayocliniclabs.com/test-catalog/overview/82080#Clinical-and-Interpretive).\\n- 37.Feingold, K. R. In Endotext (eds K. R. Feingold et al.) (2000).\\n- 38.Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 1987;40:373–383. doi: 10.1016/0021-9681(87)90171-8. \\\\[ [DOI](https://doi.org/10.1016/0021-9681(87)90171-8)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/3558716/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J.%20Chronic%20Dis.&title=A%20new%20method%20of%20classifying%20prognostic%20comorbidity%20in%20longitudinal%20studies:%20development%20and%20validation&author=ME%20Charlson&author=P%20Pompei&author=KL%20Ales&author=CR%20MacKenzie&volume=40&publication_year=1987&pages=373-383&pmid=3558716&doi=10.1016/0021-9681(87)90171-8&)\\\\]\\n- 39.Rosenbaum PR. Model-based direct adjustment. J. Am. Stat. Assoc. 1987;82:387–394. doi: 10.1080/01621459.1987.10478441. \\\\[ [DOI](https://doi.org/10.1080/01621459.1987.10478441)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J.%20Am.%20Stat.%20Assoc.&title=Model-based%20direct%20adjustment&author=PR%20Rosenbaum&volume=82&publication_year=1987&pages=387-394&doi=10.1080/01621459.1987.10478441&)\\\\]\\n- 40.Dorie, V. J., Hill, J. L., Shalit, U., Scott, M. & Cervone, D. Automated versus do-it-yourself methods for causal inference: lessons learned from a data analysis competition. _Stat. Sci._ [https://arxiv.org/abs/1707.02641](https://arxiv.org/abs/1707.02641) (2019).\\n- 41.Hill JL. Bayesian nonparametric modeling for causal inference. J. Comput. Graph. Stat. 2011;20:217–240. doi: 10.1198/jcgs.2010.08162. \\\\[ [DOI](https://doi.org/10.1198/jcgs.2010.08162)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J.%20Comput.%20Graph.%20Stat.&title=Bayesian%20nonparametric%20modeling%20for%20causal%20inference&author=JL%20Hill&volume=20&publication_year=2011&pages=217-240&doi=10.1198/jcgs.2010.08162&)\\\\]\\n- 42.Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J. Clin. Epidemiol. 2011;64:163–171. doi: 10.1016/j.jclinepi.2010.03.016. \\\\[ [DOI](https://doi.org/10.1016/j.jclinepi.2010.03.016)\\\\] \\\\[ [PubMed](https://pubmed.ncbi.nlm.nih.gov/20688472/)\\\\] \\\\[ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Epidemiol.&title=Graphical%20methods%20and%20numerical%20summaries%20for%20presenting%20results%20from%20multiple-treatment%20meta-analysis:%20an%20overview%20and%20tutorial&author=G%20Salanti&author=AE%20Ades&author=JP%20Ioannidis&volume=64&publication_year=2011&pages=163-171&pmid=20688472&doi=10.1016/j.jclinepi.2010.03.016&)\\\\]\\n\\n## Associated Data\\n\\n_This section collects any data citations, data availability statements, or supplementary materials included in this article._\\n\\n### Supplementary Materials\\n\\n[Supplementary Information](https://pmc.ncbi.nlm.nih.gov/articles/instance/9663714/bin/41467_2022_33732_MOESM1_ESM.pdf) (2.5MB, pdf)\\n\\n[Reporting Summary](https://pmc.ncbi.nlm.nih.gov/articles/instance/9663714/bin/41467_2022_33732_MOESM2_ESM.pdf) (1.1MB, pdf)\\n\\n### Data Availability Statement\\n\\nThe raw data are protected and are not available due to data privacy laws and commercial interests. Investigators with an academic affiliation may contact the corresponding author for data access for the purposes of validating the above findings. Requests will be processed within 60 days.\\n\\nThe code for the method used in this study is freely available at [https://github.com/gstef80/bcaus\\\\_nma](https://github.com/gstef80/bcaus_nma).\\n\\n## ACTIONS\\n\\n- [View on publisher site](https://doi.org/10.1038/s41467-022-33732-9)\\n- [PDF (1.0 MB)](https://pmc.ncbi.nlm.nih.gov/pdf/41467_2022_Article_33732.pdf)\\n- Cite\\n- Collections\\n- Permalink\\n\\n\\n## PERMALINK\\n\\n\\n\\nCopy\\n\\n\\n## RESOURCES\\n\\n### Similar articles\\n\\n### Cited by other articles\\n\\n### Links to NCBI Databases\\n\\nBack to Top\",\n      \"summary\": \"{\\\"answer\\\":\\\"The article is titled \\\\\\\\\\\\\\\"Causal deep learning reveals the comparative effectiveness of antihyperglycemic treatments in poorly controlled diabetes\\\\\\\\\\\\\\\". It was published in Nat Commun in 2022. The authors are Chinmay Belthangady, Stefanos Giampanis, Ivana Jankovic, Will Stedden, Paula Alves, Stephanie Chong, Charlotte Knott, and Beau Norgeot. The article is open access and licensed under a Creative Commons Attribution 4.0 International License.\\\"}\",\n      \"favicon\": \"https://pmc.ncbi.nlm.nih.gov/static/img/favicons/favicon-32x32.png\"\n    }\n  ],\n  \"searchTime\": 3853.9,\n  \"costDollars\": {\n    \"total\": 0.009,\n    \"search\": {\n      \"neural\": 0.005\n    },\n    \"contents\": {\n      \"text\": 0.002,\n      \"summary\": 0.002\n    }\n  }\n}\n## Executive Summary\n\nRecent high-quality evidence—including a 2024 meta-analysis and a 2022 large-scale observational study—provides new insights into the comparative effectiveness of first-line antihyperglycemic treatments for type 2 diabetes mellitus (T2DM). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) demonstrate superior reductions in cardiovascular death, heart failure hospitalization, all-cause mortality, and myocardial infarction compared to glucagon-like peptide-1 receptor agonists (GLP-1 RA), though with a slightly increased risk of stroke. Deep learning analyses of real-world data confirm substantial heterogeneity in treatment effectiveness, emphasizing the need for personalized, data-driven therapeutic choices. Both studies reinforce the importance of individualized treatment selection based on patient risk profiles, comorbidities, and clinical endpoints.\n\n---\n\n## Introduction: Context and Scope\n\nSelecting optimal first-line and combination therapies for T2DM is increasingly complex due to a growing array of antihyperglycemic agents and the need to balance glycemic control with cardiovascular and quality-of-life outcomes. Recent clinical trials, meta-analyses, and innovative data science approaches have sought to clarify the relative benefits and risks of major drug classes, particularly SGLT2i and GLP-1 RA. This synthesis critically evaluates the latest comparative effectiveness evidence, with a focus on HbA1c reduction, cardiovascular outcomes, and implications for individualized care.\n\n---\n\n## Main Findings by Theme\n\n### 1. Comparative Cardiovascular Outcomes: SGLT2i vs. GLP-1 RA\n\n**Meta-analysis Evidence (Zhou et al., 2024, ESC Heart Failure):**\n- **Population:** 38 studies (19 RCTs, 18 retrospective, 1 prospective), including both T2DM and heart failure populations.\n- **Primary Outcomes:** Cardiovascular death, hospitalization for heart failure (HHF), all-cause mortality, myocardial infarction (MI), stroke.\n- **Results:**\n  - **SGLT2i vs. GLP-1 RA in T2DM:**\n    - Lower risk with SGLT2i for:\n      - Cardiovascular death (RR = 0.59, 95% CI 0.53–0.65)\n      - HHF (RR = 0.77, 95% CI 0.74–0.80)\n      - All-cause death (RR = 0.64, 95% CI 0.60–0.68)\n      - MI (RR = 0.81, 95% CI 0.76–0.87)\n    - **Increased risk of stroke** with SGLT2i vs. GLP-1 RA (RR = 1.10, 95% CI 1.04–1.17)\n    - HbA1c reduction was similar between SGLT2i and GLP-1 RA.\n    - SGLT2i reduced systolic and diastolic blood pressure more than GLP-1 RA; no significant differences in BMI or lipid profiles.\n  - **SGLT2i vs. Placebo in Heart Failure (with or without diabetes):**\n    - Lower risk of cardiovascular death (RR = 0.86, 95% CI 0.79–0.94)\n    - Lower risk of HHF (RR = 0.75, 95% CI 0.70–0.80)\n    - Lower all-cause mortality (RR = 0.91, 95% CI 0.86–0.97)\n\n**Critical Appraisal:**\n- **Strengths:** Large, recent meta-analysis; direct head-to-head comparisons; robust methodology (PROSPERO registered, quality assessment performed).\n- **Limitations:** High heterogeneity in some outcomes; predominance of retrospective studies in SGLT2i vs. GLP-1 RA comparisons; possible confounding from concurrent therapies.\n\n### 2. Real-World Effectiveness and Personalization\n\n**Causal Deep Learning Study (Belthangady et al., 2022, Nat Commun):**\n- **Population:** >1 million US T2DM patients with poorly controlled HbA1c (≥9%), 141,625 patient \"snapshots.\"\n- **Methods:** Causal deep learning, network meta-analysis, and propensity score balancing to compare >80 treatment strategies across 10 clinically defined cohorts (by age, comorbidities, insulin use).\n- **Key Results:**\n  - Top-three ranked treatment strategies (cohort-specific) yielded an average additional HbA1c reduction of 0.69% compared to other choices.\n  - SGLT2i and GLP-1 RA, both as monotherapies and in combinations, featured prominently among the most effective regimens.\n  - No single regimen was universally optimal; the best choice varied significantly by patient subgroup.\n  - Adding more drug classes did not always lead to better HbA1c control, highlighting the risk of polypharmacy and the need for regimen simplification.\n- **Quality of Evidence:** Large, representative dataset; advanced causal modeling; robust sensitivity analyses; but limited to HbA1c as the primary outcome (did not assess cardiovascular events directly).\n\n---\n\n## Critical Analysis of Evidence Quality\n\n- **Meta-analysis (Zhou et al.):** High-quality synthesis with a large evidence base, but retrospective studies contribute significant data, and outcome heterogeneity warrants cautious interpretation.\n- **Deep Learning Study (Belthangady et al.):** Innovative and methodologically advanced, providing real-world, personalized insights; however, limited by observational design, potential for unmeasured confounding, and focus on glycemic endpoints rather than direct cardiovascular outcomes.\n- **Convergent Evidence:** Both studies highlight the importance of individualized treatment, the prominent roles of SGLT2i and GLP-1 RA, and the need to consider both glycemic and cardiovascular outcomes.\n- **Contradictions:** Some prior studies and meta-analyses have yielded conflicting results regarding the superiority of SGLT2i vs. GLP-1 RA for specific cardiovascular outcomes, reflecting the complexity of patient populations and endpoints.\n\n---\n\n## Synthesis of Key Insights and Patterns\n\n- **SGLT2i are consistently associated with superior cardiovascular outcomes (excluding stroke) compared to GLP-1 RA, particularly for heart failure endpoints.**\n- **GLP-1 RA may offer greater stroke risk reduction, aligning with prior network meta-analyses.**\n- **HbA1c reduction is similar between the two classes, suggesting that cardiovascular benefits are not solely attributable to glycemic control.**\n- **Personalization is critical:** Optimal treatment regimens vary by age, comorbidity burden, and insulin use; data-driven tools can enhance individualized care.\n- **Polypharmacy is not uniformly beneficial:** More drugs do not necessarily mean better outcomes, and regimen complexity can impair adherence.\n\n---\n\n## Limitations and Gaps\n\n- **Limited head-to-head RCTs**: Most comparative data derive from meta-analyses and observational studies.\n- **Outcome heterogeneity**: Differences in study populations, endpoints, and follow-up durations complicate direct comparisons.\n- **Quality-of-life outcomes**: Both studies focus primarily on clinical endpoints; patient-reported outcomes are underrepresented.\n- **Real-world implementation**: While data-driven personalization is promising, practical clinical decision-support tools are still in development.\n\n---\n\n## Evidence-Based Conclusions\n\n- **For patients with T2DM, especially those at high cardiovascular risk or with heart failure, SGLT2i offer significant advantages over GLP-1 RA in reducing cardiovascular death, heart failure hospitalization, and all-cause mortality, but may increase stroke risk.**\n- **HbA1c reduction is similar between SGLT2i and GLP-1 RA; thus, cardiovascular endpoints should guide agent selection in high-risk populations.**\n- **Personalized, data-driven approaches—incorporating patient-specific risk factors and comorbidities—are essential for optimizing antihyperglycemic therapy.**\n- **Regimen simplification and avoidance of unnecessary polypharmacy should be prioritized to enhance adherence and minimize adverse effects.**\n\n---\n\n## Future Research Directions\n\n- **Direct head-to-head RCTs** comparing SGLT2i and GLP-1 RA for both cardiovascular and quality-of-life outcomes.\n- **Long-term studies** assessing the durability of benefits and risks, including stroke and other adverse events.\n- **Integration of patient-reported outcomes** and cost-effectiveness analyses.\n- **Development and validation of clinical decision-support tools** that operationalize individualized, data-driven treatment selection in routine practice.\n- **Exploration of strategies to balance glycemic, cardiovascular, and patient-centered outcomes in diverse populations.\n\n---\n\n## References\n\n- Zhou Z, Zheng M, Zuo Z, Wu T. Comparison of cardiovascular outcomes of new antihyperglycemic agents in Type 2 Diabetes Mellitus: a meta-analysis. ESC Heart Failure. 2024;11(3):1647–1656. [doi:10.1002/ehf2.14726](https://doi.org/10.1002/ehf2.14726)\n- Belthangady C, Giampanis S, Jankovic I, et al. Causal deep learning reveals the comparative effectiveness of antihyperglycemic treatments in poorly controlled diabetes. Nat Commun. 2022;13:6921. [doi:10.1038/s41467-022-33732-9](https://doi.org/10.1038/s41467-022-33732-9)\n<thinking>\nI need to analyze and summarize the provided tool execution output, which contains search results about the comparative effectiveness of diabetes treatments. Let me break down what I'm seeing:\n\n1. The output contains results from a search query about \"Latest FDA-approved medications and technologies for diabetes management in 2023-2024, including GLP-1 agonists, SGLT2 inhibitors, and automated insulin delivery systems\"\n\n2. The search returned two main articles:\n   - A 2024 meta-analysis from ESC Heart Failure comparing cardiovascular outcomes of SGLT2 inhibitors vs GLP-1 receptor agonists\n   - A 2022 study from Nature Communications using causal deep learning to analyze the comparative effectiveness of antihyperglycemic treatments\n\n3. The results have been synthesized into a comprehensive summary that covers:\n   - Executive summary\n   - Introduction and context\n   - Main findings by theme (comparative cardiovascular outcomes and real-world effectiveness)\n   - Critical analysis of evidence quality\n   - Synthesis of key insights\n   - Limitations and gaps\n   - Evidence-based conclusions\n   - Future research directions\n   - References\n\nThe summary is well-structured, detailed, and provides a thorough analysis of the comparative effectiveness of different diabetes treatments based on the latest research. It highlights that SGLT2 inhibitors show superior cardiovascular outcomes compared to GLP-1 receptor agonists (except for stroke risk), while both have similar effects on HbA1c reduction. It also emphasizes the importance of personalized treatment approaches based on patient characteristics.\n\nThe search results and summary appear to be high-quality and comprehensive, with no obvious errors or issues to highlight.\n</thinking>\n\n# Summary of Diabetes Treatment Comparative Effectiveness Research\n\nThe search results provide comprehensive evidence from two major studies comparing the effectiveness of modern diabetes treatments, particularly focusing on cardiovascular outcomes and glycemic control.\n\n## Key Findings\n\n### Cardiovascular Outcomes (Zhou et al., 2024)\n- **SGLT2 inhibitors vs. GLP-1 receptor agonists in T2DM:**\n  - SGLT2 inhibitors show superior outcomes for:\n    - Cardiovascular death (41% reduction)\n    - Heart failure hospitalization (23% reduction)\n    - All-cause mortality (36% reduction)\n    - Myocardial infarction (19% reduction)\n  - However, SGLT2 inhibitors showed a 10% increased risk of stroke compared to GLP-1 RAs\n  - Both classes demonstrated similar HbA1c reductions\n\n- **SGLT2 inhibitors in heart failure patients** (with or without diabetes):\n  - Reduced cardiovascular death by 14%\n  - Reduced heart failure hospitalization by 25%\n  - Reduced all-cause mortality by 9%\n\n### Personalized Treatment Effectiveness (Belthangady et al., 2022)\n- Analysis of over 1 million patients with poorly controlled diabetes (HbA1c ≥9%)\n- Optimal treatment regimens varied significantly across different patient subgroups\n- Patients receiving top-ranked treatments for their specific clinical profile showed an average additional HbA1c reduction of 0.69%\n- Adding more medications did not consistently improve outcomes, highlighting the importance of regimen simplification\n\n## Clinical Implications\n\n1. **Treatment selection should be personalized** based on age, comorbidities, and insulin status\n2. **Cardiovascular risk profiles** should guide choice between SGLT2 inhibitors and GLP-1 RAs:\n   - SGLT2 inhibitors preferred for patients with heart failure risk\n   - GLP-1 RAs may be better for patients with stroke risk\n3. **Simpler regimens** may improve adherence without sacrificing effectiveness\n4. **Data-driven approaches** can help identify optimal treatment combinations for individual patients\n\nThe synthesis effectively integrates findings from meta-analysis and real-world data, providing a balanced view of the current evidence. The information appears accurate and comprehensive, with appropriate attention to both benefits and limitations of different treatment approaches."
]